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ABSTRACT 
 
 
  DESIGN AND PHARMACOLOGICAL CHARACTERIZTION OF INHIBITORS 
OF INFLUENZA A VIRUS M2 PROTON CHANNEL 
 
 Jun Wang 
 
Supervisor: Professor William F. DeGrado 
 
Influenza A virus M2 (A/M2) forms a homotetrameric channel in viral membranes that is 
highly selective for protons. A/M2 has been extensively studied by electrophysiologists, 
biophysicists, structural biologists and biochemists in order to understand the mechanism 
and selectivity of proton conductance from the structural basis. Medicinal chemists have 
also studied A/M2 as therapeutic target for anti-flu drugs. However, research on A/M2 
drug binding lead to entirely different binding sites of two very similar anti-flu drugs. In 
light of the urgency in developing novel antivirals against drug resistant A/M2 mutants, it 
is imperative to solve this discrepancy in order to guide the next generation of antiviral 
discovery. This highly contentious debate was settled in favor of pore blocking through 
collaborate efforts with Dr. Mei Hong in Iowa State University. We showed by solid state 
NMR that the single high affinity pharmacologically relevant drug binding site locates at 
the N-terminal lumen with amine pointing towards C-terminal using 
13
C-
2
H rotational-
echo double-resonance NMR distance measurement of 
13
C-labeled M2TM and deuterated 
amantadine in lipid bilayers. Guided by the high resolution structure of drug-complexed 
 vi 
 
 
M2, rational drug design based on BL-1743 scaffold lead to a series of spiran amines, 
which are not only 10 fold more active than amantadine, but also has moderate activity 
against drug resistant mutants V27A and L26F. Subsequent optimization improved the 
potency with IC50s down to low micromolar range. By substituting the carbon quaternary 
center with silicon, silaspiran amines were designed and synthesized and show higher 
antiviral potency than their carbon analogs. Finally in searching for novel scaffolds, a 
library of inhibitors was selected based on the structure and activity relationship results 
from previous studies and screened against M2. It was found that A/M2 is able to 
accommodate inhibitors with diverse scaffolds. In conclusion, this thesis study solved the 
A/M2 drug binding site controversy and developed a series of potent A/M2 inhibitors that 
are promising as drug candidates. 
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Chapter 1 
Introduction of influenza A virus M2 proton channel and its importance 
as antiviral drug targets 
 
 1.1 Influenza A virus infection is a serious human health threat 
The influenza virus, most notably the H1N1and H5N1 strains, poses a serious threat to 
human health. Each year in the US, the virus is directly responsible for the death of 
36,000 people, 114,000 hospitalizations,
1
 70 million missed workdays and 38 million lost 
school days in a regular flu season.
2
 The estimated loss to the economy is $3-15 billion. 
During pandemics (1957 and 1968) approximately 70% of the US population was 
infected and in 1918/19 the estimate of death associated with Spanish influenza ranges 
from 20-40 million (1 in 100 people worldwide). Typical flu infections are mild and 
generally lead to a full recovery, whereas highly pathogenic strains of the virus often 
cause life-threatening illness even among healthy adults. The outbreak of highly 
pathogenic H5N1 avian influenza virus in 1997 and 2004/5 caused the death of millions 
of chickens and had a very high mortality rate among the limited number of infected 
humans. During the H1N1 pandemic in 2009,
3
  the flu virus rapidly spread throughout the 
world when no vaccine was available. This caused great concern about the transmission 
of avian virus mutants among humans. Influenza viruses can mutate in two ways: 
antigenic drift and antigenic shift.
4
 Antigenic drift due to point mutations of the viral 
negative strand RNAs generates slightly modified antigens on the virus surface, while 
antigenic shift causes reassortment of RNAs between viruses that infect avian 
2 
 
populations and viruses that infect humans (Figure 1.1). The latter is a more serious 
problem since it produces different antigenic determinants, for which there is little pre-
existing immunity. Thus there is a great need for anti-influenza therapeutics. Currently 
there are two classes of licensed small-molecule drugs in use to treat influenza virus 
infection: amantadine and rimantadine, which target the virus′ M2 proton channel, and 
Tamiflu (oseltamivir), which targets the virus surface protein neuraminidase.
5
  
 
Figure 1. 1 | Reassortment of influenza viruses from different species. Figure from 
(Carolyn Buxton Bridges, MD, Influenza Branch, Division of Viral and Rickettsial 
Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia: "Human 
influenza viruses and the potential for inter-species transmission." ) 
 
 1.2 Influenza virus family and compositions 
There are three types of influenza viruses (A, B and C), all belong to orthomyxoviridae 
family.
6
 Influenza B and C viruses both infect humans, but are less pathogenic compared 
3 
 
with influenza A and do not cause pandemics. Influenza A viruses infects multiple 
species, including human, swine, birds and ferrets. It is one of the most serious human 
diseases. Symptoms of flu infection include high fever, headache, tiredness, dry cough 
and body aches, and it is more deadly for people with health complications, like pregnant 
women, young children, seniors older than 65, and people with chronic medical 
conditions (such as asthma, diabetes, and heart disease).
7
 Flu viruses are transmitted 
through the airway by sneeze or cough of infected people. Occasionally, people can also 
get infected by indirect contact mediated by viruses contaminated surfaces, then touching 
their eyes, mouth and nose.  
 
Influenza virus contains a genome made up of 8 single strand RNA segments, each 
encoding a different viral protein (Figure 1.2). The reassortment of RNA segments from 
different species of influenza A viruses, called antigenic shift, allows the virus to avoid 
detection by the human immune defense system. This is highly problematic from the 
standpoint of vaccine development since it is impractical to predict when, where and how 
reassortment may occur.  Antigenic shifts can lead to viruses with novel immunological 
signatures to which pre-existing immunity in the population is lacking. This has the 
potential to cause deadly worldwide pandemic disease if the virus also has high 
replicative fitness and human-human transmissibility. In comparison, antigenic drift 
caused by point mutation of one particular virus species only leads to annual epidemic 
flu.  
4 
 
 
Figure 1. 2 | Influenza virus membrane proteins and genetic compositions. Figure from 
8
 
with permission from Elsevier. 
 
 
There are three membrane associated proteins displayed on influenza virus’ surface, 
hemagglutinin (HA), neuraminidase (NA), and M2 protein, each of which play an 
essential role in the viral replication cycle and are targets of vaccines and antivirals. 
Currently there are 16 hemagglutinin subtypes (H1-H16) and 9 neuraminidase subtypes 
(N1-N9), and they are the antigenic determinants of influenza virus and can undergo all 
possible combinations giving rise to different influenza A viruses subtypes, e.g. H1N1, 
H5N1, H3N2 etc.  The majority of viral envelop proteins are hemagglutinin (80%) and 
neuraminidase (17%) at approximately a 4 to 1 ratio. M2 represents a small portion (3%) 
with 5-10 channels per virion.
9
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Inside the virus are viral ribonucleoproteins (vRNPs) structures that contain eight 
different segments of negative sense, single stranded RNA, encoding for the eleven viral 
proteins
10
 (Figure 1.2). RNA segment 1 codes for polymerase basic protein 2 (PB2), 2 for 
polymerase basic protein 1 (PB1), 3 for polymerase acidic protein (PA), 4 for 
hemagglutinin (HA), 5 for nucleocapsid protein (NP), 6 for neuraminidase (NA), 7 for 
matrix protein 1 (M1) and 2 (M2) and 8 for non-structural protein 1 (NS1) and 2 (NS2). 
PB1, PB2 and PA are the three P(polymerase) proteins, which are present at 30-60 copies 
per virion. NP is the predominant structural protein subunit of the nucleocapsid and also 
plays an essential role in viral RNA replication. Viral matrix protein (M1) underlies the 
lipid bilayer through association with the cytoplasmic tail of M2, and is the most 
abundant virion protein. NS2 (also known as NEP) protein is a structural component of 
the virion and appears to form an association with M1 protein and is involved in the 
export RNP complex from the nucleus. NS1 protein, when expressed, is not packed 
inside the virions and plays a role in suppressing host antiviral responses. 
 
Standard nomenclature for a specific influenza strain is summarized in Figure 1.3. 
 
6 
 
Figure 1.3 Nomenclature of influenza virus. Figure from
11
 
 
1.3 Influenza A virus replication cycle and antiviral drug targets
8, 12-15
 
Influenza virus enters the cell by first interacting with the cell surface receptor containing 
sialic acid through hemagglutinin, then internalized through receptor mediated 
endocytosis (Figure 1.4). Once in the endosome, the low pH inside the endosome 
activates the M2 proton channel, which functions to equilibrate the pH of the virus 
interior with that of the acidic endosome. The lowering of the pH within the virus has two 
outcomes: first, it triggers the conformational change of hemaglutinin to the low-pH 
form, leading to fusion of viral and cellular membrane. Second,  the low pH in viral 
interior leads to disruption of the interactions between viral ribonucleoprotein (vRNP) 
complex and the M1 protein, an important step in viral uncoating.
16
  The structure of 
hemagglutinin was solved by X-ray crystallography
17
 which lead to the design of viral 
fusion inhibitors that either prevent or accelerate the low pH form HA formation.  
Additionally, for some subtypes of influenza A virus, the M2 proton channel activity 
helps maintain a neutral pH in the lumen of the trans-Golgi network to prevent premature 
triggering of the hemagglutinin to the low-pH form.
18-20
 The adamantane class of 
antivirals block this uncoating process.
21
  Once the viral RNA is transported to the 
nucleus, the negative sense strands of RNA are transcribed to positive sense RNA 
(mRNA) first before being replicated and translated into viral proteins. Viral RNA 
replication and transcription are carried out by three polymerase subunits, PA, PB1, PB2 
and nucleoprotein NP in the nucleus can be inhibited by viral RNA polymerase 
7 
 
inhibitors,
22
 and there is a growing interest in developing viral polymerase inhibitors as 
structural information becomes available.
23
 Next, the translation of mRNA into viral 
proteins can be inhibited by small interfering RNAs (siRNAs),
24
 and its efficiency was 
further demonstrated in an animal study.
25
  In the late stage of viral replication, the viral 
proteins repack into progeny virions, but before they can be released into the circulation 
system, neuraminidase has to cleave the sialic acid receptor. This process can be inhibited 
by neuraminidase inhibitors (eg, Tamiflu and Zanamivir).
26
 Moreover, 
immunomodulators are also in development to reduce the inflammation initiated by 
influenza A virus infections.
12
 
 
 
8 
 
Figure 1. 4 | Influenza virus replication cycle and checkpoints for antivirals inhibition.  
Figure from 
27
 with permission from NPG. 
 
              
1.4 Influenza A virus chemotherapy 
While immunization offers the first line defense against influenza A virus infection, its 
effectiveness is greatly diminished due to the extraordinary ability of the viruses to 
change their genetic makeup and escape from the host immune system. Thus, novel 
antivirals are in great need to fight against influenza virus infections during pandemics 
and seasonal epidemics.  In theory, small molecule inhibitors targeting any of the 
checkpoints during influenza virus replication cycle can be developed into antiviral 
drugs.
28
 Currently there are two classes of small-molecule drugs on the market to treat 
influenza virus infection (Figure 1.5): amantadine and rimantadine, which target the 
virus′ M2 proton channel, and Tamiflu (oseltamivir) and zanamavir, which targets the 
virus surface protein neuraminidase. A few other anti-flu drugs targeting NS1, NP and 
viral polymerases are in still in development.
12
 
 
Figure 1. 5 | Chemical structures of four proven antivirals drugs for treatment of influenza 
virus infection. 
 
Compared with neuraminidase, A/M2 protein is more conversed with only a few major 
mutations like V27A, S31N and L26F conferring drug resistance and transmissibility.
29-31
 
9 
 
Part of the reason for the low mutation rate of A/M2 is due to the stringent sequence 
requirement for A/M2 function. To conduct protons, A/M2 has to allow formation and 
interchange of a number of functional conformers, each required for gating and 
conducting protons (Figure 1.6). Any mutation which shifts these low energy barrier 
interconvertable ensembles to one or more stable conformations is potentially disfavored 
due to the loss of function. It has been shown in vitro through analytical 
ultracentrifugation (AUC) experiments that mutation of pore lining residues and residues 
at the helix-helix interface of A/M2 to alanine and phenylalanine result in a more stable 
homotetramer compared with wild-type, except His37, which is required for selective 
proton conductance.
32, 33
 Thus, the amino acid sequence of M2 is not optimized for 
overall thermodynamic stability, but rather a compromise between stability and function. 
From the drug development point of view, it would be ideal to target the most 
conservative protein such that antivirals are effective across different subtypes of flu 
viruses.  In this regard, A/M2 is advantageous over neuraminidase as a drug target in 
influenza virus inhibition; despite both of them are proven drug targets. Nevertheless, a 
combination of antivirals drugs are desired in the case of highly virulent flu outbreaks. 
12, 
34
 
 
 
 
 
 
10 
 
a) 
 
b)
 
Figure 1. 6 | Representation of A/M2 ensemble and conformation selection by A/M2 
inhibitors. a) A/M2 conducts proton through equilibrium of a series of low energy barrier 
ensembles. The channel opens outside to allow protons to diffuse into the channel or 
open inside to release the proton. The conformational change is mediated by His37 
protonation and deprotonation. b) Channel blockers like amantadine inhibits the A/M2 
channel by binding one or more conformations and stabilizes them, thus creating a large 
energy barrier for conformational interconversion. 
 
 
11 
 
A large number of drug resistant mutations were selected in cell culture under 
amantadine selection pressure, including L26F; V27 to A, S, G, or D; A30 to T, E, or P; 
S31N 
19, 35
 (Figure 1.7), and a subset of these mutations were also found in infected 
patients that were treated with amantadine.
36
 Not all of the mutant viruses maintain the 
transmissibility of wt viruses and many of these mutations have the tendency to revert in 
the absence of drugs.
19, 37
 Only three major mutations were identified from large scale 
genome sequencing of transmissible viruses from 1918 to 2008,
29, 38
 among which S31N 
is the predominant drug resistant mutation in H3N2 and H1N1 subtypes, followed by 
V27A and L26F. The latter two mutations were found to be predominant in certain flu 
seasons. A highly conductive channel would be toxic to the infected host cell and would 
lead to cell death before the assembly and budding of the progeny virus. Another function 
of A/M2 is to equilibrate the pH across the Golgi in order to prevent the premature 
conformational change of the viral fusion protein, hemagglutinin (HA).
18-20
 A/M2 and 
hemagglutinin have co-evolved and acted in concert with each other. A particularly acid-
labile hemagglutinin would require an A/M2 variant like D44N with higher proton 
conductance capability to maintain neutrality in the late Golgi to prevent a premature 
conformational change in the hemagglutinin before reaching the cell surface.
39
  Taken 
together, only three major mutations in A/M2, namely S31N, V27A and L26F satisfy 
both the functional and evolutionary requirements of influenza viruses, thus becoming 
dominant in currently circulating strains. 
 
 
12 
 
a) 
 
b) 
 
Figure 1. 7 | Amino acid sequence of influenza A virus strain A/Udron/72 and its 
mutations. a) Domain structure of influenza A virus M2 protein. b) A/M2 drug resistant 
mutations isolated from cell culture treated with amantadine.   
 
 
1.5 A/M2 structure and drug binding site 
AM2 is a homotetrameric, type III integral membrane protein containing: 1) a short N-
terminal region that is important for the protein’s incorporation into the virion;40 2) a 
transmembrane (TM) helix that is required for tetramerization, drug binding and proton 
channel formation;
41-44
 3) a C-terminal amphiphilic helix that is involved in membrane 
localization, budding and scission;
45, 46
 and 4) a C-terminal tail that interacts with the 
matrix protein M1.
47
 Although native A/M2 protein is palmitoylated (Cys50) and 
phosphorylated (Ser64), these modifications have no effect on its channel-forming 
properties in cell membrane.
48, 49
 The protein also has cysteine residues at position 17 and 
19 on the viral N-terminal exterior, which form a mixture of covalent dimers and 
tetramers.
50
 However, these disulfides are not essential for M2 assembly into functional 
tetrameric channel, and the mutants whose Cys17 and Cys19 are mutated to Ser are still 
13 
 
fully active in oocytes.
48, 51
 Structures of the drug complexed transmembrane domain of 
A/M2 (A/M2TM) were solved using X-ray crystallography
52
 and solution NMR
53
 (Figure 
1.8). The overall structures were similar, showing left handed packing of a 
homotetrameric bundle. The differences between these two structures are: (1) The helix 
tilt in the X-ray structure is 30-40
o
, while the solution NMR structure is 23
o
. This 
difference might result from several factors: (a) Solubilization environment - crystal was 
grown in octylglucoside (OG) micelle at pH 5.5, which confers the open conformation of 
M2. In contrast, the NMR structure was solved in 1,2-Dihexanoyl-sn-
glycerophosphocholine (DHPC) at pH 7.5, which confers the closed conformation of M2. 
(b) The protein sequences used for X-ray and solution NMR studies were different. The 
X-ray structure was solved with transmembrane segment (residues 25-46), solution NMR 
study used a longer sequence with an extra C-terminal amphiphilic helix (residues 20-
60). (2) The striking difference is where the drug binds. In the X-ray structure, the 
electron density inside the cavity at the N-terminal lumen matches that of amantadine, 
leading to a pore blocking mechanism of drug action. In solution NMR, four rimantadine 
molecules were found on the C-terminal exterior side at the helices interface. The 
transmembrane helices are in close contact such that there was not enough room to 
accommodate rimantadine inside the channel. Based on this structure, an allosteric 
inhibition mechanism was proposed where the drug would selectively stabilize the closed 
conformation of M2, thus preventing channel opening. 
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From a drug discovery perspective, it is imperative to figure out which drug binding site 
is the pharmacological relevant binding site. This is one of the goals of my thesis work. 
 
Figure 1. 8 | X-ray and solution NMR structures of drug bound A/M2TM. Left: X-ray 
structure of A/M2TM (25-46)G34A with electron density inside the channel matching 
amantadine (PDB code: 3C9J). Right: Solution NMR structure of A/M2TMC (21-61) 
with four rimantadine binding to the peripheral of the channel (PDB code 2RLF). Figures 
from 
52, 53
 with permission from ACS and NPG. 
 
 
1.6 Literature review of A/M2 inhibitors 
Amantadine was first discovered by scientists at DuPont to have antiviral activity in 1964 
21
 and was approved by the U S Food and Drug Administration (FDA) in 1966 for the 
treatment of influenza A virus infection in 1966. Subsequently, a close structural analog 
of amantadine, rimantadine, received FDA approval in 1994 and has been shown to have 
higher potency and reduced central neuron system (CNS) side effects. Unfortunately 
most of the currently circulating strains of influenza virus have become resistant to the 
adamantane class of drugs, causing the CDC to issue a recommendation to discontinue 
their use.
54
 Thus oseltamivir (Tamiflu) is the only remaining orally administered anti-flu 
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drug on the market. Increasing number of oseltamivir resistant cases have been reported 
in recent years.
55, 56
 Thus there is great need to develop novel antivirals with higher 
potency and broad spectrum inhibition. Extensive medicinal chemistry efforts have been 
devoted to synthesize amantadine analogs, including 1-substituted adamantane,
57, 58
 2-
substituted adamantane,
59-61
 2,2-disubstitued adamantane, 2,2-spiro adamantane
57, 62, 63
 
and 1,2-annulated adamantine
64
 (Figure 1.9). Quite a few compounds have been 
identified to be more potent than rimantadine.
4, 5
 But the cytopathic effect (CPE) assay
65
 
that was used to test these compounds is not target specific, so it is difficult to correlate 
the structures with M2 inhibition. Moreover, the influenza A virus strains that were tested 
lack the S31N or V27A M2 mutation, so it is not clear whether any of these compounds 
might work against virus carrying amantadine resistant mutations.  
 
Figure 1.9 | Structures of representative adamantane anlogs as anti-flu inhibitors. 
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Aside from amantadine, only very few scaffolds other than adamantane have been 
explored for antiviral activities against influenza A virus (Figure 1.10), including 1-
norbornylamine,
66
 tricyclic ICI 130685,
67
 BL-1743,
68
 bicycle[2,2,2]octane
69
 and 
isopinocampheylamine.
70
  There are also a few patented polycyclic compounds that claim 
to have antiviral activity, e.g. pentacycloundecane amines,
71
 aminopolycyclodecanes,
72
 
aminotricyclononanes,
73
 pentacycloalkane amines,
74
 but their detailed mechanism of 
action have not been fully explored. In this regard, despite the importance of A/M2 as a 
proven drug target and the urgency to develop potent A/M2 blockers, there is very 
limited structure and activity relationship information about A/M2 inhibitors.  Moreover, 
a majority of the current circulating influenza A viruses carry drug resistant mutations 
such as L26F, V27A, S31N and S30T, none of which have been shown to be druggable. 
In this thesis study, I aim to identify novel scaffolds that may provide new avenues for 
developing antagonists of A/M2. The spirene guanidine analogue, 2-[3-
azaspiro(5,5)undecanol]-2- imidazoline (BL-1743) was choosen as an initial hit 
compound for the structure and activity relationship study, as its antiviral activity has 
been shown to be A/M2 specific, and it is also easier to synthesize and diversify from the 
chemistry point of view.   
17 
 
 
Figure 1. 10 | Structures of non-adamantane based anti-influenza A viruses agents. 
 
 
1.7 Introduction of M2 drug screening assays 
1.7.1 Two electrode voltage patch clamp assay 
The gold standard of measuring compound activity on an ion channel is the patch clamp. 
Even though it is low throughput, the high quality data generated from this assay offers 
insights in guiding drug design. In the patch clamp assay, a constant electrical potential 
(voltage clamp) is applied across an electrically isolated area (patch) of membrane 
containing the protein of interest, and the current is recorded directly in real time under 
different conditions, e.g. in the presence or absence of inhibitor.  
 
The protein assayed can either be expressed in cell membrane or reconstituted in 
artificially formed bilayer-like vesicles. Both single channel and whole cell current 
recording are possible, but in the case of A/M2, due to the extremely small conductance 
per channel, whole cell recording are applied for drug screening purpose. In a typical 
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screening assay experiment, Oocyte expressing A/M2 channel is clamped at -20 mV. 
Xenopus laevis (African clawed frog) oocytes are large cells with exceeding 1 mm in 
diameter and are therefore easy to manipulate, and can be induced to express transport 
proteins of interest by intracytoplasmic injection of mRNA encoding the desired protein. 
Initially oocyte is bathing at pH 8.5 buffer, where A/M2 channel is closed; then A/M2 
channel is activated by lowering the buffer solution to pH5.5. When the inward A/M2 
current reaches maximum, the 100 μM inhibitor was applied for 2 min at pH5.5 buffer 
solution. The remaining current after 2 min application was compared to the maximum 
current before the application of the inhibitor. The potency of the inhibitors was 
expressed as percentage inhibition of A/M2 current by 2 min application of 100 μM 
inhibitors. Typical trace of the current change is shown in Figure 1.11. 
 
 
Figure 1. 11| Current trace of A/M2 channel upon acidic activation and compound 
inhibition. 
 
1.7.2 Plaque reduction assay 
To test the in vivo activity of inhibitors, plaque reduction assay of recombinant influenza 
A virus was performed. In the plaque reduction assay, the infectious ability of virus on 
MDCK cells was monitored in the presence of different doses of inhibitors. If the 
inhibitor is inactive, the virus particle will multiply and infect MDCK cells, thus forms 
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localized area of ‘plaque’, which can be monitored as areas of dead/destroyed cells 
detected by general cellular stains or as areas of infected cells detected by immuno-
staining.  On the other hand, if the virus replication is inhibited by potent inhibitors, no or 
less plaque will form under the same condition. In a typical procedure, confluent 
monolayers of MDCK cells were incubated with the wt Udorn virus [100 plaque-forming 
units (pfu) per well] and V27A/L38F mutant virus (1000 and 100 pfu per well) in a 
DMEM/1%bovine serum albumin mixture for 1 h at 37 
o
C. The inoculums were 
removed, and the cells were washed with phosphate-buffered saline (PBS). The cells 
were then overlaid with DMEM-containing 0.6% Avicel microcrystalline cellulose (FMC 
BioPolymer, Philadelphia, PA) and NAT (2.0 μg/mL). To examine the effect of drugs on 
plaque formation, monolayers were preincubated with DMEM supplemented with the 
indicated concentrations of the drugs at 37 
o
C for 30min, and virus samples were 
preincubated with a DMEM/1% BSA mixture with the indicated concentrations of the 
drugs at 4 
o
C for 30 min before infection. Two to three days after infection, the 
monolayers were fixed and stained with a naphthalene black dye solution (0.1% 
naphthalene black, 6% glacial acetic acid, and 1.36% anhydrous sodium acetate). 
 
Figure 1. 12 | Plaque reduction assay of influenza A virus in the presence of different 
concentrations of amantadine. Figure from
75
 with permission from ACS. 
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1.7.3 Circular Dichroism binding assay 
The structural changes resulted from drug binding to M2TM can be monitored by circular 
dichroism (CD) spectroscopy.  M2TM adopts a α-helix structure when reconstituted in 
detergents, showing minimal at θ223 and θ209 in CD spectrum. Under condition of 
intermediate to high peptide/detergent ratio (>1:400), binding of drug promotes a shift of 
monomer/tetramer equilibrium to drug bound tetramer, which has significantly higher 
intensity of ellipticity at 223nm (θ223). Drug binding constants are derived by plotting the 
change at θ223 against drug concentration. In practice, the ellipticity ratio θ223/ θ209 instead 
of the absolute value at θ223 is used for data fitting in order to minimize the small 
concentration differences during titration. This assay was first used for amantadine 
binding and later applied to other inhibitors. Binding constants derived from the CD 
binding assay are in general agreement with electrophysiology assay data. Typical trace 
of a CD binding assay is shown below (Figure 1.13): 
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Rimantadine
Amantadine
 
Figure 1. 13 | CD binding assay of amantadine and rimantadine to M2TM in DPC 
micelle. Figure from
75
 with permission from ACS. 
 
1.8 Drug design principle of A/M2 inhibitors 
The design of A/M2 inhibitors started with our X-ray crystal structures of A/M2TM (25-
46) (PDB: 3C9J, 3BKD) solved in n-octylglucoside (OG) micelle
76
 (Figure 1.14), and 
also the most recent SSNMR structure of amantadine complexed A/M2TM
77
 (PDB: 
2KQT). These structures represent conformational states from higher (pH 7.5) to lower 
pH (pH 5.5). In principle, any conformation of A/M2, either at high, medium or low pH 
can be used for the design of A/M2 inhibitors, because amantadine binds at both high and 
low pH, despite its higher potency at elevated pH.
78
 A high resolution (1.6 Å) X-ray 
structure
76
 of drug free A/M2TM (PDB: 3LBW) that was recently solved reveals not only 
packing of the viral channel interior pore, but more importantly uncovers well-organized 
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water clusters in the channel. This water-His37 box like structure was suggested to play 
an important role in A/M2 proton conductance mechanism by delocalizing protons over 
the entire region.
76
 This high resolution structure offers a new starting point for the next 
generation of anti-flu drug design. 
                               a)                                            b) 
 
                              c)                                                d) 
             
Figure 1.14 | Structures of A/M2TM used for M2 inhibitor design. a) X-ray structure, 
PDB: 3BKD. b) X-ray structure, PDB: 3C9J. c) SSNMR structure, PDB: 2KQT. d) X-ray 
structure, PDB: 3LBW.  
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All previous reported A/M2 inhibitors share the same structural similarity: a positively 
charged amino or amino derivative (guanidine, etc) group attached to a large hydrophobic 
aliphatic scaffold. A variety of amantadine analogues with more hydrophobic and bulkier 
positively charged groups have several-fold greater potencies against most forms of the 
virus that lack the S31N mutation.
4, 5
 The large variety of amines that can be 
accommodated in the site argues against a highly specific interaction between the amine 
and the channel.
58
 This conclusion is consistent with the amantadine-complexed AM2-
TM structure (PDB: 3C9J), in which the electron density map fits better with the 
positively charged amantadine amine pointing down toward His37, but the distance is too 
far (6.8 Å) for effective hydrogen bonding between the imidazoles and the amine (or 
ammonium group). Overlaying the SSNMR structure of amantadine complexed 
A/M2TM (PDB: 2KQT) with the high resolution X-ray crystal structure of drug free 
A/M2TM (PDB: 3LBW) generates a model of wt M2 with the crystal waters in the entry 
cluster (Figure 1.15). In this model, amantadine is within hydrogen bonding distance with 
the crystal waters which suggests amantadine inhibiting M2 by not only physically 
blocking the channel, but also altering the pKas of the His37 residue
79
 such that it can no 
longer be protonated at physiological pH.  
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Figure 1.15 | Overlaying A/M2TM structures of SSNMR structure (PDB: 2KQT) and X-
ray structure (PDB: 3LBW). 
 
The pore lining residues of wt A/M2 in the drug binding site are V27, A30, S31 and G34 
that forms a hydrophobic pore. In the SSNMR structure of amantadine complexed 
A/M2TM (PDB: 2KQT), V27 constrains the drug binding site in the N-terminal with the 
pore dimension ~4 Å, and the channel expands to the widest at G34 with an inner 
diameter of ~8 Å (Figure 1.16).  In the channel axis, the drug binding site consists of two 
α-helix turns of A/M2 backbone with the distance of ~ 9 Å (the distance of one turn α-
helix is 5.4 Å, the tilt angle of the helix is 30
o
, thus the distance in the channel axis is 5.4 
Å*2*cos30
o
 = 9.4 Å). The drug binding site dimension in the channel axis can be further 
extended to 11 Å if the water clusters above His37 are displaced. This suggests the A/M2 
drug binding site has enough room to accomendate molecules larger than 
amantadine/rimantadine. 
25 
 
 
Figure 1. 16 | A/M2 drug binding site dimension analysis 
 
For the inhibitor to fit inside the channel, it has to meet two criteria: hydrophobic match 
and Shape complementary. These are the guidelines for A/M2 inhibitor drug design.  
 
The general procedure of A/M2 inhibitor discovery (Figure 1.17) starts from a rational 
drug design based on the hit compounds identified from high throughput screening or a 
de novo structural based design. The inhibitors designed are next synthesized and assayed 
in A/M2 specific electrophysiology assay. The structure and activity relationship (SAR) 
correlation results from the assay are used as guidelines for the next round of structure 
based rational design using the same scaffold, or selection of structurally diverse 
compounds that meet the criteria of SAR results. The inhibitors designed or selected are 
subjected to the next round of electrophysiology assays. The most potent inhibitors are 
further characterized both in plaque reduction assay and in biophysical assays such as 
CD, NMR, etc to gain insights about how inhibitor binding affects the conformational 
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change of A/M2. The ultimate goal is to identify drug candidates that can be further 
pursued in animal test and clinical trials. 
 
Figure 1. 17 | A/M2 inhibitor discovery scheme. 
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Chapter 2 
Aim, focus and perspective of influenza virus M2 channel inhibitor 
development 
 
2.1 Aim and focus of A/M2 inhibitor development 
Studying the mechanism of proton conductance through A/M2 and how drug binding 
affects A/M2 dynamics is the first step towards structure-based design of M2 inhibitors. 
The knowledge learned through structural and functional studies of A/M2 drug binding 
can be used to guide rational design of potent A/M2 inhibitors targeting not only wild 
type (wt), but more importantly pharmacologically relevant drug resistant mutants.  
 
Structural studies of membrane protein are often challenging due to the difficulties 
associated with production, assay, functional reconstitution, and structural 
characterization of this class of proteins. Production of large quantities (tens to hundreds 
of milligrams) of A/M2 protein and its fragments in high purity (>98%) are required for 
structural and functional studies. This problem was addressed in two ways in this study: 
(1) Bacterial expression with controlled protease digestion. This provided both 
isotopically labeled A/M2 fragments (19-49 and 19-53) for NMR studies and natural 
abundance full length A/M2 for liposome flux assay. (2) Solid phase synthesis. The 
optimized protocol was applied for synthesis of selectively labeled (
15
N, 
13
C or 
15
N + 
13
N) 
A/M2 peptides with different lengths for NMR or large scale natural abundance A/M2 for 
X-ray crystallography. Once enough material was obtained, the next step is to identify 
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reconstitution conditions for NMR studies of A/M2. A wild range of common detergents 
and detergent/lipid combinations were screened using circular dichrorism (CD) 
spectroscopy or 
15
N-
1
H HSQC NMR to identify conditions that stabilize M2TM in a 
native like conformation in solution. It was found that n- dodecylphosphatidylcholine 
(DPC), n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (C14-betaine) and n-
dodecyl-α-D-maltoside (DM) gave high quality of 15N-1H HSQC spectra, highlighting 
their promise for M2 structural determination by NMR.  
 
Structural studies of drug-complexed A/M2 raised controversy about the mode of action, 
specifically whether the drug inhibits the M2 function by directly blocking the channel or 
allosterically modulating a conformational change of M2. From the drug design point of 
view, it is imperative to solve this discrepancy so that medicinal chemists can focus on 
the correct drug binding site. In collaboration with Dr. Mei Hong (Iowa State University), 
we resolved the controversy using REDOR solid state NMR experiments using deuterium 
labeled amantadine and M2TM with selective isotope labeled residues at both of the 
above proposed drug binding sites.
1
 As shown in Chapter 3, this study showed that the 
primary high affinity site was located at the N-terminal lumen, occupied by a single 
amantadine; a secondary low affinity site at the C-terminal helices interface was only 
detected with excess amantadine. Moreover, the pore binding model is further supported 
by a large body of functional data.
2-4
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Even though the N-terminal lumen was confirmed as a pharmacologically relevant drug 
binding site, the orientation of the amine from drug inside the channel was not 
determined. Extensive computational investigations have been carried out to define the 
mechanism of amantadine/rimantadine action as well as orientation of the amine, 
including molecular dynamics simulations,
5-8
 rigid-body docking,
9, 10
 and small molecule 
probe mapping.
11, 12
 Since these studies used a variety of different M2 structures/models 
as starting points with varying protonation states, it is not surprising that no consensus 
has yet emerged. A recent molecular dynamic simulation study by Khurana et al
5
 found 
that the orientation of the amine were not the same under different protonation states of 
His37: the amine was almost equally distributed up and down at low protonation, while it 
preferentially pointed towards His 37 when His37 was more solvated at greater 
protonation.  Clearly, there is a need to experimentally determine the precise location of 
drug in the site. Depending on whether the amine points towards the N or C-terminus, the 
mechanism by which drug binding inhibits this proton channel is different. These results 
will facilitate the optimization of existing drugs.  In Chapter 4, this question has been 
addressed using both M2TM reconstituted in lipid bilayers as well as DPC micelles. 
13
C-
2
H rotational-echo double-resonance (REDOR) NMR experiments of 
13
C-labeled M2TM 
and methyl-deuterated rimantadine in lipid bilayers showed that the polar amine points to 
the C-terminus of the channel, with the methyl group located close to Gly34. Specific 
2
H-
labeling of the drugs permitted assignment of drug-protein cross peaks in solution NMR 
experiments of A/M2TM(22-46) in dodecylphosphatidylcholine (DPC) micelles, 
indicating that amantadine and rimantadine bind to the pore in the same fashion as the 
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bilayer-bound M2TM. These results strongly suggest that adamantane drugs inhibit 
A/M2 function by direct physical occlusion of the pore and perturb the pKa of the proton 
sensing His37 through water mediated hydrogen bonding. 
 
A major effort in this dissertation is devoted to structure based rational design of A/M2 
inhibitors presented in Chapter 5, 6, 7, 8 and 9. Guided by the X-ray crystal structures of 
M2TM and pore binding model, a series of spiran amines have been designed, 
synthesized and assayed. Highly potent inhibitors were identified that are not only active 
against the wt A/M2, but also against the drug resistant mutants V27A and L26F.  
 
 2.2 Two controversial A/M2 drug binding sites 
Two studies published in 2008 raised a controversy about the A/M2 drug binding site 
among the public.
13-15
 From the drug discovery standpoint, it is imperative to validate 
which site is the pharmacological relevant drug binding site. Before planning experiments 
to solve the issue, it is necessary to closely examine the two structures to see whether 
either one of the structures agree with existing functional assay data, models built based 
on experimental data and biophysical assays. The top and side view of the two drug 
bound forms of A/M2 TM structures and their sequence are shown in Figure 2.1. 
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              a)                                                      b) 
  
              c)                                                        d) 
 
e) 
  
37 
 
Figure 2.1 | Structures of drug-bound transmembrane domain of A/M2. a) Side view of 
X-ray structure of AM2(25-46)-G34A with amantadine
14
 (PDB: 3C9J). b) Side view of 
solution NMR structure of AM2(18-60) with rimantadine
13
 (PDB: 2RLF). c) Top view 
(N to C terminal) of X-ray structure of AM2(25-46)-G34A with amantadine. d) Top view 
of solution NMR structure of AM2(18-60) with rimantadine. e) Sequences of 
transmembrane A/M2 domains used for structural determination. 
 
 
These two structures are similar in terms of both showing left handed four-helix bundles 
with the same pore lining residues. The differences are dramatic and summarized in table 
2.1. The striking difference, which has raised public debate, is where the drug binds. In 
the X-ray structure,
14
 the electron density inside the channel matches that of amantadine, 
and fits better with amino group pointing down toward the C-terminus. The amino head 
group is too far from other polar groups to form any specific interaction (hydrogen 
bonding, electrostatic, etc.).  But due to the low resolution of 3.5 Å, one cannot 
definitively assign the structure of amantadine. On the other hand, the solution NMR 
structure shows four rimantadines per A/M2 channel sitting in between the helices with 
the positively charge ammonium group forming electrostatic interaction  with D44 
residues.
13
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Table 2.1 | Comparison of X-ray and solution NMR structures of drug-bounded A/M2 TM 
 
 
X-ray structure 
(PDB code: 3C9J) 
Solution NMR structure 
(PDB code: 2RLF) 
Similarities 
Left-handed four helix bundle 
Pore lining residues are V27, A30, S31, G34, His37 and W41 
Differences 
Shorter sequence: BrF-AM2(25-46) G34A Longer sequence: AM2(18-60) 
Condition: pH 5.3 in octyl glucoside (OG) micelle 
2eq Amantadine 
Condition: pH 7.5 in 1,2-dihexanoyl-sn-
glycerophosphatidylcholine (DHPC) micelle 
213eq Rimantadine 
~35o tilt angle 
C-terminal wide open with W41 ~9.5 Å 
Helix crossing point: L26 
~23o tilt angle 
C-terminal closed with W41 ~1.4 Å 
Helix crossing point: I33 
Drug binding site: Amantadine inside the channel 
Binding stoichiometry:  1 drug per tetramer 
Drug binding site: Rimantadine at the interface of 
helices 
Binding stoichiometry:  4 drug per tetramer 
 
Neither of the two structures were determined in a viral membrane mimetic environment 
under physiological conditions;
16
 and both were solved in micelles. It has been well 
documented that detergents play an essential role in membrane protein solubilization and 
can modulate protein structure due to hydrophobic mismatch.
17
 So differences between 
these two structures were not unexpected. The question is which structure recaptures 
A/M2’s native conformation. Several aspects of the solution NMR structure seem to be 
the result of experimental artifacts. (1) Rimantadine, being an amphiphilic molecule, 
would strongly prefer locating at the interface of detergent/aqueous face.
18
 Moreover, the 
electrostatic interaction with D44 was found to be non-essential, since the D44A mutant 
remains amantadine sensitive and was fully inhibited by amantadine.
2
 A/M2 has also 
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been shown to accommodate inhibitors with a wide variety of bulky amine head groups, 
which argues against specific interaction between the inhibitor and the protein.
19, 20
 (2) 
The helices are nearly parallel to the membrane normal, which results in a tightly packed 
bundle pore that is too small to accommodate rimantadine. This contradicts the function 
of A/M2 as a proton selective channel, which has to undergo a conformational change. 
But the tight packing the helices might prevent the transition of cation-π interaction 
between protonated His37 and Trp41 indole ring.
21
 (3) The C-terminal amphiphilic helix 
aggregated into a bundle and partitioned into the aqueous phase. This is not consistent 
with the electron paramagnetic resonance (EPR)
22
 experiments which showed that the C-
terminal helix was membrane associated and nearly parallel to the membrane surface in 
lipid bilayers.  It is unclear whether it is the dynamics of M2 that result in the different 
orientations of the C-terminal helix. It is worth noting that the activities of penta-Ala 
A/M2 mutant (F47A, F8A, I51A, Y52A and F55A) in oocyte cells showed no difference 
from those of wt A/M2 in terms of surface expression level, proton conductance rate, and 
drug binding, 
3
 suggesting the C-terminal helix does not contribute to A/M2 function. So 
despite the lack of the C-terminal helix in the X-ray crystal structure construct (25-46), 
the TM domain alone is sufficient to form functional tetramer that is conducive to drug 
binding.
23
 Thus A/M2TM (22-46) is a valid model to study M2 structure and function.  
 
2.3 Identification of the pharmacologically relevant A/M2 drug binding site 
In order to definitely assign the drug binding site, the critical experiment is to detect the 
drug-protein intermolecular nuclear Overhauser effect (NOE) signals by NMR. In doing 
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that, we first need to identify experimental conditions that allow for reconstitution of 
A/M2 fragments into a native-like conformation. The longer sequences A/M2TMC (22-
62) and A/M2TMC (18-60) gave good dispersion and the correct number of accountable 
peaks in the 
1
H-
15
N HSQC spectra when reconstituted in LPPG
24
 and DHPC
13
 
respectively, indicating conformational homogeneity. However, under both conditions, 
A/M2TMC did not show or failed to be amenable to drug binding, indicating a non-
native like conformation. Thus, a broader detergent/lipid screening is needed to identify 
the right conditions for reconstituting A/M2TMC into a native-like structure. Instead, we 
focus on the TM helix of M2-A/M2 (22-46), previously shown to be necessary and 
sufficient for tetramerization, proton channel formation, and drug binding
3
. In chapter 3, 
in collaboration with Dr. Mei Hong in Iowa State University, we showed by solid-state 
NMR (ssNMR) spectroscopy that two amantadine- binding sites exist in A/M2TM in 
phospholipid bilayers using distance measurements between 
13
C-labeled A/M2TM (22-
46) and 
2
H-labeled amantadine (Amt).
1
 The high affinity site, occupied by a single 
amantadine, is located in the N-terminal channel lumen, surrounded by residues mutated 
in amantadine-resistant viruses, consistent with the X-ray structure.  The second, low-
affinity, site was observed on the C-terminal protein surface as shown in the solution 
NMR structure, but only when the drug reaches high concentrations in the bilayer. The 
tilt angle and dynamics of the drug are distinct in the two sites, as shown by 
2
HNMR.These results indicate that amantadine physically occludes the M2 channel and 
rules out the allosteric inhibition mechanism proposed based on the exterior drug binding 
site. A recent magic angle solid state NMR study investigated rimantadine binding to 
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A/M2 (18-60) in both 1-hexadecanoyl-2--(9Z-octadecenoyl)-sn-glycero-3-
phosphocholine (POPC) and 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) 
bilayers. The large chemical shift induced upon drug binding mapped across the entire 
transmembrane region indicating drug binding by conformational selection, instead of 
allosteric inhibition as proposed.
25
 
 
In chapter 4, the dynamics and orientation of amine-containing drugs in the pore of the 
A/M2TM was further investigated by solution NMR. The orientation of the polar amine 
inside the channel is important as it reveals the mechanism of drug inhibition, whether it 
physically occludes the channel or it perturbs of pKas of His37 by water mediated 
hydrogen bonding (Figure 2.2).  Using 
13
C-
2
H rotational-echo double-resonance NMR 
experiments (REDOR) of 
13
C-labeled A/M2TM (22-46) and methyl deuterated 
rimantadine, it was found that the polar amine pointed to the C-terminus of the channel, 
near Gly34, thus supporting the hypothesis that the drug forms hydrogen bonds with 
water molecules associated with His37. Drug titration of A/M2TM (22-46) in 
dodecylphosphatidylcholine (DPC) micelles monitored by 1D proton NMR revealed that 
drug bind in the pore at a stoichiometry of one drug per channel. Moreover, drug binding 
causes significant chemical shift perturbations of the protein, consistent with those 
observed for A/M2TM (22-46) and A/M2 (18-60) in phospholipid bilayers, but distinct 
from the A/M2(18-60) structure in 1,2-diheptanoyl-sn-glycero-3-phosphatidylcholine 
(DHPC) micelles. These data suggest that the structure of the cytoplasmic helix C-
terminal to the transmembrane domain adopts a non-native conformation in DHPC 
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micelles, which may have indirectly altered the conformational and drug binding 
properties of the protein.  
        a)                             b)                                  
 
Figure 2.2 | Docked conformations of amantadine inside the pore of A/M2TM tetramer 
with up or down amine orientations. A/M2TM structure was taken from the high 
resolution X-ray crystal structure. (PDB code: 3LBW). 
 
 
Additional evidence supporting a pore binding model includes drug binding 
stoichiometry measurements in different lipid/detergent compositions and sample 
preparation conditions. Trp41 fluorescence changes upon drug titration with full length 
M2 reconstituted in N,N-Dimethyldodecylamine N-oxide (LDAO) micelles revealed 1:1 
drug per A/M2 tetramer binding.
26
 Surface plasmon resonance (SPR)
27
 and isothermal 
titration calorimetry (ITC)
3
 measurements in liposomes, which are better mimics of the 
lipid bilayer viral environment, both showed one drug per tetramer binding 
stoichiometry.  The critical residue D44, as proposed in the allosteric binding mechanism, 
turned out to be not essential for A/M2 inhibition, as the D44A mutant was completely 
inhibited by amantadine in a dose dependent manner in two electrode voltage clamp 
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(TEV) assays.
4
 Taken together with our NMR distance measurement, we can conclud that 
amantadine inhibits A/M2 by binding inside the channel. 
 
2.4 Synthesis of A/M2 fragments for structural studies 
Throughout the course of structural studies of M2, tens to hundreds of milligram 
quantities of M2 peptides are needed. Solid phase synthesis of peptides and proteins has 
the advantage over biological expression in terms of large scale production and selective 
incorporation of isotopically labeled or unnatural amino acids in any desired position.
28
 
However, solid phase synthesis of peptides, especially hydrophobic membrane segments, 
often gives truncated products that are difficult to separate. The major problems of 
hydrophobic membrane peptide segments synthesis include aggregation of elongating 
peptide chains among themselves or with the resin matrix, incomplete deprotection, 
racemization and side reactions such as aspartimide formation (Figure 2.3). Initial trial 
synthesis of the M2 transmembrane domain (22-46) using the traditional Fmoc chemistry 
on rink amide resin at room temperature gave low crude yields (<30%), Yields slightly 
improved to 45% with double coupling at each step. Impurities, which eluted as shoulder 
peaks of the desired peptide, were difficult to separate and often required two or even 
three rounds of HPLC purification. The synthesis was optimized in several aspects: (1) 
Hydrophilic PEG based Chemmatrix rink amide resin or ester based Clear rink amide 
resin was chosen instead of the hydrophobic polystyrene based resin. This minimizes 
aggregation between growing peptide chains and the resin beads. (2) The synthesis (both 
coupling and deprotection) was performed at elevated temperature (75 
o
C) using either 
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microwave irradiation or conventional heating, both were equally effective.
29
 The 
synthesis was performed on a semi-automated Quest synthesizer with 5 mins of coupling 
and deprotection at 75 
o
C.  Up to 12 peptides can be synthesized in parallel. (3) 5% 
piperazine + 0.1 M HOBt instead of 20% piperidine was used to deprotect Fmoc group. 
This is to suppress a major side reaction of aspartimide formation
30, 31
 between Asp44 
and Arg45. Using optimized conditions described above, the crude purity of A/M2TM 
(22-46) was dramatically increased to ~85% with only single coupling and deprotection 
steps. No significant shoulder peaks were detected (Figure 2.4 a). One round of HPLC 
purification gave the final peptide at >98% purity. Subsequently, these conditions were 
used for synthesis of 41 residue long A/M2TMC (21-61) that includes both the 
transmemrbane domain and the C-terminal amphiphilic membrane interacting helix. The 
synthesis of this longer fragment was initially found to be challenging due to the 
complication of broad shoulder peaks. Subsequently, all three Arginines (Arg 45, 53 and 
61) and the residues immediately following (Asp 44, Tyr52 and Lys60) were double 
coupled, and this protocol gave A/M2TMC (21-61) with ~75% crude purity (Figure 2.4 
b).  
45 
 
 
Figure 2. 3 Mechanism of aspartimide side reactions. 
 
 
a) HPLC trace of crude A/M2TM (22-46) 
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b) HPLC trace of crude A/M2TMC (21-61) 
 
Figure 2.4 | HPLC traces of M2 peptide fragments synthesized using the optimized solid 
phase synthesis protocol. The peptide was cleaved from the resin using 95% TFA, 2.5% 
TIS, 2.5% H2O.  Crude peptides were dissolved in 50% B’ (59.9% isopropanol, 30% 
acetonitrile, 10% H2O, and 0.1% TFA) and 50% A (99.9% H2O, 0.1% TFA) and purified 
by preparative C4 reverse phase HPLC with a linear gradient of 70% B’ to 85% B’. 
A/M2TM and A/M2TMC eluted at 83% and 78% B’ respectively. Purity and identify of 
the peptide was confirmed by analytical HPLC and MALDI-MS. 
 
 
2.5 Structure-based design of A/M2 inhibitors 
A/M2 is a challenging drug target, partially due to the lack of structural  information until 
very recently.
13, 14, 32, 33
 More importantly, it is difficult to assay because the A/M2 proton 
conductance function can only be monitored in a lipid bilayer environment. The 
challenge to prepare large quantities of uniformly sized liposomes limits high throughput 
screening of small molecule libraries in vitro. Instead, researchers working on influenza 
antiviral development rely on virus induced cytopathic effect (CPE) assay,
34, 35
 which is 
not A/M2 target specific and makes the structure and activity relationship studies 
difficult. Nevertheless, there has been a substantial progress in developing in vitro A/M2 
target specific high throughput assay.
36
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Since most current circulating influenza viruses carry drug resistant mutations in the 
A/M2 transmembrane region (like S31N, V27A and L26F),
37, 38
 it is urgent to develop 
potent broad spectrum antivirals that are capable of targeting all influenza strains. There 
are two general approaches to identifying the initial hits: high throughput screening and 
structure-based rational design. High throughput screening with influenza A virus failed 
to identify hits that were active against A/M2 mutants,
34, 39-41
 despite the fact that several 
hits demonstrated inhibition against amantadine resistant viruses, but their action was 
distinct from A/M2 inhibition.
42
 In contrast, rational design based on an adamantane 
scaffold yielded a series of potent inhibitors with reduced cell toxicity. Whether these 
inhibitors are active against A/M2 mutants has yet to be determined.
19
 We started with 2-
[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-174), initially discovered through a high-
throughput screen based on the ability of inhibitors to reverse toxicity associated with M2 
channels expressed in the yeast Saccharomyces cerevisiae membranes.
39
 It is one of the 
few examples of nonadamantane-based M2 inhibitors reported in the literature. The spiro 
structure is unique, as the nearly perpendicular cyclohexane ring configuration fits the 
cylinder shape A/M2 channel better than planer molecules. In chapter 5, the first 
generation spiro amine compound library was synthesized and 3-azaspiro[5,5]undecane 
hydrochloride (M2WJ10) was found to be the one of the most potent wt A/M2 inhibitor 
so far (IC50 = 0.92 ± 0.11 μM)
43
 (Figure 2.5).  Structure and activity relationship (SAR) 
studies found that the simple amine is the favored head group, and hydrophobicity is 
critical for high affinity binding as active inhibitors all had LogP > 1.5. In chapter 6, 
further modifications to extend the piperidine in M2WJ10 to cyclohexane amine gave 
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spiro[5.5]undecan-3-aminium chloride (M2WJ34),
44
 which was active against the wt 
A/M2, but more importantly for the first time showed moderate inhibition against A/M2-
V27A mutant (IC50 = 84.9 ± 13.6 μM). Mutation of the bulky V27 to smaller alanine 
residue appears to create a larger binding pocket which favors binding a more extended 
molecule. Following this rational, in chapter 7, a series of ring expanded spiran amines 
were designed and synthesized, and all had improved potency against A/M2-V27A 
mutant compared with M2WJ34. A spiroadamantane inhibitor (M2WJ206) designed to 
occupy the extra space created by the V27A mutation was found to be highly potent 
against wt, V27A and L26F mutants, and this compound is currently undergoing tests in 
animals. In chapter 8, introducing silicon in the quaternary spiro center increases both the 
size and hydrophobicity of the inhibitor, and the silaspiran amines were indeed more 
potent than their carbon counterparts. Finally, guided by structural and activity 
relationship study results provided above, a library of scaffold and head group diverse 
compounds were selected and assayed in two electrode voltage clamp assay in chapter 9. 
The aim is to identify novel scaffolds and head groups that can be further optimized in 
order to target the S31N mutant. It has been found that not only amine, but also hydroxyl, 
aminooxyl, guanidine, amidine compounds are active against the A/M2 proton channel. 
Moreover, A/M2 proton channel is able to accommodate a wide range of structural 
variation in the apolar scaffold. 
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Figure 2.5 | Structures of spiran amines 
 
2.6 Perspective  
To aid rational drug design, we first need high-resolution A/M2 mutant structures, 
especially S31N. But due to the dynamic and conformational heterogeneity, neither NMR 
nor crystallization efforts to solve the A/M2-S31N structure have been so far successful. 
To identify the optimal detergents to stabilize the S31N mutant, we screened commonly 
used detergents using circular dichrorism (CD) and 
1
H-
15
N TROSY-HSQC assay. Initial 
results indicated that C14-betaine gave the best results, as judged by amide NH peak 
dispersion, number of peaks and intensity. With this optimized reconstitution condition, 
we are now pursuing to solve the A/M2TM-S31N structure by NMR. In terms of X-ray 
crystallization, since there is no available small molecule drug to stabilize the S31N 
tetramer, tethering the monomer together to form a covalent tetramer would presumably 
stabilize the complex. Moreover, in meso cubic phase crystallization is another option 
that has been successful in crystallizing a number of membrane proteins, such as 
bacteriorhodopsin, cobalamin transporter, light harvesting complex etc.
45
 High resolution 
structural information will not only clarify the drug resistant mechanism of the S31N 
mutant, but also will guide the inhibitor design. 
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3.1 Abstract 
The M2 protein of influenza A virus is a membrane-spanning tetrameric proton channel 
targeted by the antiviral drugs amantadine and rimantadine 
1
. Resistance to these drugs 
has compromised their effectiveness against many influenza strains, including pandemic 
H1N1. A recent crystal structure of M2(22-46) showed electron densities attributed to a 
single amantadine in the N-terminal half of the pore 
2
, suggesting a physical occlusion 
mechanism for inhibition. However, a solution NMR structure of M2(18-60) showed four 
rimantadines bound to the C-terminal lipid-facing surface of the helices 
3
, suggesting an 
allosteric mechanism. Here we show by solid-state NMR spectroscopy that two 
amantadine-binding sites exist in M2 in phospholipid bilayers. The high-affinity site, 
occupied by a single amantadine, is located in the N-terminal channel lumen, surrounded 
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by residues mutated in amantadine-resistant viruses. Quantification of the protein – 
amantadine distances resulted in a 0.3 Å-resolution structure of the high-affinity binding 
site. The second, low-affinity, site was observed on the C-terminal protein surface, but 
only when the drug reaches high concentrations in the bilayer. The orientation and 
dynamics of the drug are distinct in the two sites, as shown by 
2
H NMR. These results 
indicate that amantadine physically occludes the M2 channel, thus paving the way for 
developing new antiviral drugs against influenza viruses. The study demonstrates the 
ability of solid-state NMR to elucidate small-molecule interactions with membrane 
proteins and determine high-resolution structures of their complexes.  
 
3.2 Maintext 
The M2 protein of influenza A viruses is a modular, multifunctional protein that plays 
important roles in the acidification and uncoating of the endosome-entrapped virus and in 
viral assembly and budding 
1,4
. Its proton-conducting activity is mediated by a single 
transmembrane (TM) domain that forms a four-helix bundle, which acts as a pH-
activated proton channel. The TM domain alone is sufficient for tetramerization 
5,6
 and 
for amantadine-sensitive proton conductivity in vesicles and cell membranes 
7,8
.  
 
The recent low pH crystal structure of micelle-solubilized M2(22-46) shows a single 
molecule of amantadine (Amt) in the N-terminal pore lumen, consistent with the known 
stoichiometry of binding 
8
 and the location of resistant mutations, including Leu 26, Val 
27, Ala 30, Ser 31, and Gly 34 
9-11
. However, the low-pH state of the protein is only 
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transiently populated in acidifying endosomes, whereas the drug first binds with higher 
affinity to the protein near neutral pH 
9
. Thus, determining the structure of the drug-
complexed M2 protein at neutral pH is important for understanding its mechanism of 
inhibition. The solution NMR structure of micelle-solubilized M2(18-60) at pH 7.5 failed 
to show strong nuclear Overhauser effects (NOEs) between the drug and pore-lining 
residues, but it would have been difficult to observe NOEs between the fast-relaxing 
pore-lining residues and unlabeled rimantadine undergoing restricted motion in the pore. 
Weak NOEs were observed between residues on the protein surface and the drug, which, 
however, comprised 13% of the detergent in which the protein was dissolved (200-fold 
excess over protein tetramers). We thus turned to solid-state NMR (SSNMR), which 
allows for investigation of the dynamics and contacts of drug molecules bound at variable 
concentrations to membrane proteins in phospholipid bilayers, which are far better 
mimics of biological membranes than are micelles.  
 
Rotational-echo double-resonance (REDOR) NMR is a powerful method to measure sub-
nanometer inter-atomic distances with up to 0.1-Å accuracy 
12
. The M2 peptide (residues 
22-46), reconstituted into DMPC vesicles at pH 7.5 under fully tetrameric conditions 
6,13
, 
contained uniformly 
13
C-labeled residues whose 
13
C chemical shifts were assigned from 
2D correlation spectra (Supplementary Fig. 1). Amantadine was perdeuterated, thus 
enabling 
13
C{
2
H} REDOR distance measurements.  
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To select for the highest-affinity binding site, we first measured the REDOR spectra of 
Amt-complexed M2 at an Amt/peptide molar ratio (Amt/P) of 1:4 (one drug per 
tetramer). At this stoichiometric concentration, Amt binds only to the luminal site: Fig. 1a 
shows 
13
C{
2
H} REDOR spectra without (S0) and with (S) multiple 
2
H dephasing pulses 
14
. The Ser31 C signal is strongly dephased by the deuterons (

S S0  0.76 0.03 at 10.1 
ms), indicating that Amt binds near Ser 31. In contrast, the Asp44 C signal in the 
peripheral site is unaffected. A double-quantum-filtered REDOR experiment that 
removed all lipid signals confirmed the lack of Asp 44 dephasing (Supplementary Fig. 2). 
  
To search for additional, lower-affinity, binding sites, we increased the Amt 
concentration to 

Amt P  4 : 4 , making the drug 7% of the amphiphiles composing the 
bilayer, which approaches the large excess of drug in the solution NMR experiments. 
Now the Asp44 C signal is also dephased (

S S0  0.86 0.02 at 10.1 ms), but to a 
lesser extent than Ser31 C (Fig. 1b). Thus, when free amantadine is a major component 
of the membrane, Amt contacts the C-terminus of the protein as in the solution NMR 
structure, 
3
 but without displacing the drug in the luminal site. Consistently, Amt 
deuterons also dephased other residues in the luminal site, particularly Val27 C  and 
Gly34 C (Fig. 1c, d), but more weakly than Ser 31. This Ser 31-proximal binding is 
consistent with the large chemical shift perturbation of Ser 31 by Amt 
15
.  
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Figure 1| Drug-protein proximities from 
13
C{
2
H} REDOR spectra of Amt-bound M2 
in DMPC bilayers at two Amt/P ratios. Control (S0), dephased (S, red), and difference 
(S) spectra at specified mixing times are shown. a. Ser31, Ile32, Asp44-labeled (SID) 
M2 at the stoichiometric ratio of 

Amt P 1: 4 . b. SID-M2 at the 4-fold excess ratio of 

Amt P  4 : 4 . Ser31 C is dephased under both conditions but Asp44 C is dephased 
only when Amt is in excess. c-d. Leu26, Val27, Ala29, and Gly34-labeled (LVAG) M2 
at 

Amt P  4 : 4 . c. Gly34 C region. d. Val27 C1 region.  
 
2
H NMR provided exquisite details on the orientation and dynamics of amantadine, 
whose unique symmetry and rigidity simplify analysis. Amantadine is a rigid amphiphile 
with a polar amine and a hydrophobic adamantane centered around a 3-fold axis, 

ZM . 
Three axial C-D bonds are parallel to 

ZM  while twelve equatorial C-D bonds are at 70° 
or 110° (

PM ) from 

ZM  (Fig. 2d). Amantadine partitions strongly into protein-free 
DMPC vesicles and exhibit 
2
H quadrupolar splittings of 36 and 123 kHz with a 4:1 
intensity ratio at 243 K (Fig. 2a). These splittings indicate fast anisotropic rotation of the 
molecule around 

ZM , which scales the couplings from the rigid-limit value of 125 kHz 
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by 

3cos2PM 1  2 , giving 40 kHz for the twelve equatorial bonds and 125 kHz for 
the three axial bonds. Wobbling of the 

ZM  axis by ~6° likely accounts for the additional 
motional averaging. As the temperature increased to 303 K, the couplings decreased 
twofold (18 and 58 kHz) while maintaining the same 1:3 frequency ratio and 4:1 intensity 
ratio. The ±0.46 scaling factor indicates Amt rotates rapidly around the normal (

n ) of the 
liquid-crystalline bilayer in addition to its own axis, with 

ZM  tilted by 37˚ or 80˚ from 

n  
(Fig. 2e) 
16
.  
 
When a stoichiometric amount (

Amt P 1: 4) of protein is present, the Amt spectrum at 
243 K resembles the lipid-only spectrum, but the couplings remain unchanged from 243 
to 303 K across the membrane phase transition (Fig. 2b), indicating sequestration of the 
drug from the lipids. The constant scaling factor (0.93) compared to pure rotation around 

ZM  indicates that the first equivalent of Amt rotates rapidly around 

n  in a slightly tilted 
orientation (~13˚) between 

ZM  and 

n (Fig. 2d). An isotropic peak grows at high 
temperature, indicating a small fraction (~12% at 303 K) of Amt either near 54.7˚ from 
the membrane normal or undergoing large-angle tumbling in the channel. Finally, a weak 
18-kHz splitting is observed at 303 K that matches the lipid-only coupling at this 
temperature. The spectrum is consistent with a 9:1 combination of the 283 K M2-bound 
spectrum without the 18-kHz splitting and the 303 K lipid-bound spectrum, suggesting 
that 10% of the drug partitions into the bilayer at 303 K.   
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To confirm that the lumen-bound drug persists under drug excess and to probe for 
additional binding sites, we measured the 
2
H spectra under 4-fold excess Amt over the 
tetramer (corresponding to 12% of the lipid concentration). Fig. 2c shows that the 
spectroscopic signatures of the lumen-bound drug persists, but the 303 K spectrum is now 
the 1:3 combination of the stoichiometric spectrum (Fig. 2b) and the lipid-bound 
spectrum (Fig. 2a). No additional bound species was detected. Since the 4-fold symmetry 
of the channel requires four peripheral sites for each luminal site, the 9:1 intensity ratio of 
the 303 K stoichiometric spectrum suggests that Amt has at least a 40-fold greater affinity 
for the channel lumen than the peripheral site.  
 
Figure 2| 
2
H NMR spectra of d15-Amt in DMPC bilayers as a function of 
temperature and Amt/P. a. No M2. The calculated spectrum for 303 K reproduces the 
1:3 frequency ratio and 4:1 intensity ratio of the two splittings. b. 

Amt P 1: 4 . The sum 
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spectrum reproduces the 303 K spectrum by 1:9 combination of the lipid-bound 303 K 
spectrum and peptide-bound 283 K spectrum (not shown). c. 

Amt P  4 : 4 . The sum 
spectrum uses a 1:3 combination of the M2-bound spectrum (II) and lipid-bound 
spectrum (I). d. Amt orientation in the M2 channel. e. One of the two possible Amt 
orientations in the lipid bilayer.  
 
These 
2
H NMR and distance data indicate that M2 has a single high-affinity site for 
amantadine, located in the channel lumen centered at Ser 31. In this site, Amt is nearly 
aligned with the channel axis, but given sufficient thermal energy a small fraction of drug 
is also able to undergo nearly isotropic motion, as suggested by molecular dynamics 
simulations 
17,18
. Excess Amt adopts a significantly tilted orientation in the membrane, 
with or without the protein. The peripherally bound rimantadines in the solution NMR 
structure are tilted by 80˚ 3, precisely one of the two possible orientations found for the 
lipid-associated drug. Since the same peripheral site is detected here in the TM peptide, 
its existence is independent of the protein length or the membrane environment; it is the 
result of excess drugs in the micelles and lipid bilayers.  
 
To determine the sub-angstrom resolution structure of the high-affinity binding site, we 
quantified the M2-Amt distances using an alternative REDOR experiment containing 
multiple 
13
C pulses and one 
2
H pulse, thus minimizing 
2
H pulse imperfections and 
yielding REDOR intensities closely following the universal curve 
19
 (Supplementary Fig. 
3). The experiment yielded significantly faster REDOR dephasing (Fig. 3) while 
confirming the relative dephasing of different sites in Fig. 1.  
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Due to the 4-fold symmetry of the tetramer, we parameterized the REDOR simulations in 
terms of the distance R of each peptide carbon from the channel axis and the distance Z 
of each carbon plane from the Amt center (Fig. 3c). We considered the twelve deuterons 
in the two equatorial planes with rotational averaging and neglected the three axial 
deuterons due to poor inversion of their broad 
2
H spectra. A series of REDOR curves 
were calculated for R of 2.7–6.2 Å and various Z values for each R, capturing the 
geometry of previous M2 structural models, (Fig. 3d-f). The curves are quite sensitive to 
geometry. The Ser31 C pore radius is most tightly constrained, to 5.7–6.3 Å. Larger R 
would not give sufficient dephasing even when 

Z  0 while smaller R would shift the 
drug up or down the channel too much to comply with the observed intensities of Val27 
C1 and Gly34 C. The best-fit Z places Ser31 C in the middle of the two planes of 
deuterons.  
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Figure 3| M2-Amt distance quantification. a-b. 
13
C{
2
H} REDOR spectra of Amt-
bound M2 (

Amt P  4 : 4) obtained by the single-2H-pulse REDOR. a. SID-M2 at 4.2 
ms mixing. b. LVAG-M2 at 6.1 ms mixing. c-f. REDOR simulations. c. Definition of the 
pore radius R and height difference Z from the center of Amt. d. Ser31 C simulation. e. 
Val27 C1 simulation. f. Gly34 C simulation.  
 
We computed an ensemble of structures using these protein-drug distances and previous 
SSNMR constraints.  The structures cluster tightly with a heavy-atom root-mean-square 
deviation (RMSD) of 0.3 Å (Fig. 4). The four helices are kinked at Gly 34, with the 
helical axis tilted by 30˚ for the N-terminal segment and 19˚ for the C-terminal segment, 
consistent with 
15
N SSNMR orientational constraints 
20
. The narrowest points of the pore 
lie at the N-terminal Val 27 and C-terminal His 37/Trp 41, which are responsible for pH 
sensing and proton conduction 
21
. Amantadine fits snugly into the N-terminal lumen, 
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surrounded by residues whose mutation confers resistance 
9
. The surrounding backbone 
amides and Ser31 hydroxyl group engage in intra-helical hydrogen bonding, imparting a 
hydrophobic character to the site. The luminal binding indicates that M2 inhibition is by 
physical occlusion, interrupting water-wires and perturbing the protonation equilibrium 
of His37 
22
. The N-terminal location is consistent with the fact that Amt inhibits only 
when added to M2-expressing cells from the outward-facing N-terminal side 
9
. Moreover, 
the V27 vestibule is too small to permit drug dissociation without a 1–2 Å radial 
expansion, consistent with the very slow association and dissociation of the drug 
compared to a diffusion-controlled process 
9
. Finally, the drug is most likely oriented 
with the adamantane packed against the hydrophobic Val27 sidechains and the polar 
amine towards the cavity near His 37 residues, whose pKa’s are affected by Amt binding 
22
.  
 
Figure 4| SSNMR structure of Amt-bound M2 in lipid bilayers. a. Side view showing 
Ser 31, Val 27, Gly 34, His 37, Trp 41, and Amt in the high-affinity luminal site. Ser31 
C lies in the mid-plane between the two rings of deuterons. The instantaneous 
orientation of Amt, which is slightly tilted from the channel axis, is shown. The time-
averaged Amt orientation is parallel to the channel axis. b. Top view showing the Ser 31 
and Val 27 pore radii. This ribbon diagram was generated using the program Insight II.  
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The present SSNMR structure has significant differences from previous proposed 
structures of the Amt-M2 complex 
2,3
. While the drug location is very similar to that of 
the low-pH crystal structure, the shape of the binding site differs dramatically (3.4-Å C 
RMSD between the structures). In the crystal structure, the helices splay far apart near the 
C-terminus (Fig. 5b), to minimize electrostatic repulsions among the protonated His 37. 
In the high-pH SSNMR structure, the helices close off the bottom of the site, fully 
sequestering the drug and explaining the improved affinity at higher pH (Fig. 5a). The 
backbone of the SSNMR structure is more similar to the high-pH solution NMR 
structure, with comparable distances involving Val27 C, Ser31 C, and Gly34 C 
(Supplementary Fig. S5). Thus, the drug may have been present in the lumen in the 
solution NMR sample but not observable without isotopic labeling.  Alternatively it 
might have been truly absent from the lumen due to reduced affinity to the micelle-bound 
and structurally plastic protein 
23-25
. The current high-resolution structure also revises an 
earlier SSNMR chemical-shift-constrained M2 model, where the lack of protein-drug 
distances resulted in a large N-terminal vestibule, which would yield a highly solvent-
accessible low-affinity drug (Supplementary Fig. S6-S7).  
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Figure 5| Comparison of the high-pH SSNMR structure of Amt-bound M2 in lipid 
bilayers with the low-pH crystal structure of Amt-bound M2. a. Side view of the 
high-pH SSNMR structure, showing Amt to be enclosed by Val 27 at the top and His 37 
at the bottom. b. Side view of the low-pH crystal structure 
2
. The helices are splayed far 
apart near the C-terminus. c. C-terminal view of the high-pH structure, showing a well-
sequestered drug. d. C-terminal view of the low-pH structure, showing a more solvent-
accessible drug. The figure was generated using the program PyMOL.  
 
What is the significance of the peripheral site? Since it is occupied only at drug/lipid or 
drug/detergent ratios above 7 mol%, the protein-drug interactions at this site must be 
weak, and largely a consequence of the high local concentration and preference of the 
drug for the membrane-water interface 
16
.  The peripheral site may in some way be 
related to the partial inhibition of M2 by polyamines in the absence of sodium ions 
26
.  
Since amantadine undergoes significant motion in the N-terminal lumen, its structure 
appears to be not fully optimized to fit the M2 channel. Thus, other drugs may be 
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designed to access the most conserved regions of the pore and evade drug resistance. 
Indeed, a potent and structurally distinct class of inhibitors has been recently reported that 
binds the same site 
27
. Solid-state NMR spectroscopy, especially the multi-deuteron 
13
C-
2
H distance strategy, opens a new avenue for structure elucidation of drug-complexed 
membrane proteins in lipid bilayers, yielding distances with longer range and higher 
accuracy than NOE measurements in solution.  
 
3.3 Methods Summary 
The 
13
C-labeled wild-type Udorn M2(22-46) peptide was synthesized by solid-phase 
methods and reconstituted into DMPC bilayers at pH 7.5 by detergent dialysis 
25
, giving 
fully tetramerized protein in the liposomes 
6
. 
13
C{
2
H} REDOR experiments were 
conducted on a 9.4-Tesla wide-bore NMR spectrometer (Bruker Biospin) using a 4 mm 
1
H/
13
C/
2
H MAS probe. The distances were measured at 243 K, where the peptide was 
immobilized 
28
 while Amt was uniaxially mobile. Static 
2
H spectra were measured on a 
14.1-Tesla SSNMR spectrometer.  
 
An ensemble of 17 lowest-energy SSNMR structures was computed using 24 (6x4) long-
range 
13
C-
2
H distances, four inter-helical distances among Trp41 indole rings 
13
, 60 
(15x4) backbone amide orientational constraints 
20
, two sidechain rotamer constraints 
29
, 
and idealized covalent geometry. For comparison, the previous solution NMR M2 
structure ensemble was constrained by 12 inter-helical NOEs and 18 amide residual 
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dipolar couplings for the TM region 
3
. The structure ensemble has been deposited in the 
Protein Databank (ID: 2KQT) and the BMRB (ID: 16612).  
 
3.4 METHODS 
Sample preparation. The wild-type Udorn M2(22-46) sequence 
SSDPLVVAASIIGILHLILWILDRL was synthesized with 
13
C, 
15
N-labeled amino acids 
at Leu 26, Val 27, Ala 29 and Gly 34 in one sample (LVAG), and Ser 31, Ile 32, and Asp 
44 in another sample (SID). The peptide was reconstituted into DMPC vesicles by 
detergent dialysis using octyl--D-glucopyranoside. The peptide/lipid molar ratios were 
1:8 for all 
2
H NMR experiments and 1:8 or 1:15 for the REDOR experiments. A 
phosphate buffer (pH 7.5) was used for lipid vesicle preparation and throughout detergent 
dialysis. The dialyzed proteoliposome solutions were centrifuged at 150,000 g to obtain 
~40% hydrated membrane pellets. Amantadine was directly titrated into the membrane 
pellet to the desired amount.  
 
Solid-state NMR spectroscopy. A triple-resonance 
1
H/
13
C/
2
H magic-angle-spinning 
(MAS) probe was used for the 
13
C-
2
H REDOR experiments and a 
1
H/
13
C/
15
N probe was 
used for 2D correlation experiments for resonance assignment. The 
2
H pulse length in the 
REDOR experiments was 6.2 s, and 13C and 15N pulse lengths were 5-6 s.  
 
13
C-
2
H REDOR experiments were carried out at MAS frequencies of 4250 Hz or 4750 
Hz. A REDOR pulse sequence containing a single selective 
13
C pulse and multiple 
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composite 
2
H pulses was used to obtain clear qualitative dephasing at long mixing times, 
since the selective 
13
C pulse suppressed the 
13
C-
13
C scalar coupling and gave rise to long 
13
C T2 relaxation times. However, the use of multiple 
2
H pulses is known to slow down 
dipolar dephasing by the cumulative effects of imperfect inversion of the broad 
2
H 
quadrupolar spectra 
30
. Thus, a second version of REDOR experiment consisting of 
multiple 
13
C non-selective pulses and a single composite 
2
H pulse was carried out to 
obtain quantitative dephasing values at shorter mixing times. Distance quantification was 
possible because the multiple heteronuclear couplings commute and the uniaxial rotation 
of amantadine removes the effects of 
2
H-
2
H homonuclear couplings. Perdeuteration 
speeded up 
13
C-
2
H REDOR dephasing by ~

15 -fold compared to a single 
13
C-
2
H pair. 
The inversion efficiency of the deuterons in the single-
2
H-pulse REDOR experiment was 
70% based on measurements of the model compound 
13
C, 2H-labeled alanine 
(Supplementary Fig. 3).  
 
REDOR distance simulations. Using a motionally averaged model, we calculated 
REDOR curves for various published M2 models (Supplementary Fig. S4-6), with pore 
radii R of 2.7 – 6.2 Å. For each R, several REDOR curves with different Z values were 
calculated. The best-fit Z values for a specific R were compared with the carbon plane 
separations in the structural model. Plane separations that are inconsistent with the 
differences in Z values exclude the structural model. The Ser31 C pore radius is 
constrained by the M2-drug distances to be 5.7 – 6.3 Å. Once amantadine is confined 
within 1 Å vertical distance of the Ser31 C plane, the Val27 C1 and Gly34 C pore 
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radii are jointly constrained by the Val27 C1 – Gly34 C plane separation, which is 10.5 
± 1.0 Å in all M2 structures so far. We found that neither 

RV  nor 

RG  can exceed 6.0 Å, 
as it would lead to overly small plane separations.  
 
In the final refined SSNMR structure, Val27 C1 is fit by 

RV  3.8 Å  with 

ZV  5.3 Å , 
indicating that the Val27 C1 plane is 5.3 Å above the center of amantadine. Gly34 C is 
fit by 

RG  4.9 Å with a distance of 5.0 Å below the amantadine center.  
 
Structure calculation and refinement.  The process of generating a helix that is 
consistent with the protein-drug distances, backbone N-H orientational constraints, and 
sidechain rotameric conformations, was carried out in two phases. In the first phase, we 
constructed an ideal helix with the sequence SSDPLVVAASIIGILHLILWILDRL whose 
/ angles were set to (-65˚, -42˚). The helix was then split at the Gly34-Ile35 bond and 
reconnected using a rigid-body optimization procedure that maximized agreement with 
the SSNMR 
15
N-
1
H dipolar couplings 
20
 and the internal geometry at that bond. Rotamer 
preferences were taken from the high-resolution X-ray structure of M2 (PDB ID: 3BKD).  
25 In the second phase we refined our model to maximize agreement with the 
13
C-
2
H 
REDOR distances (Supplementary Table S2) and the backbone 
15
N-
1
H dipolar couplings 
(Supplementary Table S3). To do this, we combined an inverse kinematics algorithm 
with a Monte Carlo/Simulated Annealing (MC/SA) minimization procedure that would 
gradually relax the backbone of the helix subject to REDOR distance constraints and the 
N-H dipolar couplings. Rotamer preferences were also changed to maximize agreement 
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with the χ1 angle constraints (Supplementary Table S4).  The MC/SA minimization 
procedure was used to generate an ensemble with a maximum heavy-atom RMSD of 0.3 
Ǻ between any two models. Since the REDOR distances provided excellent constraints 
between the drug and M2, we positioned the amantadine molecule near Ser 31 without 
the need for further minimization. Fig. 5 was created using the PyMOL Molecular 
Graphics System.  
 
Supplementary information is linked to the online version of the paper at 
www.nature/com/nature.  
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(A) Chemical shift assignment of amantadine-bound M2 in DMPC bilayers.  
 
 
 
Supplementary Figure S1. 2D 
13
C-
13
C and 
15
N-
13
C correlation spectra of amantadine-
bound M2(22-46) in DMPC bilayers for chemical shift assignment. (a) 2D DARR 
spectrum of LVAG-M2 (L26, Val27, A29, and Gly34 labels) with 40 ms mixing. (b) 2D 
DARR spectrum of SID-M2 (S31, I32 and D44 labels) with 40 ms mixing. (c) 2D 
15
N-
13
C correlation spectrum of LVAG-M2. (d) 2D 
15
N-
13
C correlation spectrum of SID-M2. 
All spectra were measured at 243 K under 7 kHz MAS.  
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Supplementary Table S1. 
13
C and 
15
N isotropic chemical shifts of amantadine-bound 
M2(22-46) in DMPC bilayers. 
13
C chemical shifts are referenced to -Gly 13CO (176.4 
ppm) on the TMS scale and 
15
N chemical shifts are referenced to 
15
N-acetylvaline (122.0 
ppm) on the NH3 scale.  
 
Residue Site  (ppm) Residue Site  (ppm) 
L26 N 117.5 Ser31 N 120.8s, 114.1w 
 C’ 176.3  C’ 172.8 
 C 55.8  C 61.0 
 C 39.5  C 59.5 
 C 25.1 I32 N 122.8 
 C 24.2  C’ 175.6 
 C 21.2  C  64.0 
Val27 N 119.8  C  35.9 
 C’ 178.3s, 177.5w  C1 28.2 
 C 61.4s, 64.2w  C2 15.2 
 C 29.6  C  12.4 
 C 21.2 Gly34 N 110.2 
 C 19.3  C’ 175.1 
A29 N 121.6  C 44.9 
 C’ 177.0 D44 N 118.7 
 C 53.4  C’ 175.7 
 C 16.2  C  55.6 
    C  42.4 
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(B) Additional 
13
C-
2
H REDOR spectra, REDOR simulation details and model 
compound result 
 
 
 
 
Supplementary Figure S2. Double-quantum filtered 
13
C{
2
H} REDOR spectra of 
amantadine-bound M2 in DMPC bilayers. As shown before 
1
, the experiment 
incorporates a SPC5 dipolar recoupling sequence 
2
 before the REDOR period to generate 
13
C-
13
C double-quantum coherences, which suppress all natural abundance 
13
C signals of 
the lipids in the spectra. The experiments were carried out at 243 K under 4750 Hz MAS. 
(a) SID-M2 spectra at Amt/P = 1:4, corresponding to a stoichiometric amount of Amt per 
channel. The D44 C signal shows no dephasing. (b) SID-M2 spectra at Amt/P = 4:4, 
corresponding to 4-fold excess Amt to channel. D44 C is now dephased to a small 
extent, indicating that the excess amantadine binds to the C-terminus near D44.  Ser31 
C is dephased significantly at both amantadine concentrations, thus it is the high-
affinity binding site.  
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13
C-
2
H REDOR simulations.  The dephasing of a 
13
C spin in the peptide by the 
recoupled dipolar fields of 12 equatorial deuterons on the amantadine molecule was 
simulated in detail by considering the uniaxial rotation of amantadine. The coupling of 
13
C to 15 deuterons increases the second moment (i.e. the sum of the squares) of the 
13
C-
2
H dipolar couplings 15-fold compared to a single 
13
C-
2
H spin pair, thus speeding up the 
dephasing by a factor of 

15  3.9 .  
 
The three axial deuterons have a three times wider spectrum, which makes their inversion 
significantly incomplete under the 
2H 90˚ pulse length of 6.2 s. Thus, they were 
neglected in the simulations.  
 
The inversion efficiency of the 12 deuterons was about 70%, as determined by 
measurements on Ala-CD3 (Supplementary Figure S3), which has a very similar 
motionally narrowed 
2
H spectrum to amantadine.  
 
The geometry of the 12 equatorial amantadine deuterons is as follows. Six deuterons are 
located on one ring of 2.20 Å radius centered on the C-N bond axis. The other six 
deuterons lie on two rings of 2.48 Å radius that are so close (separated by only 0.37 Å) 
that they were combined into one ring. The planes of the two rings are separated by 2.10 
Å along the C-N axis.   
 
The orientation-dependent 
13
C-
2
H REDOR frequency (

CD) under MAS is   
 
  

CD ,,r  CD r 
2

 sin2sin , (1) 
 
where  is the polar angle between the C-D vector and the rotor axis and  is the 
azimuthal angle of the internuclear vector around the rotor axis. The coupling constant 

CD  depends on the 
13
C-
2
H distance 

r  according to:  
 
  

CD r  2
0
4
CD
r3
 2 9.3 kHz 
1
r 1 Å 
3
 (2) 
 
The 

CD values were calculated for ,  and r values that correspond to various locations 
of the deuterons on each ring, which are sampled at 10˚ steps around the channel axis. 
Since each ring undergoes uniaxial rotation, the REDOR frequencies were then averaged 
to give 

CD.  
 
For 
13
C coupled to an I = 1 spin of a deuteron, the 2I + 1 = 3 allowed values of the z-
component of the deuterium spin angular momentum result in three equally spaced 
spectral lines of equal intensity, at 0 and ± 

CD, for each orientation of the C-D vector. 
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Thus, the single spin-pair 
13
C-
2
H REDOR time signal after N rotor periods, 

tr , for one 
channel orientation is:  
 
  

S S0 single spin pair  1 2cos CDNtr   3.  (3) 
 
For M deuterons, the REDOR time signal is the product of the single-spin-pair signals,  
 
  

S S0 M spin pairs
1
3M
m1
M 1 2cos CD,mNtr  . (4) 
 
Due to the fast rotation of the amantadine molecule around the C-N axis, all six deuterons 
on each ring have the same motionally averaged 
13
C-
2
H dipolar coupling. Thus, the 
motionally averaged REDOR frequencies for each ring, 

CD
A  and 

CD
B , are multiplied to 
give the total REDOR signal experienced by each peptide 
13
C:  
 
  

S S0 12 amantadine deuterons 
1
312
12cos CD
A Ntr 


6
 12cos CD
B Ntr 


6
 (5) 
 
This REDOR signal is finally powder averaged for all channel orientations relative to the 
rotor axis. Powder averaging was performed in a molecule- (peptide-) fixed frame, by 
sweeping the rotor-axis orientation over the surface of a unit sphere and by rotation 
around the rotor axis, each in 10˚ steps.  
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Supplementary Figure S3. 
13
C-
2
H REDOR data of 
13
C, 3,3,3-2Hlabeled alanine for 
determining the amplitude scaling of the single-
2
H-pulse REDOR experiment.  
 
(a) The REDOR pulse sequence contains a single 
2
H composite  pulse (90˚90˚90˚) of 
18.6 s in the middle of the mixing period, and multiple 13C  pulses of 10 s spaced half 
a rotor period apart. The phase cycles are: 1= +x +x +y +y –x –x –y –y; 2 = 1, 1 +90˚, 
1 +180˚, 1 +270˚; 3= R, R+90˚, R+180˚, R+270˚, where R is a 32-step cycle of (1 
+90˚, 1 +180˚, 1 +270˚, 1); The receiver phase 4= Q, Q, Q, Q, -Q, -Q, -Q, -Q, where 
Q = +x –x +y –y –x +x –y +y.  
 
(b) Representative REDOR control (S0) and dephased (S) spectra of 
13
C, 3,3,3-2H 
labeled alanine diluted in unlabeled alanine at a 1:9 ratio. The spectra were measured at a 
MAS frequency of 4.250 kHz. The C signal experiences significant dephasing to the 
three intramolecular methyl deuterons, whereas the C signal mostly (90%) results from 
2
H-unlabeled alanine without any significant dephasing.  
 
(c) REDOR S/S0 values (circles) and simulations (solid lines). Black line is the 
SIMPSON simulation 
3
 for an ideal -function 2H pulse, which completely inverts the 2H 
quadrupolar spectra. The motionally averaged 
13
C - 2H dipolar coupling is 364 Hz for 
each of the three 
13
C-2H spin pairs based on the crystal structure C–H distance of 
2.04 Å 
4
. The simulation curves have been corrected for the natural abundance 
13
C 
intensity. The time point for the first REDOR minimum from the simulation is very 
similar to that of the experimental data, verifying that this single 
2
H-pulse REDOR 
experiment does not slow down dipolar evolution 
5
. The effects of incomplete inversion 
of the 
2
H spectrum and the imperfection of the 
2
H pulse is manifested as a 70% scaling of 
the theoretical maximum dephasing to the measured dephasing. This scaling factor is 
used for all simulated M2-amantadine REDOR time signals.  
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(C) REDOR simulations for various M2 structural models  
 
 
 
Supplementary Figure S4. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H} 
REDOR data using the pore sizes of the low-pH crystal structure of amantadine-bound 
M2(22-46) (PDB code: 3C9J) 
6
. Val27 C1 has a best-fit ZV of –6 Å while the Gly34 C 
best-fit ZG is 3.5 Å. Ser31 C has a best-fit Z of 2 Å or –2 Å. Either ZS value agrees only 
marginally with the Val27 C1 – Ser31 C plane separation (4.8 Å) and the Ser31 C - 
Gly34 C plane separation (4.6 Å) in the model. Thus, the low-pH structure of Amt-
bound M2 in detergent is different, as expected, from the high-pH SSNMR structure of 
bound M2 in lipid bilayers.  
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Supplementary Figure S5. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H} 
REDOR data using the pore sizes of the solution NMR structure of DHPC micelle-bound 
M2(18-60) (PDB code: 2RLF) 
7
. The two Val27 C carbons have similar R values in this 
structural model. The 19.5-ppm Val27 C signal in the REDOR spectra has been recently 
stereospecifically assigned to C1 8. To be complete, the pore radii of both C1 and C2 
in the solution NMR structure were used in the REDOR simulations. For the C2 radius 
of 3.6 Å, the best-fit ZV of -5.7 Å ± 0.5 Å combined with the Gly 34 best-fit ZG of 5.0 ± 
0.5 Å gives a Val27 C2-Gly34 C height difference of 10.7 Å, which is inconsistent 
with the C2-C plane separation of 12.2 Å in the structure model. If Val27 C1 is 
considered, then its best-fit ZV of  -5.5 Å indicates a height difference of 10.5 Å from 
Gly34 C, which agrees well with the Val27 C1 – Gly34 C plane separation of 10.7 Å 
in the structure. However, the Ser31 C best-fit ZS of either 1 Å or -1 Å does not agree 
well with the height of the Ser31 C in the structure model, which is equidistant between 
Val27 C1 and Gly34 C. Thus, the solution NMR structure is not fully consistent with 
the M2-Amt distances.  
 84 
 
  
 
Supplementary Figure S6. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H} 
REDOR data using the pore sizes of the DLPC bilayer-bound M2(22-46) structure (PDB 
code: 2KAD) obtained from SSNMR 
9
. The best-fit ZV, using the Val27 C1 pore radius 
of 6.2 Å in the structure, is -3.5 Å. The best-fit ZG for Gly34 C is 4.5 ± 0.5 Å. The 
resulting Val27-Gly34 height difference of 8.0 Å is significantly smaller than the 9.5 Å 
plane separation in the model. Thus, this model is not consistent with the M2-amantadine 
distance results.  
 
The DMPC-bound M2(22-46) structure model (PDB: 1NYJ) obtained from oriented-
sample SSNMR experiments 
10
 is similar to the 2KAD model. Thus it is also not 
compatible with the REDOR distance constraints. In the 1NYJ model, the Val27 C1 
pore radius is even larger (7.3 Å), which would result in an even shorter ZV.  
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Supplementary Figure S7. Comparison of SSNMR structures of M2 in lipid bilayers 
determined with and without protein-amantadine distances.  a. Current structure 
restrained by protein-drug distances (PDB: 2KQT). The side view shows the closest 
contact between amantadine and Ser 31 (magenta). The N-terminal top view shows that 
the drug is tightly enclosed in the protein. b. Structural model restrained by 
13
C, 
15
N 
chemical shifts and three inter-helical distances but no protein-drug distances (PDB: 
2KAD). The drug location in the picture is hypothetical 
9
. The N-terminal view shows a 
more solvent-accessible binding pocket. The ribbon diagrams were generated using 
Insight II and the space-filling models were generated using PyMOL.  
 
 
 
 
 
 
 
 
 
 
 86 
 
Supplementary Table S2.  
13
C-
2
H M2-Amt distances from REDOR measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Planes  Plane separations (Å)  Uncertainty  
V27 C1 – S31 C  5.3 Å  ± 0.5 Å  
S31 C - G34 C  5.0 Å  ± 0.5 Å  
V27 C1 – G34 C  10.3 Å  ± 1.0 Å  
Carbons  Pore radius (Å)  Uncertainty  
V27 C1  3.8 Å  ± 0.5 Å  
S31 C  5.9 Å  -0.2 Å, + 0.4 Å  
G34 C  4.9 Å  ± 0.5 Å  
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(D) Computation procedure for the SSNMR structure ensemble of amantadine-
bound M2 in lipid bilayers 
 
An ideal helix with the sequence SSDPLVVAASIIGILHLILWILDRL was constructed 
using standard internal geometry and by setting the () values to (-65˚, -42˚). Side 
chain rotamer conformations were taken from the high-resolution M2 crystal structure 
(PDB ID: 3BKD). The ideal helix was then split at the Gly34-Ile35 amide bond to 
generate two separate helices. Each helix fragment was then transformed to the global 
frame of reference such that the helical axes were coincident with the global Z axis. The 
Gly34-Ile35 bond was then rebuilt using a rigid-body optimization procedure composed 
of a harmonic potential to optimize the internal geometry between Gly34-Ile35, and a 
harmonic potential to optimize the fit to the 
15
N-
1
H dipolar couplings from SSNMR 
11
.  
To simplify coordinate transformation, Gly34 C was set as at the origin. The rigid-body 
optimization procedure resulted in a helix that agreed with the N-H bond orientations to 
within ±10˚ of the previous SSNMR results.  
 
To maximize agreement with the 
15
N orientational constraints further, an inverse 
kinematics algorithm (IKA) was used to gradually relax the backbone 
12
. To reduce large-
scale movements between the N-terminal and C-terminal segments of the helix, the 
wriggling algorithm was used to construct a set of suitably local dihedral-angle moves 
along the protein chain without distorting the internal bond lengths and bond angles. The 
stochastic nature of this algorithm allowed us to easily integrate in a Monte 
Carlo/simulated annealing (MC/SA) minimization strategy. Thus, small random 
perturbations to the () angles (up to ±1º) were introduced along the backbone of the 
helix subject to the following potential: 
 
 
 
       
2 2 2 2
0 0 0 0 12 6
dipolarradial dihedral dist nonb
I i II i III i IV i
i i i i i i j
A B
V C r r C C C d d
R R
   

 
              
 
    
 
 
The temperature was initially set to 10
6
 K and decreased by 10% every 100 steps until a 
temperature of 25 K was reached.  The constants (CI-CIV) were obtained through a trial-
and-error process.  Some side chain rotamers were changed to maximize agreement with 
the radial distances (Supplementary Table 2). An ensemble of models was obtained by 
selecting the top scoring model after one round of MC/SA minimization and refining 
again with the IKA.  The constant CIII was set to 50 kcal/mol-radian
2
.  Since the radial 
distance provided excellent restraints between the drug and M2, we were able to position 
the amantadine molecule near S31 without the need for further minimization.  
 
A brief description for each of the terms in the above potential energy function is 
provided below: 
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1) Radial potential—used to improve the fit between the distance belonging to atoms in 
Supplementary Table S2 and the channel axis (i.e., the global Z axis).  The constant CI 
was set to 1000 kcal/mol-Ǻ2.   
2) Dipolar angle potential—used to improve the fit with the 15N dipolar coupling data 
measured by SSNMR (PDB ID: 2H95) (Supplementary Table S3) 
11. The angle θ is 
measured between the channel axis and the bond vector formed between the amide 
backbone nitrogen and the corresponding amide hydrogen. The constant CII was set to 
1000 kcal/mol-radians
2
. 
 
3) Dihedral potential—used to maintain the helical geometry by forcing the dihedral 
angles to stay in an acceptable region of Ramachandran space.  The constant CIII was set 
to 100 kcal/mol-radians
2
.  The starting dihedral angle value was set as the target value. 
 
4) Distance potential—used to maintain the helical geometry by forcing the hydrogen 
bond distances between the backbone of the i
th
 carbonyl-oxygen and i+4
th
 nitrogen to 
remain close to the starting value.  This potential was also used to restrain the Trp41 
distance in Supplementary Table S4. The constant CIV was set to 100 kcal/mol-Ǻ
2
.  
 
5) Lennard-Jones potential—the parameters for this potential were taken directly from 
the CHARMM22 force field parameter file in XPLOR-NIH 
13
.  Interactions between the 
i
th
 and i+4
th
 bonded neighbor interactions were not considered and non-bonded cutoffs 
were not utilized.  After each pass of the local sampling algorithm, a C4 operation about 
the channel axis was performed to generate the four equivalent chains before calculating 
the energy. 
 
 
Supplementary Table S3. N-H vector angles with respect to the channel axis used to 
constrain the current structure. The angles are based on 
15
N SSNMR data of M2 in 
DMPC bilayers at high pH with amantadine bound (PDB: 2H95) 
11
.  
 
Residue Angle (º) Residue Angle (º) 
V27 17.2 H37 NA 
V28 40.1 L38 12.0 
A29 43.5 I39 31.5 
A30 29.8 L40 32.7 
S31 26.4 W41 9.74 
I32 44.1 I42 15.5 
I33 36.1 L43 43.0 
G34 15.5 D44 17.2 
I35 31.5 R45 40.1 
L36 32.1 L46 43.5 
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Supplementary Table S4. Additional restraints for M2 structure calculation.  
 
Residue    angles Uncertainty  
V27  +158˚ or –158˚ ±4˚ 
V28  +158˚ or –158˚ ±4˚ 
 Residue Diagonal distance  Uncertainty 
W41 5-
19
F (Hz3)  16.5 Å ±0.8 Å 
 
 
(E) Synthesis of perdeuterated amantadine  
All chemicals were purchased from commercial vendors and used without further 
purification unless otherwise noted. 1-adamantane-d15-carboxylic acid was purchased 
from C/D/N isotopes Inc. 
13
C NMR spectra were recorded on a DMX-360 NMR 
spectrometer. Chemical shifts are reported in parts per million (ppm) and referenced to 
the residual solvent (CD3OD) signal at 49.15 ppm. The following abbreviations were 
used in reporting the NMR spectra: s: singlet, p: pentet. 
 
All reactions were carried out under a N2 atmosphere unless otherwise stated. HPLC 
grade solvents were used for all reactions. Column chromatography was performed using 
silica gel (230-400 mesh). Low-resolution mass spectra were obtained using an ESI 
technique on 3200 Q Trap LC/MS/MS system (Applied Biosystem).  
 
 
 
Scheme 1: 1-aminoadamantane-d15-hydrochloride 
14
.  
 
Diphenylphosphorylazide (DPPA) (1.29 ml, 6 mmol) and triethylamine (0.84ml, 6mmol) 
were added to a solution of 1-adamantane-d15-carboxylic acid (0.98 g, 5 mmol) in 10 ml 
CH2Cl2 at ambient temperature. The reaction was stirred for 2 hours. An additional 10 ml 
CH2Cl2 and 10 ml H2O were added to the reaction mixture, the organic layer was 
separated and washed sequentially with H2O, saturated NaHCO3 and brine and dried over 
MgSO4. Solvent was removed by rotary evaporation and t-BuOH (50 ml) was added. The 
solution was heated to reflux under N2 atmosphere for 5 hours. Excess t-BuOH was 
removed in vacuo and the residue was treated with 50% TFA/CH2Cl2 at ambient 
temperature for 2 hours. N2 was purged through the mixture to remove excess TFA and 
CH2Cl2 to give yellow oil. 4M HCl in dioxane (3 ml) was added and the mixture was 
added dropwise to cold diethyl ether. A white solid was collected by centrifugation and 
subsequent decanting of the ether supernatant. Further flash column chromatography 
purification gave 1-aminoadamanta-d15-hydrochloride as a white power (0.83g, Yield: 
82%). 
13
C NMR (90 MHz, CD3OD) gave signals at 52.62 ppm (s), 40.51 ppm (p, J = 
 90 
 
18.9 Hz), 35.11 ppm (p, J = 20.7 Hz), and 29.47 ppm (t, J = 21.6 Hz). The calculated 
mass for C10H2ND15 (M + H)
+
 is 167.3, and the measured value by ESI-MS was 167.2. 
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(F) Complete set of 
2
H spectra of perdeuterated amantadine in lipid bilayers. 
 
 
 
Supplementary Figure S8. Variable-temperature 
2
H spectra of perdeuterated 
amantadine in DMPC bilayers. a. Without any M2. b. With M2 at 

Amt P 1: 4 . c. With 
M2 at 

Amt P  4 : 4 . The spectra were measured from 243 K to 313 K.  
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4.1 Abstract  
The transmembrane domain of the influenza M2 protein (M2TM) forms a tetrameric 
proton channel important for the virus lifecycle. The proton-channel activity is inhibited 
by amine-containing adamantyl drugs amantadine and rimantadine, which have been 
shown to bind specifically to the pore of M2TM near Ser31. However, whether the polar 
amine points to the N- or C-terminus of the channel has not been determined so far.  
Elucidating the polar group direction will shed light on the mechanism by which drug 
binding inhibits this proton channel and will facilitate rational design of new inhibitors.  
In this study, we determine the polar amine direction using M2TM reconstituted in lipid 
bilayers as well as DPC micelles. 
13
C-
2
H rotational-echo double-resonance NMR 
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experiments of 
13
C-labeled M2TM and methyl-deuterated rimantadine in lipid bilayers 
showed that the polar amine pointed to the C-terminus of the channel, with the methyl 
group close to Gly34. Solution NMR experiments of M2TM in dodecylphosphocholine 
(DPC) micelles indicate that drug binding causes significant chemical shift perturbations 
of the protein that are very similar to those seen for M2TM and M2(18-60) bound to lipid 
bilayers.  Specific 
2
H-labeling of the drugs permitted the assignment of drug-protein 
cross peaks, which indicate that amantadine and rimantadine bind to the pore in the same 
fashion as for bilayer-bound M2TM. These results strongly suggest that adamantyl 
inhibition of M2TM is achieved not only by direct physical occlusion of the pore but also 
by perturbing the equilibrium constant of the proton-sensing residue His37. The 
reproduction of the pharmacologically relevant specific pore-binding site in DPC 
micelles, which was not possible with another detergent, DHPC, underscores the 
significant influence of the detergent environment on the functional structure of 
membrane proteins.  
 
4.2 Introduction 
The M2 protein of the influenza A virus is a membrane-spanning tetrameric proton 
channel responsible for a number of functions, including the acidification of the virion 
with concomitant uncoating of the viral RNA,
1,2
 inhibition of autophagosome-lysosome 
fusion,
3
 filamentous virus formation and viral membrane budding/scission.
4-6
 This 
essential protein is the target of the adamantane class of anti-influenza drugs, amantadine 
(Amt) and rimantadine (Rmt). M2 has a modular structure
7
 containing: 1) a short N-
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terminal region that is important for the protein’s incorporation into the virion;8 2) a 
transmembrane (TM) helix required for tetramerization, drug-binding and proton channel 
formation;
7
 3) an amphiphilic cytoplasmic helix important for filamentous virion 
formation, budding and ESCRT-independent vesicle membrane scission;
4-6
 and 4) a C-
terminal tail that interacts with the matrix protein, M1.
9
  
 
Mutagenesis and electrophysiological measurements of full-length M2 in oocytes showed 
that drug-resistant mutations occur at pore-lining residues (Leu26, Val27, Ala30, Ser31, 
Gly34) of the N-terminal portion of the TM helix.
10-13
 These residues line the Amt-
binding site, as seen in the crystal structure of Amt-bound M2TM.
14
 Solid-state NMR 
(SSNMR) distance measurements between 
13
C-labeled M2TM and 
2
H-labeled Amt in 
lipid bilayers
15
 showed Amt bound to this site when the drug was present at a 
stoichiometric concentration relative to the number of tetramers. However, when Amt 
was in excess to the channels and formed a significant fraction of the lipid bilayer (>5 
mol% of the phospholipids), it also showed dipolar interactions with Asp44 on the 
surface of the four-helix bundle.
15
 This peripheral interaction had previously been seen in 
the solution NMR structure of M2(18-60) in mixed micelles consisting of 7.5 : 1 
DHPC/Rmt, which was equivalent to a 200-fold excess of drug relative to tetramers.
16
 
The pharmacological relevance of the two sites was addressed by a series of 
electrophysiological studies
10-12
 that assessed the drug sensitivities of reverse-engineered 
viruses in which either the peripheral site or the pore site was mutated.  These studies and 
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other functional assays
17
 supported the high-affinity binding site within the pore to be the 
pharmacologically relevant binding site.  
 
There are several possible mechanisms of M2 inhibition by Amt and Rmt in the pore. 
First, the location of the drug physically occludes the pore, as in the classical mechanism 
of channel blockers. Second, the M2 transmembrane domain is structurally plastic, 
switching between multiple conformational states during proton conduction as well as 
triggered by other environmental factors.
14,18-23
 Any drug that locks the protein into a 
single form will inhibit the structural transitions required for conduction, particularly if 
the drug-stabilized conformational state is a non-conducting resting state. Indeed, 
channel-blockers have been known to be able to act in part via conformational 
selection,
24,25
 Finally, drug-binding was observed to strongly perturb the acid dissociation 
constants (pKa’s) of the proton-sensing His37 residues,26,27 through a mechanism that has 
not yet been fully understood.  
 
To elucidate the mechanism with which Amt and Rmt perturb the His37 pKa, it is 
important to determine the direction of the polar moiety of these drugs. Both Amt and 
Rmt contain a hydrophobic adamantyl cage connected to a polar moiety, which is an 
amine in Amt and ethylamine in Rmt. Perturbation of the His37 pKa can be understood if 
the polar group points down toward the C-terminus of the channel rather than up toward 
the N-terminus.
28
 However, the amine direction of these drugs has not been directly 
determined. In a number of computational studies, energetically reasonable solutions with 
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the amine either up or down were both found, furthermore the amine direction varied 
with pH and mutation of the pore-lining residues.
29-34
 Experimental efforts to determine 
the amine direction are also inconclusive: the crystal structure of the Amt-bound M2TM 
did not have sufficient resolution (3.5 Å) to unambiguously define the amine direction, 
although the C-terminus-facing direction was favored.
14
 The recent high-resolution 
SSNMR study based on cage-perdeuterated Amt (d15-Amt) did not probe the amine 
direction.
15
 Therefore, the polar group direction of the adamantyl drugs in the pore 
remains an open question; its elucidation will be important for the design of second-
generation compounds against drug-resistant variants of M2.  
 
The purpose of this study is two fold. First, we determine the polar group direction of the 
adamantyl drugs in the pore using solid-state NMR 
13
C-
2
H dipolar coupling 
measurements in lipid bilayers. We use methyl-deuterated Rmt as the probe for the amine 
direction of the drugs in the pore, and 
2
H quadrupolar spectra of cage-perdeuterated Rmt 
(d15-Rmt) to determine the tilt angle of Rmt in the pore as well as in the lipid bilayer. 
Second, these solid-state NMR measurements were complemented by isotope-edited 
solution NMR experiments that show that M2TM exhibits the same specific drug-binding 
site in DPC micelles as in lipid bilayers. The parallel solution and solid-state NMR 
experiments were motivated by the fact that the previous solution NMR study of M2(18-
60) in DHPC micelles
16
 did not observe a pore-bound drug. By comparing the NMR 
spectra of M2TM in micelles and in native-like lipid bilayers, we wish to address whether 
detergent micelles in general perturb the pore binding site,
35
 or whether it is the specific 
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combination of the longer M2 construct with the DHPC micelle in the previous solution 
NMR study
16
 that abolished the pore binding site. The choice of the TM constructs for 
this study, rather than the longer construct containing both the TM helix and the 
cytoplasmic helix, is based on the increasing body of evidence that the cytoplasmic helix 
is not required for Amt-sensitive proton channel activities. First, electrophysiological 
measurements of M2TM in oocytes
7
 with careful quantification of the surface expression 
level of the peptide showed that the single-channel conductivity of M2TM is within a 
factor of two of that of the full length protein, which revised the conclusions of an earlier 
study.
36
 Several liposome assays also showed that M2TM conductance was 50-100% that 
of the full-length protein or the cytoplasmic-helix-containing construct.
7,37
 Second, 
numerous biophysical studies showed that M2TM was both necessary and sufficient for 
tetramerization in detergent micelles,
14,38
 and the thermodynamics of 
tetramerization
7,20,39-45
 reproduces the unusual pKa of the essential His37 in the full-
length protein.
7,27
 Third, a large number of low-resolution biophysical studies, including 
fluorescence,
41
 isothermal titration calorimetry,
7
 and surface plasmon resonance
46
 
demonstrated that M2TM is capable of binding adamantyl drugs, and drug binding 
inhibits proton translocation through M2TM channels in vesicles.
7,27
 
 
Instead of mediating proton conductance, the latest reports make it now clear that the 
cytoplasmic helix mediates budding and release of the virus from infected cells.
4-6
 
Simultaneous mutation of five hydrophobic residues (F47, F48, I51, Y52, and F55) in 
this helix gave rise to viruses that are defective in budding but fully capable of proton 
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conductance as the wild-type protein.
5
 Site-directed spin-labeling EPR
47
 and oriented 
solid-state NMR data
48
 showed that the cytoplasmic helix is oriented parallel to and 
packed closely with the plane of the bilayer, stabilized by hydrophobic interactions 
between residues on one face of the cytoplasmic helix and the lipid bilayer. These 
findings revise the separate water-soluble helical bundle structure reported earlier by 
solution NMR.
16
  
 
4.3 Materials and Methods 
The M2 transmembrane domain spans roughly from residue 22 to residue 46. We used 
two slightly different M2TM constructs in this study: M2TM(22-46) by chemical 
synthesis and M2TM(19-49) by recombinant expression.  
 
Optimized synthesis procedure for M2TM(22-46) 
Due to the requirements for a large number of isotopically labeled peptides and the 
hydrophobic nature of M2TM, we developed an optimized procedure that delivered crude 
peptide with >80% purity of the desired peptides based on HPLC peak integration. 
Problems encountered in obtaining high-yields and purity included aspartamide 
formation at residue 44 and slow coupling near the center of the chain. M2TM(22-46) 
with uniformly 
13
C, 
15
N-labeled V27, A30 and G34 (VAG-M2TM) was synthesized 
using Fmoc chemistry at elevated temperature (75˚C for both coupling and deprotection) 
in a semi-automated Quest synthesizer using Rink Amide Chemmatrix resin (Matrix 
Innovation Inc, Canada). Coupling reagent were 5 eq amino acid, 5 eq HCTU, 10 eq 
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DIEA in NMP for 5 mins coupling. 5% piperazine and 0.1 M HOBt in DMF were used as 
the deprotection solution in order to minimize aspartamide formation. The peptide was 
cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O and precipitated from ether 
after removal of TFA. Ether was decanted after centrifugation and the peptide was 
washed with cold ether again. The final peptide was dissolved in 50% B’ (59.9% 
isopropanol, 30% acetonitrile, 10% H2O, and 0.1% TFA) and 50% A (99.9% H2O, 0.1% 
TFA) and purified by preparative C4 reverse phase HPLC with a linear gradient of 70% 
B’ to 85% B’. The peptide was eluted at 78% B’. The purity and identify of the peptide 
was confirmed by analytical HPLC (>98% purity) and MALDI-MS. Calculated MS: 
2782.38, Observed MS: 2782.90.  
 
Expression of 
15
N-labeled and 
15
N, 
13
C-labeled M2TM(19-49)  
Uniformly 
15
N-labeled or 
15
N, 
13
C double labeled M2TM(19-49) for solution NMR 
experiments were obtained by expressing the full-length protein in minimal medium 
enriched with 1 g/L 
15
N NH4Cl or 1g/L 
15
N NH4Cl and 4g/L 
13
C glucose
7
. The protein 
was reconstituted in octylglucopyranoside (OG) micelles and digested with TPCK-treated 
trypsin (Thermo Fisher), following a modification of the method described previously
40
 
and in the Supporting Information. The peptide was purified to homogeneity by reverse 
phase HPLC, and its purity and identity confirmed by analytical HPLC, MALDI-MS, and 
high resolution ESI-MS. Analytical data are provided in the Supporting Information.  
 
Synthesis of two deuterated rimantadine compounds 
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1-adamantane-d15-carboxylic acid was purchased from C/D/N isotopes Inc. CD3Li in 
diethyl ether was purchased from Sigma-Aldrich. 1D 
1
H and 
13
C NMR spectra were 
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per 
million (ppm) and referenced to the residual solvent (CD3OD or CDCl3) signals. The 
following abbreviations were used in reporting the NMR spectra: s: singlet, t: triplet, m: 
multiplet, p: pentet. All reactions were carried out under a N2 atmosphere unless 
otherwise stated. HPLC grade solvents were used for all reactions. Column 
chromatography was performed using silica gel (230-400 mesh). ESI mass spectra were 
obtained on a 3200 Q Trap LC/MS/MS system (Applied Biosystem).  
 
Synthesis of CD3-rimantadine 
Intermediate I (Scheme 1):  A solution of 0.5 M CD3Li (44ml, 22mmol) in diethyl ether 
was added dropwise to an ice-bath cooled solution of 1-adamantane carboxylic acid (1.8 
g, 10 mmol) in diethyl ether (50 ml) with stirring. The mixture was stirred at 0˚C for 30 
minutes, and then continued at ambient temperature for 4 hrs. The reaction mixture was 
slowly poured into a vigorously stirring solution of 1N HCl (100 ml) in ice water bath. 
Ether (50 ml) was added to the solution and the layers were separated, the aqueous layer 
was further extracted three times with diethyl ether. The combined ether layers were 
extracted with aqueous NaHCO3 and dried with MgSO4. The solvent was removed under 
reduced pressure and the crude product was purified by silica gel flash column 
chromatography (5-10% ethyl acetate/hexane) to give intermediate I as a white solid 
(1.57 g, Yield: 88%). 
1
H NMR (360 MHz, CDCl3) δ 2.06 (br s, 3H), 1.79-1.65 (m, 12H); 
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13
C NMR (90 MHz, CDCl3) δ 214.21, 46.63, 38.40, 36.73, 28.12; The calculated mass 
for C12H15OD3 (M + H)
+
 is 182.3, Found 182.5.  
 
A solution of Intermediate I (181 mg, 1 mmol), NH2OH•HCl (208.5 mg, 3 mmol) and 
CH3COONa (328.1 mg, 4 mmol) in anhydrous EtOH (5 ml) was heated to reflux for 2 
hrs. The solvent was removed under reduced pressure and the residue was dissolved in 
CH2Cl2 and extracted with H2O twice. The organic layer was dried with MgSO4 and the 
solvent was removed under reduced pressure to give the oxime intermediate. Without 
further purification, the oxime was dissolved in anhydrous THF (10 ml) and cooled to 
0˚C with an ice-water bath. LiAlH4 (0.4 g, 10.5 mmol) was added portion-wise to the 
stirring mixture. The solution was warmed to ambient temperature and heated to reflux 
for 4 hrs. The reaction was quenched by sequential addition of 0.4 ml H2O, 0.4 ml 15% 
NaOH solution and 1.2 ml H2O. The resulting slurry was filtered and the solvent was 
removed by rotary-evaporation under reduced pressure. 4 M HCl in 1,4-dioxane (1 ml) 
was added to the oily residue and the solvent was removed again under reduced pressure 
to give a white solid crude product, which was subsequently purified by silica gel flash 
column chromatography (10-20% CH3OH/CH2Cl2) to yield CD3-rimantadine as a yellow 
solid (164 mg, Yield: 75%). 
1
H NMR (360 MHz, CD3OD) δ 2.86 (br s, 1H), 2.03 (br s, 
3H), 1.74-1.60 (m, 12H); 
13
C NMR (90 MHz, CD3OD) δ 57.90, 38.74, 37.65, 35.29, 
29.30; The calculated mass for C12H19ND3 (M + H)
+
 is 183.3, Found 183.7. (The 
13
C 
NMR experiment did not use 
2
H decoupling, so the signal of the CD3 carbon was not 
detected due to splitting by deuterons.) 
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Synthesis of d15-Rimantadine 
The synthesis procedure of d15-rimantadine was the same as described above except 
starting with 1-adamantane-d15-carboxylic acid and CH3Li. 
Intermediate II: 
1
H NMR (360 MHz, CDCl3) δ 2.09 (s, 3H); 
13
C NMR (90 MHz, CDCl3) 
δ 214.16 (s), 46.04 (s), 37.50 (p, J = 18.0 Hz), 35.40 (p, J = 18.0 Hz), 27.12 (t, J = 18.9 
Hz), 24.34 (s); The calculated mass for C12H4OD15 (M + H)
+
 is 194.3, Found 194.3. 
D15-rimantadine: 
1
H NMR (360 MHz, CD3OD) δ 2.91 (s, 3H), 1.26 (s, 3H); 
13
C NMR (90 
MHz, CD3OD) δ 58.06 (s), 37.63 (p, J = 18.0 Hz), 36.37 (p, J = 18.0 Hz), 34.89 (s), 
28.27 (t, J = 18.9 Hz), 13.65 (s); The calculated mass for C12H7ND15 (M + H)
+
 is 195.3, 
Found 195.8.  
 
Scheme 1. Synthetic scheme for CD3-rimantadine and d15-rimantadine 
 
Solution NMR spectroscopy   
Solution NMR spectra were recorded at 313 K on a Varian INOVA 500 MHz 
spectrometer with a conventional probe, and 600 MHz and 900 MHz spectrometers 
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equipped with cryogenic 
1
H{
13
C, 
15
N}-triple resonance probes. 
15
N TROSY-HSQC, 
13
C 
HSQC, 2D H(N)CA, 2D (H)C(C)H-TOCSY spectra
49
 were collected for backbone and 
sidechain resonance assignment of 
15
N, 
13
C-labeled VAG-M2TM. 2D (
13
C)-NOESY 
spectra with a 200 ms mixing time were acquired to identify 
1
H1H NOE between the 
peptide and Amt or Rmt. Spectra were processed with the program NMRPipe.
50
 Prior to 
Fourier transformation, time domain data were multiplied by sine square bell window 
functions shifted by 90˚ and zero-filled once. 1H chemical shifts were referenced to the 
residual water signal while 
13
C and 
15
N chemical shifts were indirectly referenced to 
DSS. 
 
Membrane-bound M2TM samples for solid-state NMR 
Residue-specifically labeled M2TM(22-46) for SSNMR experiments was synthesized by 
PrimmBiotech (Cambridge, MA) and purified to >95% purity. Uniformly 
13
C, 
15
N-
labeled amino acids were incorporated at residues Val27, Ser31, Gly34 and Asp44 
(VSGD-M2TM). Unlabeled peptides were used for static 
2
H quadrupolar echo 
experiments that detect Rmt dynamics and orientation. M2TM(22-46) was reconstituted 
into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) vesicles by OG dialysis.
51
 
The final peptide/lipid molar ratio was 1 : 8. A pH 7.5 phosphate buffer (10 mM 
Na2HPO4/NaH2PO4, 1 mM EDTA, 0.1 mM NaN3) was used to prepare the lipid vesicle 
solutions. The protein-lipid solutions were dialyzed at 4°C for three days with 5-6 buffer 
changes to remove the detergent. Protein-lipid precipitates usually formed after one day 
of dialysis. The proteoliposome mixtures were centrifuged at 150,000 g to obtain ~40% 
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hydrated membrane pellets for SSNMR experiments. d15-Rmt or CD3-Rmt was dissolved 
in water and directly titrated into the membrane pellet in the MAS rotor. For 
13
C-
2
H 
REDOR experiments, CD3-Rmt was added at a ratio of 1 drug/tetramer or 5 
drugs/tetramer, which corresponded to drug/lipid molar ratios of 1 : 60 or 1 : 12, 
respectively. For static 
2
H lineshape experiments, d15-Rmt was added to unlabeled 
M2TM at 1 drug/tetramer and 4 drugs/tetramer ratios. Excess water after the addition of 
Rmt was evaporated by placing the rotor uncapped in a dessicator at room temperature 
for several hours. 
 
Solid-state NMR spectroscopy 
Static 
2
H quadrupolar echo experiments were carried out on a 14.1 T wide-bore solid-
state NMR spectrometer (Bruker Biospin) operating at a 
2
H Larmor frequency of 92.12 
MHz using a double-resonance 4 mm 
1
H/
2
H probe. The quadrupolar-echo sequence 
involved a pre-echo delay of 40-50 s, a post-echo delay that was 8 s shorter, and a 2H 
90˚ pulse length of 3.8 s. The time signal was left-shifted appropriately to capture the 
echo maximum to give Fourier-transformed spectra with flat baselines. The spectra were 
measured from 243 K to 303 K. The number of scans ranged from 30,000 to 150,000.  
 
13
C-detected and 
2
H-dephased REDOR experiments were carried out using a triple-
resonance 4 mm 
1
H/
13
C/
2
H magic-angle-spinning (MAS) probe on a 9.4 T wide-bore 
SSNMR spectrometer (Bruker Biospin) operating at a 
13
C resonance frequency of 100.71 
MHz and a 
2
H frequency of 61.48 MHz. The samples were spun under 4250 Hz MAS at 
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243 K, where the protein was immobile but the drug remained dynamic. The REDOR 
experiment involved a single selective 
13C 180˚-pulse in the center of the mixing period 
and multiple 
2H 180˚ pulses (pulse length 12.4 s) every half a rotor period apart. This 
version of the REDOR experiment removes 
13
C-
13
C scalar coupling and thus gives long 
13
C T2 relaxation times, which allows the detection of dephasing effects at long mixing 
times. An alternative REDOR version containing a single 
2
H composite 90˚90˚90˚ pulse 
and multiple 
13C hard 180˚ pulses was also conducted at one mixing time to confirm the 
dipolar dephasing (data not shown). Although the second experiment produces 
quantitative dephasing,
15
 the complex dynamics of the rotating methyl attached to a 
uniaxially diffusing adamantyl cage prohibits distance quantification from the dephasing 
curve, thus we did not attempt to measure multiple REDOR time points using the latter 
REDOR experiment.  
 
Static 
2
H lineshapes of d15-Rmt were simulated using MATLAB and the software 
EXPRESS.
52
 For each molecular orientation of Rmt, a 4 : 1 area ratio of two couplings 
with a 1 : 3 splitting ratio was always maintained to represent the equatorial and axial 
deuterons of the adamantyl cage. Since the effect of uniaxial diffusion on the quadrupolar 
coupling is known analytically, the coupling values were directly inputted into the 
EXPRESS program to generate the Pake patterns. Fitting the measured spectrum yielded 
the ratio between different orientations of Rmt in the channel pore versus in the bilayer.  
 
4.4 Results and Discussion 
107 
 
Amt and Rmt binding to M2TM in DPC micelles  
We measured the location of Amt and Rmt in the M2TM channel in DPC micelles using 
solution NMR. To evaluate the effect of drug-binding on the structure of the M2TM 
tetramer, we first examined uniformly 
15
N-labeled and 
13
C, 
15
N-labled M2TM(19-49), 
which was prepared by controlled proteolysis of the native, full-length protein expressed 
in bacteria. We explored the spectroscopic properties of M2TM(19-49) in DPC micelles, 
because the tetramerization, affinity, and stoichiometry of binding of drugs to various 
fragments of M2 had been extensively evaluated in this detergent micelle.
7,40,41
 Thus, it 
was possible to choose conditions where M2TM(19-49) was predominantly tetrameric. In 
addition to Amt and Rmt, we also examined a spiro-piperidine inhibitor, WJ10, which 
had been shown to bind to M2TM strongly and perturb its conformation in a similar 
fashion as the adamantyl drugs.
53
 Fig. 1a shows the 
15
N-
1
H HSQC spectrum of 
M2TM(19-49) in the absence of drug, which showed limited peak dispersion. Addition of 
the spiro-piperidine inhibitor
53
 and Amt (Fig. 1b, Fig. S1) into the sample resulted in the 
appearance of a new set of significantly sharper resonances in slow exchange with the 
resonances of the unbound species. Confirming the observations of SSNMR,
21
 drug 
binding stabilized a slowly exchanging conformer that is in low abundance in the absence 
of the drug (Fig. S2).   
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Figure 1. 2D 
15
N TROSY-HSQC spectra of 1 mM (monomer concentration) M2TM(19-
49) in the absence (a) and presence (b) of 2.5 mM WJ10. The spectra were measured at 
313 K in 100 mM DPC micelle (50 mM sodium phosphate, pH 7.5, in 10% D2O and 90% 
H2O) on a cryoprobe-equipped Varian INOVA 600 MHz NMR. Upon drug binding, the 
signals became better dispersed in the 
1
H dimension, and the improved lineshape and 
uniformity of the linewidths indicate that the bound protein adopts a well-folded 
conformation. Assignments are labeled for the bound protein and inset shows an 
expanded view of part of the spectrum. The chemical structure of spiro-piperidine WJ10 
(IC50 = 0.92 µM) is shown in the spectrum on the right. For comparison, Amt has an IC50 
= 16 µM.
53
 
 
The drug-bound conformation shows large chemical shift changes of the resonances 
throughout the peptide relative to the unbound form. In particular, drug binding perturbed 
the chemical shifts of Val27, Ala30 and Gly34 (Fig. S3, S4) as well as the aromatic 
resonances of His37 and Trp41 away from their frequencies typically seen in proteins 
(Fig. 2, Fig. S5, S2). The changes are especially pronounced in the 
1
H dimension, in 
which the dispersion of the amide 
1
H chemical shifts increased by 2-fold (Fig. 1), 
indicating the formation of a uniquely folded tertiary structure. The increased spectral 
dispersion is similar to that seen upon titration of drug into M2TM
51,54
 or M2(18-60)
23
 in 
phospholipid bilayers, but contrasts with the minimal changes seen when the drug was 
titrated into M2(18-60) in DHPC micelles
16
.  
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Having determined conditions that are conducive to specific binding of Amt and Rmt to 
the protein in the DPC micelle, we conducted solution NMR titration experiments to test 
whether the drugs bind directly to the pore as observed in lipid bilayers by SSNMR. To 
more closely match the SSNMR conditions, we used M2TM(22-46) for these 
experiments.  Fig. 2 shows the 1D titration spectra that confirmed specific binding to the 
channel: for example, the H signal of His37 undergoes a large upfield shift in the drug-
complexed state compared to the unbound state.  This peak shift is consistent with the 
influence of Amt on the His37 tetrad pKa’s observed by solid-state NMR experiments 26. 
The titration data are well described by a theoretical curve generated using independently 
determined optical titrations in micelles and isothermal titration calorimetry in 
phospholipid bilayers. 
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Figure 2. Titration of 2 mM M2TM (residues 22-46) by Amt. The intensities of the 
major peak of His HD2 at 6.0 ppm are plotted as a function of drug/tetramer molar ratio. 
The curve has a well-defined break at a molar ratio of one drug/tetramer. Circles: data at 
298 K, pH 8.0, 80 mM DPC, corresponding to a protein : DPC molar ratio of 1:40. 
Squares: data at 313 K, pH 7.5, 200 mM DPC (protein : DPC ratio 1:100). Two datasets 
are shown to demonstrate that the curves are essentially the same over a range of 
temperature, peptide/detergent ratios, and pH. The 313 K spectra are shown in the inset, 
and other titration spectra are shown in Fig. S1. The fit curve was generated using the 
binding isotherm and best-fit parameters determined previously from a circular dichroism 
binding assay (Kd= 16 M, stoichiometry=0.9 drug/tetramer) in which the protein was 
reconstituted under the same conditions.
66
 Assignments of His37 HD2 were based on 2D 
1
H NOESY spectra recorded in D2O and aromatic 
13
C-
1
H HSQC spectra (unpublished 
data).  
 
The specific location of Amt and Rmt in M2TM(22-46) was investigated using 
13
C-edited 
NOESY experiments. Due to the difficulty of conducting half-filtered experiments on 
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fast-relaxing proteins in detergent micelles, we opted to measure difference spectra of the 
peptides in the presence of deuterated versus protonated drugs. Two sets of experiments 
were carried out to detect NOE signals between the drug and 
13
C-labeled residues, one 
comparing protonated versus perdeuterated Amt, and the other comparing protonated 
versus CD3-labeled Rmt. Three residues in the pore binding site - Val27, Ala30 and 
Gly34 - were labeled with 
13
C and 
15
N. Any NOEs from the protonated drugs to these 
residues that disappear upon deuteration represent specific drug-protein interactions. 
Figure 3 shows 
13
C-edited NOESY spectra for protonated and perdeuterated Amt. The 
drugs were not 
13
C-labeled, thus the only cross-peaks associated with the drug must result 
from interactions with the 
13
C-labeled residues of the protein, and drug-drug NOEs 
cannot exist in the spectra. We observed a strong NOE cross-peak at ~0.7 ppm in the 
direct dimension and ~1.6 ppm in the indirect dimension, which was assigned to the 
γCH3 of Val27 and the C4 methylene protons of Amt (Fig. S6). This cross peak indicates 
that the hydrophobic cage of Amt points up to the N-terminus while the polar amine 
points down, consistent with the SSNMR result of cage-perdeuterated Amt 
15
 and the X-
ray structures
14
 of the complex, in which the sidechain of Val27 forms a hydrophobic lid 
of the binding site, interacting with the apolar portion of the drug. It is also consistent 
with the fact that Val27 forms closer contacts with the adamantyl cage than Ala30 in both 
the crystal and SSNMR structures (Fig. 3D). 
 
To probe the polar group direction of Rmt in the pore, we performed the same 
13
C-edited 
NOESY experiments of the peptide bound to CD3-labeled Rmt versus protonated Rmt. 
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Fig. 3B shows a weak NOE cross peak between the β CH3 of Ala30 and Rmt CH3. Taken 
together, these NOESY difference experiments indicate that both Amt and Rmt bind in 
the channel pore with the amine pointing towards the C-terminus in DPC-bound M2TM 
tetramers.  
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Figure 3. Upfield region of 2D 
13
C-edited 
1
H NOESY spectra with 200 ms mixing of 
13
C, 
15
N-labeled VAG-M2TM with 2 eq Amt (A) and Rmt (B). The left spectra are those 
of protonated drugs, and the middle spectra are from samples containing perdeuterated 
Amt and methyl-deuterated Rmt. The right spectra are the difference between the left and 
middle spectra. (C) The protons that show NOE cross peaks with M2 are highlighted in 
red in the Amt and Rmt structures. Spectra in (A) and (B) were recorded on a 500 MHz 
and a 600 MHz spectrometer, respectively. The concentrations were 2 mM peptide, 100 
mM DPC, 1 mM Amt or Rmt, and pH 7.5 phosphate buffer as in Fig. 3. The methyl 
groups of Val were not stereospecifically assigned. (D) The structure of Amt bound in the 
channel pore in the crystal structure of M2TM 
14
, viewed from the C-terminal end. 
Shown in balls are Gly34 C (orange), Val27 sidechains (green), and Ala30 sidechains 
(cyan). The hydrophobic adamantyl cage (magenta) interacts extensively with the Val27 
sidechains, while the polar group (blue) points to the C-terminus in the crystal structure. 
 
Adamantyl cage orientations of Rmt in DMPC-bilayer-bound M2TM(22-46) 
To determine the Rmt orientation and dynamics in M2TM bound to lipid bilayers, which 
better represent the virus envelope environment than detergent micelles, we measured the 
2
H spectra of d15-Rmt. Rimantadine consists of a rigid adamantyl cage attached to an 
ethylamine. Similar to Amt, the adamantyl cage has a three-fold symmetric axis 

ZM . 
Three axial C-D bonds are parallel to 

ZM  while twelve equatorial C-D bonds lie at 70° 
or 110° from 

ZM . Fast uniaxial rotation or CN jumps (N ≥ 3) of the cage around 

ZM  
results in quadrupolar splittings of 40 and 125 kHz with a 4 : 1 intensity ratio. If the drug 
undergoes additional fast diffusion about the bilayer normal 

n with a tilt angle 

nM  from 
the molecular axis, then both equatorial and axial couplings will be further scaled by an 
order parameter, 

Smol  3cos
2nM 1  2 .55,56 While the adamantyl cage moiety is 
identical between Rmt and Amt, the different polar functionality between the two drugs 
can affect the molecular orientation, as we show below.  
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Figure 4 shows the 
2
H spectra of d15-Rmt under varying drug : channel ratios from 243 K 
to 303 K. Three membrane samples were examined: Rmt bound to DMPC bilayers in the 
absence of M2TM, in the presence of a stoichiometric number of channels (1 
drug/tetramer), and in 4-fold excess of the number of channels (4 drugs/tetramer). At 243 
K, all three samples exhibited quadrupolar splittings of ~35 kHz and ~120 kHz, 
consistent with the frequency ratio expected when the adamantyl cage uniaxially rotates 
around its own molecular axis. The slight reduction of the splittings from 40 and 125 kHz 
(

Smol  0.9) indicate that 

ZM is tilted by 13˚ from the bilayer normal. These 243 K 
spectra of Rmt are identical to the spectra of d15-Amt at the same temperature.
15
 
 
Figure 4. Static 
2
H quadrupolar echo spectra of d15-Rmt for determining the tilt angle of 
the adamantyl cage in M2TM (residues 22-46) channels versus lipid bilayers. (a) d15-Rmt 
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bound to DMPC bilayers without the protein. (b) d15-Rmt bound to M2TM in DMPC 
bilayers at a ratio of 1 drug/tetramer. (c) d15-Rmt bound to M2TM at a ratio of 4 
drugs/tetramer. (d) One of the two degenerate orientations of d15-Rmt in lipid bilayers at 
303 K. (e) Orientation of d15-Rmt in M2TM channels at 303 K.  
 
When the membranes warmed to the liquid-crystalline phase at 303 K, the 
2
H spectra 
differed for the three samples. The lipid-only sample showed two splittings of 11.4 kHz 
and 35 kHz, which corresponded to a 

Smol  of ±0.28, indicating that the adamantyl cage 
is tilted from the bilayer normal by 44˚ (or 67˚) at physiological temperature (Fig. 4d). 
Simulation of the 303 K spectrum confirmed the intensity and frequency ratios of the 
underlying Pake patterns that represent the equatorial and axial deuterons (Fig. 5a). The 
44˚ tilt angle of lipid-bound Rmt is significantly larger than the 37˚ found for Amt.15 We 
hypothesize that the larger tilt angle is due to the bifurcated ethylamine structure, which 
may orient differently from the amine in Amt in order to better position the polar group to 
the negatively charged phosphate groups on the membrane surface. 
 
When a stoichiometric amount of M2 tetramers was present, the 303 K spectrum changed 
qualitatively from the lipid-only sample: the 36 kHz splitting of the equatorial deuterons 
at 243 K persisted to 303 K across the membrane phase transition, and dominated the 
spectral intensity (Fig. 4b). The persistence of this large coupling at high temperature is 
similar to what was observed for Amt
15
 and indicates that a significant fraction of Rmt 
cannot deviate from the upright orientation due to confinement by the channel (Fig. 4e), 
and the drug is well isolated from the disordered liquid-crystalline membrane. In addition 
to the 36-kHz splitting, a 13.3 kHz splitting and an isotropic peak were detected in the 
116 
 
stoichiometric spectrum at 303 K. The former corresponds to 

Smol=0.33 or 

nM=42˚, 
which can be attributed to Rmt in the lipid bilayer, since the amphipathic drug has 
affinity to both the lipids and the aqueous pore of the channel. The fact that the splitting 
is 2 kHz larger than the 11.4 kHz value seen in the lipid-only sample (Fig. 4a) translates 
to only a 2˚ reduction in the tilt angle, because the order parameter has the highest 
angular sensitivity at 45˚. The isotropic peak, which was also observed for Amt,15 may 
result from randomly tumbling drug that has escaped into the inter-bilayer aqueous phase, 
or from pore-bound drug tilted at the magic angle (54.7˚) from the channel axis. The 
fractions of the three components were found by simulation (Fig. 5b) to be 63% : 27% : 
10% for the 13˚-tilted channel-bound component, the 42˚-tilted lipid-bound component 
(13.3 kHz), and the isotropic component. The lipid-bound fraction of 27% is higher than 
the 10% fraction for Amt,
15
 suggesting that Rmt has slightly higher affinity for the 
membrane than Amt under the molar ratios used in these solid-state NMR samples.  
 
 
Figure 5. Simulations of the 
2
H spectra of d15-Rmt at 303 K. Top row: experimental 
spectra reproduced from Fig. 5. Bottom row: simulated spectra. (a) d15-Rmt bound to 
DMPC bilayers without M2. Simulation used a 4 : 1 area ratio of the small and large 
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couplings, consistent with the number of equatorial and axial deuterons in the adamantyl 
cage. (b) d15-Rmt bound to M2 at 1 drug/tetramer. Simulated spectrum used an area ratio 
of 63% : 27% : 10% for the 36 kHz, 13.3 kHz, and isotropic components, which represent 
the pore bound, lipid bound and isotropic drugs. (c) d15-Rmt bound to M2(22-46) at 4 
drugs/tetramer. Simulated spectrum used an area ratio of 13% : 83% : 4% for the 36 kHz, 
12.5 kHz and isotropic components.  
 
Fig. 4c shows the 
2
H spectra when Rmt is in four-fold excess to the M2TM tetramers and 
accounting for 8 mol% of the lipid membrane. The 303 K spectrum is now dominated by 
a 12.5 kHz splitting and a small 36-kHz component for the equatorial deuterons. Thus, 
the excess drug adopts a similarly tilted orientation as the lipid-bound drug in the absence 
of the protein, while the drug inside the pore retained the same upright orientation as in 
the stoichiometric sample.
15
 Simulation (Fig. 5c) yielded a ratio of 13% : 83% : 4% for 
the 36 kHz, 12.5 kHz and the isotropic components.  
 
Taken together, these 
2
H spectra indicate that the majority of the first equivalent of Rmt 
adopts the same upright orientation in the pore of the channel as Amt. Excess Rmt has a 
very tilted orientation of 42-43˚ from the bilayer normal, which is nearly identical to the 
44˚ tilt of the drug in the lipids in the absence of the protein. Compared to Amt, Rmt has 
a slightly different equilibrium constant between the specific pore-binding site and the 
non-specific lipid-binding site, which is likely a result of the slightly different 
hydrophobicity and size of the two drugs.  
 
Binding locations and polar group direction of Rmt in the M2TM pore 
Protein chemical shift perturbation provides independent evidence of ligand binding sites. 
To confirm the binding locations inferred from the 
2
H spectra, and to compare M2-Rmt 
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interactions with M2-Amt interactions, we measured the 
13
C and 
15
N chemical shifts of 
several key residues in M2TM. Ser31, Val27 and Gly34 defined the center and the 
boundaries of the pore binding site for Amt,
15,51
 while Asp44 probed the interaction of 
the drug with the lipid-exposed binding site. Figure 6 shows 2D 
15
N-
13
C correlation 
spectra of VSGD-M2TM(22-46) in the absence and presence of Rmt. The drug-free 
peptide shows two Ser31 peaks and two Gly34 
15
N peaks, whose relative intensities 
changed with titration of the drug: the downfield 
15
N peaks of each residue increased in 
intensity upon Rmt binding. The bound Ser31 
15
N peak is 6 ppm downfield from the 
unbound peak, while the bound Gly34 
15
N peak is 3 ppm downfield from the unbound 
peak. These peak displacements are very similar to those observed for Amt-bound 
M2TM,
15,51
 strongly suggesting that Rmt also binds to the N-terminal pore near Ser31. 
The fact that the bound Ser31 conformation is already present in the drug-free state 
indicates that Rmt shifts the conformational equilibrium of the protein to the bound state, 
rather than inducing an entirely new conformation. This observation is consistent with the 
concept of conformational selection by ligands, which has been documented for many 
globular proteins
57
 and which has also be reported for M2TM.
18
 The Val27 C chemical 
shift decreased by 2.5 ppm upon Rmt binding. In comparison, the Asp44 
15
N chemical 
shift did not change between the apo sample and the stoichiometric sample (both at 118.4 
ppm), but increased by 1.5 ppm (at 119.9 ppm) in the sample containing excess Rmt. 
Thus, only excess drug affects the Asp44 conformation, providing strong evidence that 
the first equivalent of drug binds elsewhere from Asp44.  
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Figure 6. 2D 
15
N-
13
C correlation spectra of Val27, Ser31, Gly34 and Asp44-labeled 
M2TM in DMPC bilayers without and with Rmt. (a) The spectrum of drug-free peptide. 
(b) The spectrum with 1 drug/tetramer. (c) The spectrum with 5 drugs/tetramer. Ser31 
and Gly34 
15
N chemical shift increases and Val27 C chemical shift decreases upon drug 
binding.  
 
13
C{
2
H} REDOR experiments of CD3-Rmt provided definitive proof of the binding 
location of the drug as well as the direction of the amine in the pore. If the ethylamine 
points to the N-terminus of the channel, significant REDOR effect is expected for Val27 
sidechains, whereas if the amine points to the C-terminus, significant REDOR dephasing 
should occur for Gly34. Since the Rmt 
2
H spectra and the 
15
N-
13
C correlation spectra of 
the protein with varying drug concentrations both indicate that excess Rmt does not 
remove the specific binding site, but only populates both sites, we focused the 
13
C{
2
H} 
REDOR experiment on the 5 drugs/tetramer sample. Fig. 7 shows the REDOR control 
(S0) and dephased (S) spectra measured with a single 
13C 180˚ pulse and multiple 2H 
pulses.
58
 Val27 C1 exhibited no dephasing at 16.9 ms, and the combined Ser31 and 
Val27 C peak at 61.4 ppm also showed no dephasing (S/S0 = 1.02 ± 0.03 at 15.1 ms), 
indicating that both 
13
C-labeled residues are outside the dipolar contact of the deuterated 
methyl. In contrast, significant dephasing was observed for Gly34 C, with an S/S0 value 
of 0.81 ± 0.04 at 18.8 ms. Thus, the REDOR spectra indicate unambiguously that the 
120 
 
ethylamine lies near Gly34 and points to the C-terminus of the channel, in the direction of 
the His37.  
 
Figure 7. 
13
C{
2
H} REDOR spectra of DMPC-bound M2TM with CD3-Rmt at 5 
drugs/tetramer. Intensity difference between the control (S0, black) and dephased spectra 
(S, red) indicate proximity of the 
13
C-labeled residues to the deuterated methyl group. (a) 
16.9 ms REDOR spectra of Val27 C showing S/S0 = 1.02 ± 0.04. (b) 15.1 ms REDOR 
spectra of Ser31 C (S/S0 = 1.02 ± 0.03) and Asp44 C (S/S0 = 0.89 ± 0.03). (c) Gly34 
C REDOR spectra at 18.8 ms, with S/S0 = 0.81 ± 0.04. The difference spectrum is 
shown in blue. (d) Schematic of rimantadine structure in the pore, with the polar amine 
pointing to the C-terminus and the adamantyl cage tilted by 13˚.  
 
Fig. 7b additionally shows moderate dephasing of Asp44 C to 0.89 ± 0.03 at 15.1 ms, 
indicating that at a lipid/drug molar ratio of 6.4 : 1, the drug is in dipolar contact with the 
surface-exposed Asp44. This finding is consistent with Amt binding to M2(22-46)
15
 in 
lipid bilayers and with the Rmt interaction with M2(18-60) in mixed micelles composed 
of 7.5 : 1 DHPC/Rmt.
16
 Both Rmt and Amt are amphiphilic molecules and partition into 
the membrane-water interface of lipid bilayers,
59
 at approximately the same depth as 
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Asp44. Thus, drug binding to Asp44 can be attributed to the high concentrations of the 
drugs in the bilayer and the preference of the drugs for the membrane-water interface.  
Additional REDOR experiments of the 1 drug/tetramer sample (Fig. 8) exhibited no 
significant dephasing for the four residues within experimental uncertainty, which is 
expected for Val27, Ser31 and Asp44. The lack of strong dephasing for Gly34 is partly 
due to the incomplete occupancy of the drug in the pore, since 27% of the Rmt is in the 
bilayer and 10% has vanishing quadrupolar coupling (Fig. 4), thus making ~37% of the 
drug unable to cause any dipolar dephasing. In addition, the peptide conformation may be 
slightly altered between low and high drug concentrations due to changes in the 
membrane viscosity and lateral pressure, such that the height of the CD3 group may be 
slightly different between stoichiometric and excess drug concentrations. Previously we 
did not observe different REDOR dephasing between the stoichiometric and drug-excess 
complexes between d15-Amt and M2TM.
15
 However, d15-Amt contains a large number of 
deuterons distributed over a 2.2 Å vertical distance, which minimized the effects of small 
displacements of the drug in the channel. In contrast, the current CD3-Rmt contains only 
three deuterons concentrated in a small region of space, thus even subtle changes of the 
drug height in the channel could significantly weaken the REDOR dephasing.  
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Figure 8. 
13
C{
2
H} REDOR spectra of M2TM in DMPC bilayers with CD3-Rmt at 1 
drug/tetramer. (a) 15.1 ms REDOR spectra. S/S0 values are 1.2±0.16 for Val27 C1, 1.00 
± 0.19 for Ser31 C, and 0.92 ± 0.08 for Asp44 C. (b) 16.9 ms REDOR spectra of 
Gly34 C. S/S0 = 0.94 ± 0.07.  
 
Excess drug and other membrane composition changes are known to have significant 
effects on the conformational dynamics of M2TM.
18,19,56,60
 For example, the addition of 
cholesterol at lower concentrations than the Rmt amount used here causes significant 
changes in the thermodynamic stability
44
 and the structure
21
 of the protein. 
1
H relaxation 
NMR data revealed that the uniaxial diffusion of M2TM tetramers in DLPC bilayers was 
sped up by excess Amt in the membrane,
61
 suggesting that the tetramers adopt tighter 
conformations due to the indirect influence of the drug on the membrane fluidity. Thus, 
the first equivalent of Rmt may be bound deeper in the pore, with the ethylamine outside 
the detectable (~5 Å) distance range of Gly34. As excess Rmt partitioned into the 
membrane, the tetramers tighten slightly, pushing the drug up in the channel so that the 
CD3 group approached Gly34, giving measurable dipolar dephasing.  
 
The downward orientation of the polar amine in the pore confirms that the adamantane 
drugs inhibit the M2 proton channel activity not only by steric block and dehydration of 
the channel,
22
 but also by indirect drug-His37 interactions. The C-terminus-pointing 
amine would be able to form hydrogen bonds with the clusters of water molecules 
His37.
38
 These water-mediated hydrogen bonds would tend to reduce the His37 pKa, as 
shown for Amt-bound M2TM in 
15
N chemical shift measurements.
26
 The perturbation of 
His37 pKa is relevant to inhibition, because it increases the fraction of the protein in the 
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high-pH form and decreases dynamic processes believed to be required for proton 
conduction.
14,18,62-64
 In a new spiro-piperidine inhibitor of M2 with 10-fold higher 
potency than Amt, methyl substitution of the amine was found to reduce the potency 
significantly, indicating the importance of the polar moiety.
53
 
 
4.5 Conclusions 
Both solid-state and solution NMR results shown here demonstrate that Rmt binds the 
M2TM channel in a very similar fashion to Amt. At the stoichiometric drug 
concentration, Rmt binds inside the pore with the molecular axis roughly parallel to the 
bilayer normal. The polar group points towards the C-terminus, supporting the notion that 
the drug inhibits the proton conductance not only by interrupting the water wire leading 
to His37
30,65
 but also by forming water-mediated H-bonds with His37, which perturbed 
its pKa. The proximity of the methyl group to the Gly34 backbone also suggests that the 
higher affinity of Rmt to M2 than Amt
66
 may result from better space filling of the drug 
in the channel and dehydration of the additional hydrophobic methylene and methyl 
groups. This insight suggests that new drugs to target resistant variants of the M2 protein 
may involve side groups that similarly access the space near Gly34. The dynamics of 
Rmt inside the pore suggests two possible strategies to the design of new M2 inhibitors. 
In one strategy, one can design molecules that better fill the channel, leading to molecules 
with high potency for not only the wild type but also the drug-resistant mutants V27A 
and L26F, as will be reported elsewhere. Alternatively, one can also adopt the strategy of 
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retaining the molecular dynamics as a potential mode of entropic stabilization. The new 
structural information obtained here has informed both strategies.  
 
This study not only extends the previous structural findings of Amt to Rmt, but also 
provides unique information about the polar group direction, which was absent in all 
previous high-resolution structures of the M2 protein.
1,15
 The fundamental similarity of 
Rmt and Amt in their binding locations, as well as subtle differences in their lipid 
interaction, provide a rare opportunity to examine the entire distribution of bound states, 
including the membrane-bound as well as protein-bound states. These data should 
provide essential information to test and improve molecular dynamics protocols for 
simulating the kinetic steps involved in binding a hydrophobic drug to a membrane 
protein receptor. 
 
The fact that Amt binds specifically to the pore of M2TM in DPC micelles in solution 
and cause chemical shift changes that are consistent with the effects of drug on 
M2TM
51,54
 and M2(18-60)
23
 in lipid bilayers, but distinct from the effects of drug on 
M2(18-60) in DHPC micelles,
16
 underscore the importance of the environment to the 
functional structure of the protein and the mutual influence that can exist between the 
protein and detergent micelles.
35
 The high-resolution orientational structure of the 
cytoplasmic helix recently determined by solid-state NMR in lipid bilayers
64
 differ 
significantly from the structure in DHPC micelles. How exactly the cytoplasmic helix 
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affects specific drug binding in the TM pore in a detergent environment remains an open 
question for future investigation.  
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Expression and trypsin digestion of U-
15
N and U-
15
N 
13
C labeled M2TM(19-49) for 
detergent screening of solution NMR 
BL21(DE3)pLyS E. Coli cells with pET23D(+) plasmids containing the Udorn wt M2 
gene were grown in LB agar plates with 100 µg/ml ampicilin at 37
o
C overnight. A single 
colony was picked up from the plate to inoculate 5ml LB supplemented with 100 µg/ml 
ampicilin, and was allowed to incubate at 37
o
C with 200rpm shaking for 8hrs. Next, 0.5 
ml of the above cell solution was used to inoculate 50ml of minimal media with 1g/L 
15
NH4Cl, 4g/L glucose and 100 µg/ml ampicilin and shake at 37
o
C overnight (for double 
15
N and 
13
C labeling, the minimal media was supplemented with 1g/L 
15
NH4Cl, 4g/L 
13
C 
glucose) . The overnight culture was used to inoculate 1 L of minimal media with 1g/L 
15
NH4Cl and 100 µg/ml ampicilin. When OD600 reached 0.7-1.0 (normally after 3hrs), 
M2 expression was induced with 1 mM IPTG (final concentration). Protein expression 
was halted three hours later by centrifugation at 4˚C for 30 min. The cell pellet was 
resuspended in 50 ml of 50 mM Tris (pH 8), 40 mM OG, 150 mM NaCl, 0.25 µg/ml 
lysozyme, 0.02 µg/ml DNase I and 500 µM PMSF at 0˚C. The mixture was sonicated on 
ice for 20 min (20% amplitude, 1 s on 1 s off), followed by further reconstitution using a 
homogenizer for 10 mins to make the solution homogeneous. The solution was then 
centrifuged at 15,000 g for 30 mins. The supernatant was saved for Ni-NTA column 
purification, and the pellet was subjected to another round of reconstitution as described 
above. Finally the supernatants from two rounds were combined and incubated with 10 
ml Ni-NTA super flow resin (Qiagen) and 20 mM imidazole at room temperature for 30 
min with gentle shaking. The column was washed successively with 50 mM Tris (pH 8), 
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150 mM NaCl, 40 mM OG, 20% v/v glycerol, then 50 mM Tris (pH 8), 20 mM OG, 20% 
v/v glycerol, followed by 50 mM Tris (pH 8), 4 mM OG, 20% v/v glycerol, 20 mM 
imidazole. Finally, the M2 protein was eluted with 50 mM Tris (pH 8), 4 mM OG, 20% 
v/v glycerol, 300 mM imidazole. The purity of M2 was judged by gel electrophoresis and 
HPLC to be >95%. Full length M2 was digested by TPCK-trypsin (Thermo Fisher, cat # 
PI-20233, 10mg/ml) in the elution buffer overnight at 37˚C. The resulting solution was 
separated by C4 reverse phase HP C with linear gradient of 70% B’ to 95% B’ (Eluent 
A: 89.9% H2O + 10% isopropanol + 0.1% TFA; Eluent B: 59.9% isopropanol + 30% 
acetonitrile + 10% H2O + 0.1% TFA) to give two major fragments M2(19-49) and 
M2(19-53) in 3:2 ratio. ESI-MS of the A/M2(19-49) was found to be 3507.2411, 
calculated 3505.8149. 
 
Chemical shift assignment of 
15
N, 
13
C-V27, A30, G34-labeled M2TM(22-46) in the 
absence and presence of Amt and Rmt 
Val, Ala and Gly have characteristic 
13
C chemical shifts of 62.4  2.9 ppm, 53.2  2.0 
ppm, and 45.3  1.3 ppm, respectively, thus the backbone C signals can be 
unambiguously assigned in the 
13
C HSQC spectra. The Val C chemical shift should be 
32.7 1.8 ppm, and is also straightforward to assign. The methyl carbon and protons of 
Ala are usually shifted upfield by 2.2 ppm and downfield by 0.5 ppm, respectively, 
compared to the corresponding atoms of Val, so the assignment of the methyl group is 
also clear. The 2D H(N)CA experiment correlates the amide 
1
H chemical shifts with the 
intra-residue and preceding residue 
13
C chemical shifts. Since the preceding residues of 
V27, A30 and G34 are unlabeled, the H(N)CA experiments only connect the intra-residue 
amide 
1
H and 
13
C chemical shifts. The 2D (H)C(C)H TOCSY experiment was used to 
extend and confirm the 
1
H and 
13
C assignments within a spin system. The C peak of 
G34 was too weak to observe, which may be due to high dynamics, as supported by the 
weak signals of G34 in both the 
13
C and 
15
N HSQC spectra. Nevertheless, G34 
assignment was obvious after the other two residues had been assigned and because Gly 
15
N resonates in a very unique region of the spectrum (109.7  4.0 ppm). Figure S7A, 
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S7B and S7C show the assignments of M2TM in the apo state and in presence of Amt 
and Rmt.  
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Figure S1. 2D 
15
N TROSY-HSQC spectra of 1 mM M2TM(19-49) in the absence (left) 
and presence (right) of 5 eq Amt, at 313 K in 50 mM DPC (50 mM sodium phosphate in 
10% D2O and 90% H2O). The spectra were measured on a Varian INOVA 600 MHz 
(left) and 900 MHz (right) spectrometer equipped with a 
1
H{
13
C, 
15
N}-triple resonance 
cryoprobe. Similar to the spectra in Figure 1, upon Amt binding, 
1
H chemical shift 
dispersion increases, and peak shape and linewidths become more uniform, indicating the 
drug-protein complex adopts a well-structured conformation.  
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Figure S2. Aromatic 
13
C HSQC spectrum of M2TM(19-49)  in the absence of the 
inhibitor WJ10 (red, A) shows two conformers for W41, one much stronger than the 
other. Addition of WJ10 (blue, B) shifts the equilibrium towards the one less populated in 
the apo state.  Superposition of the two spectra (C) clearly indicates that there are no 
additional new peaks for W41. The assignments of the W41 indole ring were based on 
2D 
1
H NOESY spectra recorded in H2O and D2O (unpublished data). The sample was the 
same as described in Figure 1 of the main text.  
135 
 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure S3. Overlay of 
15
N TROSY HSQC spectra of VAG-M2TM(22-46) in the absence 
(blue) and presence (red) of Amt (A) and Rmt (B) to illustrate the perturbation of the 
backbone conformation by drugs. 
1
H chemical shift changes for all three residues ranged 
from 0.2 to 0.5 ppm upon drug binding, showing the drug strongly perturbs pore-lining 
residues. Lineshape and intensity analysis shows that drug-bound peaks of the three 
residues are more uniform than the unbound peaks, indicating that the bound 
conformation is more homogeneous. The spectra were recorded on a 500 MHz and a 600 
MHz spectrometer. The peptide was reconstituted at 1 : 100 peptide/DPC, pH 7.5 (50 
mM sodium phosphate buffer), 313 K, and 2 mM peptide.  
136 
 
Figure S4 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure S4. Overlay of 
13
C HSQC spectra of VAG-M2TM(22-46) in the absence (blue) 
and presence (red) of Amt (A) and Rmt (B) to illustrate perturbation of the sidechain 
conformation by drugs. Chemical shifts are very similar for all peaks of the two bound 
forms, suggesting similar geometry of the complexes. The peptide was reconstituted at 
1 : 100 peptide/DPC, pH 7.5 (50 mM sodium phosphate buffer), 313 K, and 2 mM 
peptide.  
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        A                                                                    B 
 
Figure S5. Titration of 2 mM M2TM (residues 22-46) by Amt at 298 K, pH 8.0, 80 mM 
DPC (A) and at 313 K, pH 7.5, 200 mM DPC (B). Assignments of His37 HD2 were 
based on 2D 
1
H-
1
H NOESY spectra recorded in D2O and aromatic 
13
C-
1
H HSQC spectra 
(unpublished data). Two datasets are shown to demonstrate that the curves are essentially 
the same over a range of temperature, peptide/detergent ratios, and pH.  
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Figure S6. Amantadine remains bound in the pore in the presence of a large excess of 
drug, as assessed from intermolecular NOEs detected in the difference spectrum. The 
upfield region of the 2D (
13
C)-edited NOESY spectrum (200 ms mixing time) of M2TM 
with 20 eq protonated Amt (left) and deuterated Amt (middle) at 313 K gave rise to a 
difference spectrum (right) that shows the same intermolecular NOEs between Val27 and 
the drug as when the drug was present at much lower molar excess (Figure 3). 
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Figure S7. Chemical shift assignment of VAG-M2TM(22-46) in DPC micelles. (A) In 
the absence of drug. (B) Bound with Amt. (C) Bound with Rmt. The peptide was 
reconstituted at 1 : 100 peptide/DPC, pH 7.5 (50 mM sodium phosphate buffer in 10% 
D2O, 90% H2O), 313 K, 2 mM peptide (monomer concentration), and 1 mM Amt or Rmt.  
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5.1 ABSTRACT  
Amantadine has been used for decades as an inhibitor of the influenza A virus M2 protein 
(AM2) in the prophylaxis and treatment of influenza A infections, but its clinical use has 
been limited by its central nervous system (CNS) side effects as well as emerging drug-
resistant strains of the virus. With the goal of searching for new classes of M2 inhibitors, 
a structure-activity relation study based on 2-[3-azaspiro(5,5)undecanol]-2-imidazoline 
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(BL-1743) was initiated. The first generation BL-1743 series of compounds has been 
synthesized and tested by two-electrode voltage-clamp (TEV) assays. The most active 
compound from this library, 3-azaspiro[5,5]undecane hydrochloride (9), showed an IC50 
as low as 0.92±0.11 M against AM2, more than an order of magnitude more potent than 
amantadine (IC50=16 M). 
15
N and 
13
C solid-state NMR was employed to determine the 
effect of compound 9 on the structure and dynamics of the transmembrane domain of 
AM2 (AM2-TM) in phospholipid bilayers. Compared to amantadine, spiro-piperidine 9 
1) induces a more homogeneous conformation of the peptide, 2) reduces the dynamic 
disorder of the G34-I35 backbone near the water-filled central cavity of the helical 
bundle, and 3) influences the dynamics and magnetic environment of more residues 
within the transmembrane helices. These data suggest that spiro-piperidine 9 binds more 
extensively with the AM2 channel, thus leading to stronger inhibitory potency.   
 
5.2 Introduction 
The influenza virus, especially the H5N1 strain of influenza A, is a serious threat to 
human health. The outbreak of highly pathogenic H5N1 avian influenza virus in 1997 and 
2004/5 caused the death of millions of chickens and had a very high mortality rate among 
the limited number of infected humans. These cases cause great concern about the 
transmission of avian virus mutants among humans. The spread of influenza virus is 
mainly due to two factors: antigenic drift and antigenic shift.
1
 Antigenic drift due to point 
mutations of the virus’ negative-strand RNAs generates slightly modified antigens on the 
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virus surface, while antigenic shift causes reassortment of RNAs between viruses that 
infect avian populations and viruses that infect humans. The latter is a more serious 
problem since it produces more radically different antigenic determinants, for which there 
is little pre-existing immunity. Thus there is a great need for anti-influenza therapeutics. 
Currently there are two classes of small-molecule drugs in use to treat influenza virus 
infection 
2
: amantadine and rimantadine (Figure 1), which target the virus’ M2 proton 
channel, and Tamiflu (oseltamivir), which targets the virus surface protein neuraminidase.  
 
The AM2 proton channel plays an important role in viral replication by facilitating 
uncoating of the virus after its endocytosis into the host cells. The low pH of the 
endosome activates the AM2 channel, thus allowing proton flux into the viral interior. 
This acidification dissociates the viral RNA from its bound matrix proteins,
3
 a process 
that is required to release the viral genetic material to the cytoplasm for replication.
4
 In a 
later stage of viral replication, the M2 protein also equilibrates the pH gradient between 
the Golgi lumen and the cytoplasm, thus preventing premature conformational changes of 
hemagglutinin.
5,
 
6
 AM2 is a homo-tetrameric, type III integral membrane protein 
containing a small N-terminal periplasmic domain (23 residues), a single transmembrane 
domain (20 residues), and a C-terminal cytoplasmic tail (53 residues).
7
 
 
Structural studies of membrane proteins such as AM2 are often hampered by the 
difficulties associated with the production, functional characterization, and structure 
determination of this class of proteins. Structural analysis of AM2 has the additional 
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challenge of pH-induced changes in the TM region. Recently one of our groups solved the 
structures of the AM2 TM domain (22-46) both with (pH 5.3) and without (pH 7.3) 
bound amantadine using X-ray crystallography.
8
 In the crystal structure of amantadine-
M2TM complex, one drug binds each M2 tetramer in the pore, and the drug is surrounded 
by residues whose mutations cause amantadine resistance. This finding is consistent with 
the stoichiometry previously inferred from fluorescence titrations
9
 and 
electrophysiological measurements,
10
 which showed the binding of one drug per tetramer 
with a Hill coefficient of 1.0. Moreover, the amantadine and rimantadine sensitivity of 
AM2 channels expressed either in Xenopus oocytes or in mammalian cells revealed the 
drug-binding region in the TM domain to encompass residues V27, A30, S31, and G34. 
No mutations C-terminal to residue G34 have been found to be amantadine resistant, 
except H37 and W41, which are functionally important for the channel activity. These 
results are less consistent with the solution NMR structure of AM2(18-60) at higher pH 
(7.5), solved in the presence of 40 mM rimantadine.
11
 The solution NMR structure 
showed four rimantadine molecules per AM2 tetramer channel bound on the outside of 
the helices toward the cytoplasmic side of the membrane, with the basic amine group of 
rimantadine interacting with D44.  The authors suggested that rimantadine indirectly 
inhibits the channel by stabilizing the closed form of AM2, and that drug-resistant 
mutants escape inhibition by stabilizing the open state of the channel. However, this 
allosteric inhibition mechanism is not consistent with recent electrophysiological 
measurements of the amantadine-resistant mutations of AM2.
12
 Furthermore, mutations 
to the side chains that form the proposed surface site remained amantadine sensitive.
8
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Taken together, these data strongly suggest that the drug-binding site that is responsible 
for inhibition is located in the channel pore.  
 
 
Figure 1. Crystal structure of the amantadine-bound AM2-TM complex (PDB accession 
code: 3BKD). 
8
 
 
Amantadine targets AM2 by blocking the acidification of virus entrapped in endosomes.
13
 
Unfortunately the use of amantadine-related drugs is limited by central nervous system 
(CNS) side effects and the rapid emergence of drug-resistant viruses such as L26F, 
V27A, A30T and S31N.
14-16
  Extensive structure-activity relationship (SAR) studies of 
adamantyl derivatives 
2, 17-25
 have been evaluated, leading to a series of potent 
adamantane analogs active against H2N2 and H3N2 viruses.  However, few other 
molecular scaffolds have been explored, which led us to search for novel scaffolds that 
might provide new avenues for developing antagonists of AM2. The spirene guanidine 
analog, 2-[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-1743) (Figure 2), was previously 
discovered through a high-throughput screen based on the ability of inhibitors to reverse 
the toxicity associated with M2 channels expressed in the yeast Saccharomyces cerevisiae 
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membranes.
26
 It is one of the few examples of non-adamantane-based M2 inhibitors 
reported in the literature.
27-29
 
 
Figure 2. The chemical structures of AM2 channel inhibitors. 
 
The M2 channel, due to its proton conductance properties, disrupts the electrochemical 
potential across the yeast cell membrane when expressed in high copy numbers. This 
disruption results in retarded growth rate and eventually yeast cell death. The mechanism 
of AM2 channel inhibition by BL-1743 was further characterized by electrophysiological 
methods.
30
 BL-1743 is also able to inhibit the AM2 channel expressed in Xenopus 
oocytes, as determined using the two-electrode voltage clamp (TEV) technique. It was 
found that the majority of M2 sequences isolated from influenza viruses resistant to 
amantadine were also resistant to BL-1743, which suggests that BL-1743 binds 
competitively with amantadine. Interestingly, the kinetics of channel inhibition by BL-
1743 were more rapid, showing a fast onset of inhibition as well as a reasonably rapid 
reversal of inhibition following removal of the compound.
30,
 
31
 This behavior contrasts 
with that of amantadine, whose second-order rate constant for the onset of inhibition is 
much slower than the diffusion-controlled rate, and whose off-rate is essentially 
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irreversible on the minute to hour time scale of the experiment. The Hill coefficient for 
inhibition was 1.0, which is consistent with the binding ratio of one BL-1743 per AM2 
tetramer. Given the structural difference between BL-1743 and the amantadine class of 
compounds, and the lack of any published SAR studies for analogs of BL-17423, we have 
begun to explore this scaffold.  
 
The goals of this study are to: 1) explore the structure-activity relationship of BL-1743; 2) 
determine the binding specificity; 3) characterize the effects of the most potent inhibitor 
on the conformation and dynamics of AM2-TM in the lipid bilayer using solid-state NMR 
(SSNMR) spectroscopy.  SSNMR is ideally suited to atomic-level structural analysis of 
membrane proteins and their ligands in lipid bilayers, since it does not require long-range 
order nor fast isotropic mobility. Previously, SSNMR has been used to investigate the 
orientation, dynamics, and conformation of key residues of the influenza M2 protein; 
32-35
 
however,  it is only recently beginning to be used to investigate drug-M2 interactions in 
lipid bilayers.
36, 37
 We report herein the synthesis of our first generation BL-1743 series of 
inhibitors. Binding of the most potent compound, 3-azaspiro[5,5]undecane hydrochloride 
(9) to AM2 was characterized by 2D 
13
C and 
15
N NMR correlation experiments and 
linewidth analysis.  
 
5.3 Results and Discussion 
5.3.1 Structure-activity relationship (SAR) study of BL-1743 
 148 
 
The activity of the inhibitors were measured using the TEV technique with full length 
Udorn AM2 protein in the Xenopus oocytes membrane.
38
 All inhibitors were initially 
tested at 100 M; those that inhibited the AM2 channel activity by more than 70% (less 
than 30% remaining activity) were chosen for measurement of their IC50.  
 
Synthesis of BL-1743 started with reduction of commercially available 3,3-
pentamethylene glutarimide with LiAlH4 in refluxing THF to give 3-
azaspiro[5,5]undecane hydrochloride (9) in 75% yield after treatment with HCl/ether. 
Subsequent nucleophilic substitution of 2-methylthio-2-imidazoline with 9 furnished the 
model compound BL-1743.
39
 Reductive amination of 9 with different aldehydes using 
NaBH(OAc)3/HCO2H in dichloroethane
40
 gave 1-8 with yields of 65% to 95%. The 
results showed that replacements of the imidazoline ring of BL-1743 with either 
hydrophobic substitutions or heterocycles lacking hydrogen-bond donors (HBD) led to 
complete loss of potency at 100 M, as AM2 still retained >90% activity after inhibition. 
In contrast, inhibitors 7 and 8 with the imidazole headgroup retain moderate inhibition. 
This suggests that a hydrogen-bond donor may be necessary for the inhibitory activity. 
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Scheme 1. Synthesis of BL-1743 and N-substituted azaspiro[5,5]undecane 1-8. 
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Table 1. AM2 channel proton conductivity after applying 100 M inhibitors with cyclic 
hydrophobic and heterocyclic head groups.  
 
 
a 
As a positive control, the AM2 channel showed 6% remaining activity after 100 M 
amantadine inhibition. The IC50 of amantadine was determined to be 16 M.  
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Interestingly, the simple piperidine lacking the imidazoline group altogether, spiro-
piperidine 9 (3-azaspiro[5,5]undecane hydrochloride), had an IC50 of 0.92 ± 0.11 M 
(n = 6), representing a more than 45-fold increase in potency relative to BL-1743. Thus, 
the bulky imidazoline head group does not contribute to the affinity of BL-1743 to AM2.  
To determine whether the secondary amine is important for the activity of spiro-
piperidine 9, it was converted to the corresponding N-methyl piperidine 10 by reductive 
amination. This modification decreased the activity approximately 20-fold 
(IC50 = 20.6±2.14 M; n = 6), indicating that the polar secondary amine might be 
functionally important for inhibitor binding. To assess the potential role of charge, spiro-
piperidine 9 was modified to the corresponding unsubstituted guanidine (11), urea (12), 
thiourea (13), and sulfonamide (14). Synthesis of 11, 12, 13 were achieved using standard 
procedure by treatment of 9 with 1,3-diBoc-2-methyl-2-thiopseudourea, trimethylsilyl 
isocyanate, and trityl thioisocyanate respectively, followed by hydrolysis or acid 
deprotection  (Scheme 2).  The sulfonamide 14 was prepared using the literature reported 
sulfamoylating agent, N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-
dihydropyridin-1-ylsulfonyl]azanide.
41
  The guanidine compound 11 had a potency 
similar to the parent BL-1743, indicating that the cyclic ring in the imidazoline was not 
essential for activity.  The urea 12 and thiourea 13, by contrast, were not active. 
Interestingly, however, the sulfonamide 14 had a potency similar to BL-1743, indicating 
that a positively charged group was not a prerequisite for activity. Taken together, our 
results show that the most potent compound in this series was the simple piperidine, and 
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conversion of the secondary amine in 9 to tertiary amines decreased the potency.  
Furthermore, while compound 9 is likely to be charged at neutral pH, overall positive 
charge does not appear to be a prerequisite for activity, as long as appropriately placed 
polar groups were included as in 14. 
 
In our amantadine-complexed AM2-TM structure, the electron density map fits better 
with the positively charged amantadine amine pointing down towards H37, but the 
distance is too far (6.8 Å) for effective hydrogen bonding between the imidazoles and the 
amine (or ammonium group). However, more recent and higher-resolution AM2-TM 
crystal structures have shown two layers of well organized H2O above H37 (unpublished 
result). Thus, it is possible that the polar HBD group at the end of the inhibitor 
contributes to potency by forming hydrogen bonds with structural H2O molecules, while 
hydrophobic substituents at the same position would lead to energetically unfavorable 
dehydration of polar residues in the channel. This hypothesis might explain the reduced 
binding affinity of inhibitor 10 with methyl substitution. Similar structure-activity 
relations were also found in adamantane analogs, where methylation and ethylation of the 
amine group of all heterocycles caused a reduction of anti-influenza A virus activity 
17, 19-
22, 25
. 
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Scheme 2. Synthesis of methylated inhibitor 10, guanidine (11), urea (12), thiourea (13), 
and sulfonamide (14). 
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Table 2. AM2 channel activities after applying 100 M inhibitors with HBD acyclic head 
groups.  
 
 
 
Spiro amines with different fused ring sizes have also been synthesized to determine 
which one best fits the AM2 channel. Reduction of 8-azaspiro [4,5] decane-7, 9-dione by 
LiAlH4 gave 8-azaspiro [4,5]decane hydrochloride 15 after treatment with HCl/ether. 2-
azaspiro[4,5]decan-3-one was reduced and acidified to give 2-azaspiro[4,5]decane 
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hydrochloride (16) under the same condition. Ketal (17) and dithiene (18) versions of the 
spiro-piperidine 9 were synthesized by polyphosphoric acid catalyzed condensation.
42
 
Compared to 9, the contraction of the bottom cyclohexane ring to cyclopentane (15) led 
to a significant loss of activity (IC50 = 8.14±0.18 M).  Similarly, contraction of the 
piperidine ring to a pyrolidine (16) was also found to be unfavorable. These comparisons 
showed that the spiro[5,5] undecane was the most active. The ketal (17) and dithiene (18) 
retain the spiro 6-membered ring of spiro-piperidine 9, but have increased hydrophilicity 
compared to 9 (clogP = 3.38). The introduction of a ketal in 17 completely abolished the 
binding affinity (IC50>100 M), while dithiene 18 retained moderate binding 
(IC50 = 37.6±2.67 M). Presumably this finding reflects the energetics of dehydration of 
17, which has a clogP of -0.30 as compared to that of 18 (clogP = 1.28).    
 
To further test the role of the spiro system, the 6,6-fused decahydroisoquinoline (cis/trans 
mixture and trans isomer) was also tested and found to be less active than the 
corresponding spiro[5,5]undecane scaffold based inhibitors.  Two 4,4-disubstituted 
piperidines (19 and 20) were also synthesized and found to be no more advantageous than 
the corresponding spiro-piperidine. Thus, the [5,5] spiro ring system appeared to provide 
the greatest activity. 
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Scheme 3. Synthesis spiro-amines 15, 16, 17 and 18 with different ring sizes and 
substitutions. 
 
 
 
Table 3. AM2 channel activities after applying 100 M inhibitors of 3-azaspiro 
[5,5]undecane analogs. 
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Scheme 4. Synthesis 4,4-disubstituted piperidines. 
 
 
Table 4. Potency of decahydroisoquinoline and 4,4-disubstituted acyclic piperidines. 
 
 
5.3.2 Structural basis for activity   
The most active compound, spiro-piperidine 9, was selected for docking experiments 
with AM2-TM. The minimum energy conformation of 9 was docked into the previously 
published high resolution AM2-TM structure (PDB code: 3BKD). As would be expected, 
the optimized docking conformation showed spiro-piperdine 9 located inside the channel 
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with the amine group pointing either up or down the channel. The amine group of 9 could 
be hydrated in both orientations, but in neither case a specific interaction was formed 
between the amine and the AM2-TM protein.  
 
(a)  (b)
 (c)  
Figure 3. Docked conformation of spiro-piperidine 9 in AM2-TM channel (Only three of 
four helices are shown to enhance viewing of the inhibitor). a) Crystal structure of the 
amantadine-AM2 complex (PDB: 3BKD). Minimized conformation of spiro-piperidine 9 
inside the AM2 channel with the amine group pointing down (b) and up (c). Docking 
experiments are performed using Autodoc. Side chains of drug-surrounding residues V27, 
A30, S31, G34 and functionally essential residues H37 and W41 are shown. 
 
When overlaying the optimized docking conformation of the 9-AM2-TM complex with 
the X-ray crystal structure of amantadine-bound AM2-TM, we found that spiro-piperidine 
9 and amantadine occupied approximately the same region in the channel, spanning 
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residues 27-34.  A new structure was generated when overlaying the bottom cyclohexane 
ring of spiro-piperidie 9 with amantadine. Interestingly this hybrid molecule was recently 
reported in the literature to have highly potent anti-influenza activity, being 12-fold more 
active than amantadine and 2-fold more active than rimantadine when tested in virus 
infection assays. It is interesting to note that spiro-piperidine 9 is also 10 to 20-fold more 
active than amantadine 
20
.  Thus, it is likely that the bulky, hydrophobic adamantyl group 
of the spiro adamantane compound is not required for potent activity.   
 
 
Figure 4. Conformational analysis of spiro-piperidine 9. 3D conformations of amantadine 
and spiro-piperidine 9 are minimized using MOPAC in Chem3D. Models are generated 
in Pymol.  
 
5.3.3 Solid-state NMR characterization of AM2-TM bound to spiro-piperidine 9 
To investigate the interaction between AM2-TM and spiro-piperidine 9 as well as the 
effect of the drug on the peptide structure, we measured the 
15
N and 
13
C SSNMR spectra 
of bilayer-bound AM2-TM peptide complexed to the drug. The 
15
N cross-polarization 
(CP) spectra of the peptide were measured at both 313 K and 243 K. The low-temperature 
spectra report the conformation and conformational distribution of AM2-TM, while the 
high-temperature spectra reflect the dynamics of the peptide channel. AM2-TM (22-46) 
 160 
 
was bound to DLPC bilayers at a peptide : lipid molar ratio of 1 : 15, where the peptide is 
known to form tetramers based on previous 
19
F spin diffusion NMR experiments.
43
 
Figure 5a compares the low-temperature 
15
N spectra of the apo, amantadine-bound and 
spiro-piperidine 9-bound AM2-TM. The spiro-piperidine-bound peptide shows 
significantly narrower linewidths for all four labeled sites (L26, A29, G34, and I35) than 
either the apo or the amantadine-bound peptide. Since at low temperature all 
conformations are present, the narrower linewidths suggest that spiro-piperidine binding 
induces more homogeneous conformation of AM2-TM. To verify this possibility, we 
carried out 
15
N spin-echo measurements at 243 K. Residues L26, A29 and the upfield 
G34 peak (G34a) show very similar 
15
N T2 values of 10 – 11 ms for both the amantadine-
bound peptide and the spiro-piperidine-bound peptide, confirming that the line narrowing 
by spiro-piperidine 9 indeed results from reduced conformational heterogeneity of these 
residues. However, the downfield G34 peak (G34b) increased its 
15
N T2 from 12 ms to 15 
ms while the I35 
15
N T2 increased from 13 ms to 22 ms in the presence of 9. These 
significant T2 increases indicate that the G34-I35 junction of the peptide is more 
immobilized by spiro-piperidine 9 than by amantadine, thus part of the line narrowing for 
these two sites is due to the reduction of dynamic disorder.  
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Figure 5. 
15
N CP-MAS spectra of LAGI-AM2-TM in DLPC bilayers at (a) 243 K and (b) 
313 K. Three states of the peptide are compared: apo (bottom), bound to amantadine 
(middle row), and bound to spiro-piperidine 9 (top row).  
 
2D 
15
N-
13
C correlation spectra in Figure 6 confirm the increased conformational 
homogeneity of AM2-TM upon spiro-piperidine binding. The most significant line 
narrowing is found at I35 and L26, whereas more modest line narrowing is observed at 
A29 and G34 (Table 5). The line narrowing of L26 is interesting, because this residue is 
at the edge of the binding pocket of amantadine based on the crystal structure.
8
 Indeed, 
amantadine-bound AM2-TM did not show narrower L26 
15
N linewidth than apo AM2-
TM. This suggests that the bulkier spiro-piperidine 9 has a larger rigidifying effect that 
extends over a larger area of the AM2 channel. Similarly, based on the 
15
N linewidth, I35 
exhibits little conformational ordering by amantadine but is significantly ordered by 
spiro-piperidine 9. Taken together, the data indicate that spiro-piperidine 9, compared to 
amantadine, induces a more homogeneous structure of AM2-TM from L26 to I35. 
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Figure 6.  2D 
15
N-
13
C spectra of LAGI AM2-TM in DLPC bilayers at 243 K. (a) Apo 
peptide. (b) Amantadine-bound peptide. (c) Spiro-piperidine 9 bound peptide. (d) 1D 
15
N 
cross sections of G34. Note the separation of two G34 peaks in the spiro-piperidine-
bound sample.  
 
The 
15
N spectra in Figures 5 and 6 also show that the G34 chemical shifts are very 
sensitive to the state of AM2-TM. The apo peptide shows a broad G34 
15
N peak, 
indicating a distribution of conformations. Upon amantadine binding this broad 
15
N peak 
is partly resolved into two peaks with similar heights. Spiro-piperidine 9 shifts the 
conformational equilibrium to predominantly the downfield 
15
N conformer (G34b, 110.3 
ppm), which also becomes narrower, indicating reduced conformational heterogeneity.  
 
Table 5. 
15
N chemical shifts (N) and full width at half maximum (1/2) of LGAI AM2-
TM in DLPC bilayers at 243 K.   
 
 Apo Amantadine-bound Spiro-piperidine 9 bound 
 N (ppm) 1/2 (Hz) N (ppm) 1/2 (Hz) N (ppm) 1/2 (Hz) 
L26 117.7 340 117.5 340 117.5 210 
A29 120.9 200 121.7 210 121.2 170 
G34a 107.1 270 106.3 240 106.6 280 
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G34b - - 109.7 230 110.3 140 
I35 122.3 280 124.6 270 124.8 160 
 
In addition to 
15
N chemical shifts, we measured the 
13
C chemical shifts of the peptide 
using the 2D INADEQUATE experiment. Figure 7 shows the 2D spectra of AM2-TM in 
the three states. The main linewidth reduction is found for L26 sidechain C and C 
peaks, which became much better resolved in the spiro-piperidine-bound sample (Figure 
7b). In addition, the other L26 C peak (24 ppm) is shifted downfield compared to the 
apo and amantadine-bound peptide (Figure 7c). A recent study by London et al. 
44
 and our 
own studies of Val and Leu sidechains in protein NMR structures found that methyl 
13
C 
chemical shifts are sensitive to protein sidechain conformation. Thus, these L26 chemical 
shift changes suggest perturbation and ordering of the L26 sidechain by spiro-piperidine 
9.  
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Figure 7. (a) 2D 
13
C-
13
C INADEQUATE spectrum of spiro-piperidine-bound AM2-TM 
at 243 K. (b) The L26 C/Cregion of apo, amantadine-bound, and spiro-piperidine-
bound peptide. (c) 1D cross sections at 1 = 49 ppm shows the line narrowing and 
chemical shift changes induced by the two drugs.  
 
In the liquid-crystalline phase of DLPC lipids, it is known that the apo and amantadine-
bound AM2-TM undergoes fast (> 120 kHz) uniaxial rotational diffusion around the 
membrane normal 
32
. This is also observed for the spiro-piperidine-bound peptide based 
on 
15
N spectra measured as a function of temperature (Figure 8). The lowest (243 K) and 
highest (313 K) temperatures give the greatest intensities, whereas at intermediate 
temperatures of 263 – 293 K most 15N signals are suppressed. This trend is characteristic 
of molecular motion, which interferes with 
1
H decoupling and 
1
H-
15
N CP when the 
motional rates are comparable to the 
1
H-
15
N dipolar couplings. When the motions are 
much slower or faster than the dipolar interaction, rigid-limit or motionally averaged 
spectra with high intensities are obtained.  
 
Figure 8b and c plot the intensities of the four 
15
N peaks at different temperatures 
quantitatively. The L26, A29 and G34a intensities show the aforementioned minimum at 
intermediate temperature. In contrast, I35 and G34b do not exhibit intensity recovery at 
high temperature, indicating that these two residues are still in the intermediate motional 
regime at 313 K. Thus, the two G34 conformations have different dynamics, with the 
G34b conformer being more immobilized than G34a. The intermediate motion of G34b 
and I35 at 313 K is also consistent with their longer 
15
N T2 values at low temperature, 
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indicating that this region of the peptide is more immobilized by spiro-piperidine 9 than 
are other residues.  
 
 
Figure 8. (a) Variable-temperature 
15
N CP-MAS spectra of LAGI AM2-TM in DLPC 
bilayers from 243 K to 313 K. (b) I35 and G34 intensities as a function of temperature. 
G34a: 106.6 ppm. G34b: 110 ppm. Note the recovery of the G34a intensity at 313 K, in 
contrast to G34b and I35. (c) L26 and A29 
15
N intensities as a function of temperature.  
 
5.4 Conclusion 
In summary, a class of spirene-based AM2 inhibitors was identified from this study. The 
most potent compound from this series, 3-azaspiro[5,5]undecane hydrochloride (9), 
showed an IC50 of 0.92±0.11 M, which is more than an order of magnitude more potent 
than amantadine. Solid-state NMR data indicate that compound 9 interacts with AM2-
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TM differently from amantadine: it affects a longer stretch of the transmembrane helix, 
induces a more homogeneous conformation of the peptide, and immobilizes the G34-I35 
region. These structural findings make compound 9 an attractive molecule for atomic-
level structural investigation of drug-complexed AM2-TM. It is well known that the apo-
form of AM2-TM has extensive conformational and dynamic disorder in lipid bilayers 
32, 
36, 45
 and detergents.
11
 Amantadine was previously found to accelerate the peptide motion, 
which enhances the NMR spectral resolution at ambient temperature.
36
 However, the low 
temperature 
15
N spectra shown here indicate that substantial conformational heterogeneity 
remains in the amantadine-bound AM2-TM. Spiro-piperidine 9 significantly reduces this 
conformational heterogeneity, and immobilizes the G34-I35 region of the peptide, which 
is a hot spot of conformational change in response to environments. These favorable 
properties make spiro-piperidine a promising compound for examining the structure of 
M2-channel complex in lipid bilayers. Continuing synthetic studies have been initiated to 
generate more diversity based on the spirene scaffold, with the aim of discovering 
inhibitors to target AM2 mutants, predominantly S31N.  
 
5.5 Experimental details 
In Vitro cRNA Transcription, Heterologous Expression and Electrophysiological 
Recordings  
The cDNA encoding to the influenza virus A/Udorn/72 AM2 protein was inserted into 
pGEMHJ (a gift from N.Dascal Tel-Aviv University, Israel) for the expression on 
Xenopus oocytes. Plasmid was linearized with HindIII, and capped cRNA was transcribed 
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in vitro using T7 RNA polymerase (mMessage mMachine; Ambion, Austin, TX).  The 
quality of transcripts was assessed by agarose gel electrophoresis and ethidium bromide 
staining and analytical UV spectroscopy. Stage V-VI Xenopus laevis oocytes were 
prepared as described previously.
46
 Oocytes were injected with 5-10 ng of cRNA in 50 
nl/oocyte, and assayed 2-3 days later. Two electrode voltage clamp recordings were 
carried out using TEV-200 (Dagan, Minneapolis, MN) connected to DIGIDATA 1440A 
and pCLAMP10 (Axon Instruments, Foster City, CA). Oocytes were superfused with 
Barth’s solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM NaNO3, 
0.71 mM CaCl2, 0.82 mM MgCl2 and 15 mM HEPES for pH 8.5 or 15 mM MES for pH 
5.5. Currents were recorded at -20 mV. Dose-inhibition curves were usually constructed 
by applying 1-3 concentrations per oocyte of antagonist mixed in recording pH5.5 Barth’s 
solution, and currents were normalized to the steady-state current obtained with pH5.5 
Barth solution alone.  Data were analyzed using the ORIGIN 8.0 software (OriginLab, 
Northampton, MA).  
 
Preparation of M2 membrane samples for solid-state NMR 
13
C and 
15
N-labeled AM2-TM (22-46) of the Udorn strain 
47
 (SSDPL VVAASII 
GILHLIL WILDRL) was synthesized by PrimmBiotech (Cambridge, MA) and purified to 
>95%. 
13
C and 
15
N-labeled amino acids were placed at L26, A29, G34 and I35 in one 
sample and V27, A30, I33 and L38 in another sample.  
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AM2-TM was reconstituted into 1, 2-dilauroyl-sn-glycero-3-phosphatidylcholine (DLPC) 
or 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) bilayers by detergent 
dialysis as described before.
43, 48 
The peptide structure and dynamics have been 
extensively characterized in both bilayers.
32, 36
 AM2-TM was first dissolved in octyl--D-
glucopyranoside (OG) solution, then mixed with the lipid vesicle solution at pH 7.5. OG 
was then removed by dialysis for 3 days. The peptide-lipid suspension was 
ultracentrifuged to obtain the membrane pellet. The peptide: lipid molar ratio was 1 : 15. 
3-azaspiro [5,5]undecane was added to the membrane by either direct titration to the 
pellet at a peptide : drug molar ratio of 1 : 2, or through a 10 mM solution before 
ultracentrifugation. For the latter, the percent spiro-piperidine 9 remaining in the 
supernatant was quantified by 
1
H solution NMR to be 60%, giving a peptide: drug molar 
ratio of 1: 8 in the membrane pellet.   
 
Solid-state NMR spectroscopy 
SSNMR experiments were carried out on Bruker wide-bore AVANCE and DSX 
spectrometers at 14.1 Tesla and 9.4 Tesla (Karlsruhe, Germany) using 4 mm magic-angle-
spinning (MAS) probes. Radio-frequency pulse lengths were typically 5 s for 13C and 
15
N and 3.5-4.0 s for 1H. 1H TPPM 49 or SPINAL 50 decoupling field strengths of 60 – 
70 kHz were applied. 
13
C and 
15
N chemical shifts were referenced, respectively, to the -
Gly C’ signal at 176.49 ppm on the TMS scale and the 15N signal of N-acetyl-valine at 
122.0 ppm on the liquid ammonia scale. 2D 
13
C-
13
C correlation was carried out using the 
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INADEQUATE sequence 
51, 52
 which better resolves sidechain methyl signals than the 
standard spin diffusion experiments. 2D 
15
N-
13
C correlation was carried out using an 
HSQC-type sequence
53
 incorporating a REDOR train for 
15
N-
13
C coherence transfer.
54
 
The 2D spectra were measured at 243 K to freeze the peptide motion.  
 
The numbers of scans for the 1D 
15
N CP spectra of the apo-, amantadine-bound and 
spiro-piperidine-bound AM2-TM were 3,000-6,000 at low temperatures (< 263 K) and 
30,000-40,000 at high temperatures (> 263 K). For the 2D 
15
N-
13
C correlation spectra, 
352 scans were coadded per t1 slice and a maximum t1 evolution time of 8.8 ms was used, 
resulting in a measuring time of 21 hours for each experiment. For the 2D 
13
C-
13
C 
INADEQUATE spectra, the number of scans per t1 slice was 192 and the maximum t1 
evolution time was 6.4 ms. The measuring time was 20 hours for each experiment. 
 
Chemical synthesis 
All chemicals were purchased from commercial vendors and used without further 
purification unless otherwise noted. 3, 3-Pentamethylene glutarimide was purchased from 
Bosche, NJ. 
1
H NMR and 
13
C NMR spectra were recorded on a DMX-360 NMR 
spectrometer. Chemical shifts are reported in parts per million referenced with respect to 
residual solvent (CHCl3 = 7.26 ppm and DMSO-d6 = 2.50 ppm) or from internal standard 
tetramethylsilane (TMS = 0.00 ppm). The following abbreviations were used in reporting 
spectra: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
doublets. All reactions were carried out under N2 atmosphere, unless otherwise stated. 
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HPLC grade solvents were used for all the reactions. Column chromatography was 
performed using silica gel (230-400 mesh). Low-resolution mass spectra were obtained 
on an LC platform from Micromass using ESI technique.  
 
3-azaspiro[5,5]undecane chloride (9) 
To a solution of the LiAlH4 (0.38 g, 10 mmol) in THF (20 mL) at 0
o
C was added 3,3-
pentamethylene glutarimide (0.36 g, 2 mmol) in THF (10 mL) dropwise under a nitrogen 
atmosphere. The reaction was allowed to warm to RT over 30 min, then refluxed 
overnight. The solution was cooled to 0
o
C, and quenched with H2O (0.38 mL), 15% 
NaOH (0.38 mL), and H2O (1.14 mL) sequentially. The resulting slurry was filtered. The 
filtrate was diluted with CH2Cl2, washed with brine, dried over MgSO4, filtered, 
concentrated in vacuo and purified by flash chromatography to give 3-
azaspiro[5,5]undecane as a yellow oil. The hydrochloride salt was prepared by passing 
HCl gas into the ether solution of 3-azaspiro[5,5]undecane at 0
o
C, followed by decanting 
the ether supernatant. The final white solid (0.28 g, 75% yield) was dried in vacuo. 
1
H 
NMR (360 MHz, CDCl3)  9.29 (br s, 2H), 3.14 (t, J = 5.87 Hz, 4H), 1.74 (t, J = 5.87 Hz, 
4H), 1.43 (m, 10H); 
13
C NMR (90 MHz, CDCl3)  39.93, 35.85, 32.76, 30.60, 26.53, 
21.37; ESI-MS: Calculated for  C10H20ClN (M -Cl)
+
 154.2, Found: 154.5. 
 
3-(4,5-dihydro-1H-imidazol-2-yl)-3-azaspiro[5,5]undecane hydroiodide (BL-1743) 
3-Azaspiro[5,5]undecane (0.38 g, 2 mmol) and 2-methylthio-2-imidazoline hydroiodide 
(0.44 g, 1.8 mmol) was refluxing in CH3OH overnight, concentrated in vacuo and 
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purified by flash chromatography to give yellow oil (0.26 g, 65% yield). 
1
H NMR (360 
MHz, CDCl3)  8.27 (br s, 2H), 3.72 (s, 4H), 3.39 (t, J = 5.83 Hz, 4H), 1.50 (t, J = 5.94 
Hz, 4H), 1.47-1.44 (m, 10H); 
13
C NMR (90 MHz, CDCl3)  159.48, 43.39, 42.73, 36.02, 
35.26, 30.83, 26.65, 21.61. 21.49; ESI-MS: Calculated for C13H24IN3 (M -I)
+
 222.3, 
Found: 222.5. 
 
3-(cyclopropylmethyl)-3-azaspiro[5,5]undecane (1) 
To a solution of 3-azaspiro[5,5]undecane (0.34 g, 2.2 mmol), cyclopropanecarbaldehyde 
(0.14 g, 2 mmol) and NaBH(OAc)3 (0.64 g, 3 mmol) in dichloroethane (10 mL) were 
added AcOH (0.12 mL, 2 mmol), the resulting suspension was stirred overnight, 
quenched with NaHCO3 and extracted with CH2Cl2 twice, the combined organic layer 
was washed with brine, and dried with MgSO4. The solution was filtered, concentrated in 
vacuo and purified by flash chromatography.  The compound was converted to the 
hydrochloride by passing HCl gas into the ether solution of 3-(cyclopropylmethyl)-3-
azoniaspiro[5,5]undecane at 0
o
C, followed by decanting the ether supernatant, the final 
white solid (0.39 g, 80% yield) was dried in vacuo. 
1
H NMR (360 MHz, CDCl3)  2.45 (t, 
J=5.66 Hz, 4H), 2.23 (d, J=6.51 Hz 2H), 1.49 (t, J= 5.66 Hz, 4H), 1.48-1.40 (m, 6H), 
1.38-1.30 (m, 4H), 0.92-0.82 (m, 1H), 0.52-0.47 (m, 2H), 0.11-0.17 (m, 2H); 
13
C NMR 
(90 MHz, CDCl3)  64.55, 49.67, 36.47, 35.46, 31.00, 27.12, 21.73, 8.74, 4.19; ESI-MS: 
Calculated for C14H25N (M +H)
+
 208.4, Found: 208.4. 
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3-(cyclopentylmethyl)-3-azaspiro[5,5]undecane (2) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
95% yield. 
1
H NMR (360 MHz, CDCl3)  2.35 (t, J= 5.56Hz, 4H), 2.25 (d, J=7.08 Hz, 
2H), 2.06-2.02 (m, 1H), 1.76-1.73 (m, 2H), 1.58-1.52 (m, 4H), 1.45 (t, J= 5.56 Hz, 4H), 
1.43-1.39 (m, 6H), 1.39-1.31 (m, 4H), 1.20-1.14 (m, 2H); 
13
C NMR (90 MHz, CDCl3)  
65.52, 49.93, 37.80, 36.51, 35.47, 32.08, 31.00, 27.14, 25.44, 21.74; ESI-MS: Calculated 
for C16H29N (M +H)
+
 236.4, Found: 236.6. 
 
3-(thiophen-3-ylmethyl)-3-azaspiro[5,5]undecane (3) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
92% yield. 
1
H NMR (360 MHz, CDCl3)  7.24 (d, J= 4.88Hz, 1H), 7.09 (s, 1H), 7.04 (d, 
J= 4.88Hz, 1H), 3.35 (s, 2H), 2.37 (t, J=5.52Hz, 4H), 1.46 (t, J= 5.52 Hz, 4H), 1.37-1.34 
(m, 6H), 1.30-1.26 (m, 4H); 
13
C NMR (90 MHz, CDCl3)  129.02, 125.39, 123.11, 58.14, 
49.37, 36.77, 36.35, 30.92, 27.08, 21.72; ESI-MS: Calculated for C15H23NS (M +H)
+
 
250.4, Found: 250.4. 
 
3-((1-methyl-1H-pyrazol-4-yl)methyl)-3-azaspiro[5,5]undecane (4) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
82% yield. 
1
H NMR (360 MHz, CDCl3)  7.93 (s, 1H), 7.28 (s, 1H), 3.87 (s, 3H), 3.41 (s, 
2H), 2.38 (t, J=5.38Hz, 4H), 1.46 (t, J= 5.38 Hz, 4H), 1.39-1.34 (m, 6H), 1.30-1.24 (m, 
4H); 
13
C NMR (90 MHz, CDCl3)  141.15, 140.30, 130.18, 52.93, 48.97, 39.03, 36.29, 
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35.45, 30.90, 27.05, 21.70; ESI-MS: Calculated for C15H25N3 (M +H)
+
 248.4, Found: 
248.6. 
 
3-(3-azaspiro[5,5]undecan-3-ylmethyl)-5-methylisoxazole (5) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
75% yield. 
1
H NMR (360 MHz, CDCl3)  6.00 (s, 1H), 3.54 (s, 2H), 2.41 (t, J=5.73, 4H), 
2.39 (s, 3H), 1.46 (t, J= 5.73 Hz, 4H), 1.39-1.35 (m, 6H), 1.30-1.25 (m, 4H); 
13
C NMR 
(90 MHz, CDCl3)  169.41, 161.90, 102.05, 53.94, 49.49, 36.74, 30.75, 27.05, 21.68, 
12.47; ESI-MS: Calculated for C15H24N2O (M +H)
+
 249.4, Found: 249.6. 
 
3-(pyridin-2-ylmethyl)-3-azaspiro[5,5]undecane (6) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
84% yield. 
1
H NMR (360 MHz, CDCl3)  8.56 (d, J = 4.8 Hz, 1H), 7.63 (td, J = 7.6, 1.6 
Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 7.15-7.13 (m, 1H), 3.65 (s, 2H), 2.44 (t, J=5.58 Hz, 
4H), 1.48 (t, J= 5.58Hz, 4H), 1.39-1.36 (m, 6H), 1.30-1.25 (m, 4H); 
13
C NMR (90 MHz, 
CDCl3)  149.36, 136.47, 130.58, 123.42, 122.03, 65.32, 49.79, 36.44, 35.46, 30.87, 
27.10, 21.72; ESI-MS: Calculated for C16H24N2 (M +H)
+
 245.4, Found: 245.6. 
 
3-((1H-imidazol-4-yl)methyl)-3-azaspiro[5.5]undecane (7) 
The same procedure as described for synthesis 1. 68% yield. 
1
H NMR (360 MHz, 
CD3OD) δ 8.97 (s, 1H), 7.81 (s, 1H), 4.56 (s, 2H), 3.34 (br s, 4H), 1.77 (br s, 4H), 1.54-
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1.48 (m, 10H); 
13
C NMR (90 MHz, CDCl3)  137.47, 124.34, 123.60, 50.18, 49.86, 
34.31, 31.21, 27.58, 22.50;  ESI-MS: Calculated for C14H23N3 (M +H)
+
 234.4, Found: 
234.6. 
 
3-((1H-imidazol-2-yl)methyl)-3-azaspiro[5.5]undecane (8) 
This compound was prepared by the same procedure as described for the synthesis of 1. 
65% yield. 
1
H NMR (360 MHz, CD3OD)  7.51 (s, 2H), 4.55 (s, 2H), 3.22 (t, J=5.94Hz 
4H), 1.74 (t, J=6.01Hz, 4H), 1.47-1.45 (m, 10H); 
13
C NMR (90 MHz, CDCl3)  123.49, 
51.45, 50.37, 34.64, 31.16, 27.62, 22.51; ESI-MS: Calculated for C14H23N3 (M +H)
+
 
234.4, Found: 234.6. 
 
3-methyl-3-azoniaspiro[5,5]undecane chloride (10) 
To a solution of 3-azaspiro[5,5]undecane (0.38 g, 2 mmol), formaldehyde (0.15 g 5 
mmol) and NaBH(OAc)3 (0.42 g, 2 mmol) in dichloroethane (10 mL) were added AcOH 
(0.12 g, 2 mmol); the resulting suspension was stirred overnight, diluted with NaHCO3 
extracted with CH2Cl2 twice, washed with brine, and dried with MgSO4. The solution 
was filtered, concentrated in vacuo and purified by flash chromatography. The 
hydrochloride salt was prepared by passing HCl gas into the ether solution of 3-methyl-3-
azoniaspiro[5,5]undecane at 0
o
C, followed by decanting the ether supernatant, the final 
white solid (0.33 g, 80% yield) was dried in vacuo. 
1
H NMR (360 MHz, CDCl3)  3.35-
3.31 (m, 2H), 2.83-2.79 (m, 2H), 2.75 (d, J=4.89Hz, 3H), 2.10-2.00 (m, 2H), 1.77-1.74 
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(m, 2H), 1.45-1.39 (m, 10H); 
13
C NMR (90 MHz, CDCl3)  50.56, 43.69, 39.69, 32.91, 
31.43, 26.49, 21.55; ESI-MS: Calculated for C11H22ClN (M -Cl)
+
 168.4, Found: 168.6. 
 
3-azaspiro[5,5]undecane-3-carboximidamide (11) 
3-azaspiro[5,5]undecane (0.38 g, 2 mmol), HgCl2 (0.54 g, 2 mmol) and 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (0.58 g, 2 mmol) were stirred in DMF (10 
mL) under N2 atmosphere for 24 hr, H2O was added, and the white precipitate was 
removed by filtration.  The precipitate was washed with CH2Cl2 twice, the combined 
filtrate was extracted with CH2Cl2, washed with brine, dried with MgSO4, concentrated in 
vacuo and purified by flash column. The Boc protecting group was removed by 20% 
TFA/CH2Cl2 for 2 hr at RT. Excess TFA was removed by passing N2 through the solution 
to give yellow solid which was subsequently purified by flash column (0.28 g, 71% over 
two steps). 
1
H NMR (360 MHz, CD3CN)  5.11 (br s 2H), 3.12 (t, J = 5.74 Hz, 4H), 1.57 
(t, J = 5.74 Hz, 4H), 1.46-1.35 (m, 10H); 
13
C NMR (90 MHz, CD3CN)  157.20, 41.78, 
35.64, 35.06, 26.48, 21.26, 20.94; ESI-MS: Calculated for C11H21N3 (M+H)
+
 196.3, 
Found: 196.3. 
 
3-azaspiro[5,5]undecane-3-carboxamide (12) 
Triethylamine (0.42 mL, 3 mmol) was added to 3-azaspiro[5,5]undecane (0.38 g, 2 mmol) 
in CH2Cl2 (10 mL) at 0
o
C, then trimethylsilyl isocyanate (0.35 g, 3 mmol) was added 
dropwise to the solution under N2.  The solution was allowed to warm to RT and stirred 
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for 7 hr.  H2O was added and the solution was extracted with CHCl3 twice, the combined 
organic layer was dried with MgSO4, filtered, concentrated in vacuo and purified by flash 
column to give a white powder (0.32 g, 82% yield). 
1
H NMR (360 MHz, CD3CN)  5.23 
(br s, 2H), 3.31 (t, J = 5.87 Hz, 4H), 1.46-1.36 (m, 14H); 
13
C NMR (90 MHz, CD3CN)  
160.23, 41.09, 37.21, 36.95, 27.87. 22.57, 21.83; ESI-MS: Calculated for C11H20N2O (M-
H)
-
 195.3, Found: 195.1. 
 
3-azaspiro[5,5]undecane-3-carbothioamide (13) 
3-azaspiro[5,5]undecane (0.38 g, 2 mmol) and trityl isothiocyanate (0.54 g, 1.8 mmol) 
was stirred in THF at RT for 8 hr until the disappearance of trityl isothiocyanate (based 
on TLC), then the mixture was concentrated in vacuo and purified by flash column 
(hexane/CHCl3=1:1 to CHCl3) to give a white foam. This was followed by deprotection 
of trityl group using 20% TFA/CH2Cl2 for 2 hr at RT. TFA was removed by passing N2 
through the solution to give yellow solid which was subsequently purified by flash 
column (0.29 g, 76% yield over two steps). 
1
H NMR (360 MHz, CD3CN)  6.04 (br s 2H), 
3.70 (t, J=5.76Hz, 4H), 1.48-1.37 (m, 14H), 1.46-1.36 (m, 14H); 
13
C NMR (90 MHz, 
CD3CN)  181.49, 45.25, 37.46, 37.08, 32.16, 27.89, 22.73; ESI-MS: Calculated for 
C11H20N2S (M+Na)
+
 236.4, Found: 236.8. 
 
3-azaspiro[5,5]undecane-3-sulfonamide (14) 
The sulfamoylating agent, N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-
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dihydropyridin-1-ylsulfonyl]azanide, was synthesized according to literature protocols.
41
 
3-azaspiro[5,5]undecane (0.38 g, 2 mmol) and the sulfamoylating agent (0.602 g, 2 mmol) 
were stirred in CH2Cl2 (10 mL) at RT overnight. Solvent was removed by rotary 
evaporation and the residue was purified by flash column to give tert-butyl 3-
azaspiro[5,5]undecan-3-ylsulfonylcarbamate. The Boc protecting group was removed by 
20% TFA/CH2Cl2 for 2 hr at RT. Excess TFA was removed by passing N2 through the 
solution to give yellow solid which was subsequently purified by flash column (0.29 g, 
62% yield for 3 steps). 
1
H NMR (360 MHz, CD3CN)  5.01 (br s 2H), 3.03 (t, J = 5.78 
Hz, 4H), 1.53 (t, J = 5.78 Hz, 4H), 1.46-1.35 (m, 10H); 
13
C NMR (90 MHz, CD3CN)  
41.78, 35.62, 35.06, 26.41, 21.06, 20.84; ESI-MS: Calculated for C10H20N2O2S (M+H)
+
 
233.3, Found: 233.1. 
 
8-azoniaspiro[4,5]decane chloride (15) 
Synthesis of 15 was accomplished following the same procedure as described for 9. 72% 
yield. 
1
H NMR (360 MHz, CDCl3)  2.80 (t, J=5.62, 4H), 1.61 (t, J=5.62Hz, 4H), 1.43-
1.40 (m, 8H); 
13
C NMR (90 MHz, CDCl3)  44.18, 41.43, 38.70, 35.45, 24.46; ESI-MS: 
Calculated for C9H18ClN (M-Cl)
+
 140.4, Found: 140.6. 
 
2-azoniaspiro[4,5]decane chloride (16) 
Synthesis of 16 was accomplished following the same procedure as described for 9. 85% 
yield. 
1
H NMR (360 MHz, CDCl3)  9.67 (br s, 2H), 3.39 (Quintet, J=7.10 Hz, 2H), 3.07 
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(t, J=5.75Hz, 2H), 1.85 (t, J=7.49Hz, 2H), 1.52-1.46 (m, 10H); 
13
C NMR (90 MHz, 
CDCl3)  54.68, 43.97, 43.05, 35.86, 35.44, 25.72, 23.47; ESI-MS: Calculated for 
C9H18ClN (M-Cl)
+
 140.4, Found: 140.2. 
 
1,5-dioxa-9-azaspiro[5,5]undecane (17) 
4-Piperidone hydrochloride (0.31 g, 2 mmol), 1,3-propanediol (0.76 g, 10 mmol) and 
phosphoric acid (0.5 g) were stirred at 65
o
C for 6 hr. Saturated Na2CO3 was added and 
the solution was extracted with CHCl3 twice; the combined CHCl3 was washed with DI 
H2O, dried over Mg2SO4, and concentrated in vacuo to give yellow oil. (0.23 g, 73% 
yield). 
1
H NMR (360 MHz, CDCl3)  3.91 (t, J=5.62, 4H), 2.86 (t, J=5.58, 4H), 2.50 (s br, 
1H), 1.84 (t, J=5.58Hz, 4H), 1.73 (quintet, J=3.56, 2H); 
13
C NMR (90 MHz, CDCl3)  
108.62, 59.41, 43.26, 34.55, 25.87; ESI-MS: Calculated for C8H15NO2 (M+H)
+
 158.2, 
Found: 158.5. 
 
1,5-dithia-9-azaspiro[5,5]undecane (18) 
Synthesis of 18 was accomplished using the same procedure as described for 9. 75% yield. 
1
H NMR (360 MHz, CDCl3)  2.96 (t, J=5.39, 4H), 2.83 (t, J=5.39, 4H), 2.06-1.97 (m, 
6H), 1.56 (s, 1H); 
13
C NMR (90 MHz, CDCl3)  48.97, 42.49, 38.87, 26.20, 25.87; ESI-
MS: Calculated for C8H15NS2 (M+H)
+
 190.3, Found: 190.4. 
 
4,4-dimethylpiperidinium chloride (19) 
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Synthesis of 19 was accomplished using the same procedure as described for 9. 87% yield. 
1
H NMR (360 MHz, CDCl3)  9.37 (br s, 2H), 3.15 (t, J=5.97, 4H), 1.68 (t, J=5.97, 4H), 
1.04 (s, 6H), 1.56 (s, 1H); 
13
C NMR (90 MHz, CDCl3)  40.64, 35.21, 28.29, 27.64; ESI-
MS: Calculated for C7H16ClN (M-Cl)
+
 114.4, Found: 114.6. 
 
4-ethyl-4-methylpiperidinium chloride (20) 
Synthesis of 20 was accomplished using the same procedure as described for 9. 82% yield. 
1
H NMR (360 MHz, CDCl3)  9.38 (br s, 2H), 3.19-3.09 (m, 4H), 1.77-1.73 (m, 2H), 
1.71-1.62 (m, 2H), 1.37 (q, J=7.34Hz, 2H), 0.97 (s, 3H), 0.85 (t, J=7.45Hz, 2H); 
13
C 
NMR (90 MHz, CDCl3)  40.37, 33.41, 33.24, 30.70, 22.88, 7.52; ESI-MS: Calculated 
for C8H18ClN (M-Cl)
+
 128.2, Found: 128.4. 
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6.1 ABSTRACT  
The A/M2 proton channel of influenza A virus is a target for the anti-influenza drugs 
amantadine and rimantadine, whose effectiveness was diminished by the appearance of 
naturally occurring point mutants in the A/M2 channel pore, among which the most 
common are S31N, V27A and L26F. We have synthesized and characterized the 
properties of a series of compounds, originally derived from the A/M2 inhibitor BL-1743.  
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A lead compound emerging from these investigations, spiro[5.5]undecan-3-amine, is an 
effective inhibitor of wild type A/M2 channels and L26F and V27A mutant ion channels 
in vitro, and also inhibits replication of recombinant mutant viruses bearing these 
mutations in plaque reduction assays. Differences in the inhibition kinetics between BL-
1743, known to bind inside the A/M2 channel pore, and amantadine were exploited to 
demonstrate competition between these compounds; consistent with the conclusion that 
amantadine binds inside the channel pore. Inhibition by all of these compounds was 
shown to be voltage-independent, suggesting that their charged groups within the N-
terminal half of the pore, prior to the selectivity filter that defines the region over which 
the transmembrane potential occurs. These findings not only help define the location and 
mechanism of binding of M2 channel-blocking drugs, but also demonstrate the feasibility 
of discovering new inhibitors that target this binding site in a number of amantadine-
resistant mutants.  
6.2 INTRODUCTION 
Influenza A virus is a continuing cause of mortality and morbidity on an annual basis (1) 
and thus presents an important target for pharmaceutical investigation. Two classes of 
anti-influenza agents are available for human use: adamantane derivatives amantadine 
and rimantadine which target the virus A/M2 ion channel and oseltamivir and zanamivir, 
which targets the viral surface protein neuroaminidase (2). The use of amantadine and 
rimantadine is limited by the wide distribution of drug resistant virus variants, including 
the recently isolated influenza A (H1N1) virus (3-5). 
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The A/M2 protein of the influenza A virus forms a pH-gated proton channel that is 
essential for virus replication (6).  The mature channel consists of four identical subunits 
of 96 amino acids, each subunit is a type III integral membrane protein (Nout, Cin) (7);. 
The highly conserved H37xxxW41 motif located in the single transmembrane domain of 
the protein is responsible for its channel activity and proton selectivity (7, 8). The activity 
of wild type (wt) A/M2 channels is known to be efficiently inhibited by amantadine, BL-
1743 and its derivative azaspiro[5,5] undecane (spiro piperidine 20, Table 1) (Figure 1) 
(2, 9, 10). Naturally occurring point mutations of the pore lining residues located outside 
of the H37xxxW41 motif, such as L26F, V27A, A30T, S31N and G34E result in the 
formation of amantadine-insensitive influenza A virus phenotypes (3, 11-13). Extensive 
studies suggest that these residues are involved in the formation of the binding pocket for 
the drug (14-18). Amantadine-resistant phenotypes are prevalent in the currently 
circulating influenza A virus H3N2 and H1N1 2009 strains. Although the S31N mutation 
was observed in more then 90% of influenza A cases in certain years (19, 20), other 
amantadine insensitive phenotypes like L26F and V27A were isolated from influenza A 
patients with the emerging frequencies of 8-67% (19, 20). Other amantadine-resistant 
mutations have been found much less frequently (11, 20). Being resistant to amantadine, 
these naturally occurring mutants are also insensitive to all other known organic A/M2 
channel inhibitors, including BL-1743 and spiro piperidine 20 (9, 10). Thus there is a 
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great need for novel anti-influenza drugs that target the most common amantadine 
resistant phenotypes, S31N , V27A and L26F (19, 20). 
 
Figure 1: Chemical structures of A/M2 channel inhibitors. 
In the current study we synthesized a family of spiro-[5,5]-undecane compounds based 
on the structure of the previously investigated A/M2 channel inhibitor BL-1743. We 
found a simple amino derivative of BL-1743, spiro[5.5]undecan-3-amine  (spiran amine 8, 
Table 1) to be effective not only for inhibition of the wt A/M2 channel, but also for 
inhibition of two widely occurring amantadine resistant mutants, L26F and V27A. The 
efficiency of this compound was investigated on A/M2 channels heterologously 
expressed in Xenopus oocytes and confirmed by the in-vivo plaque reduction assay of 
recombinant influenza A virus.  
 
The pharmacologically relevant binding site for amantadine has been found to lie either 
inside (15), or outside (21, 22) the pore, although the physiological relevance of the latter 
finding has not been confirmed with either electrophysiology in oocytes or plaque 
reduction assays with recombinant virus (23). However, BL-1743 was shown to inhibit 
channel activity by binding inside the channel pore (24). Previous findings have shown 
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that the kinetics of A/M2 channel inhibition by BL-1743 are more rapid than those 
reported for amantadine (9, 25),  making it possible to test for competition between these 
drugs to determine whether they compete for the same binding site inside the channel 
pore. Our results support the previously published structural and functional studies that 
showed that amantadine inhibits the A/M2 channel by coordinating with pore lining 
residues (12, 15, 16). We found that inhibition by amantadine, BL-1743, spiro piperidine 
20 and spiran amine 8, all of which are positively charged at physiological pH, is 
independent of membrane voltage, consistent with binding in the N-terminal portion of 
the pore. 
 
The current study shows that a novel compound, spiran amine 8, is a potent inhibitor of 
the L26F and V27A amantadine resistant mutants of the A/M2 protein. Additional 
evidence supports the conclusion that amantadine binds inside the N-terminal half of the 
channel pore. These findings show that novel anti-influenza drugs, capable of targeting 
wt and amantadine resistant virus phenotypes, can be identified and that the N-ternial part 
of the pore is a good target for such drugs. 
 
6.3 MATERIALS AND METHODS  
Spiran AM2 inhibitor library synthesis - The syntheses of the primary amine analog (8) 
of spiropiperidine-azaspiro[5,5]undecane and the methyl substituted secondary amine 9 
are shown in Scheme 1. Intermediate spiro[5.5]undec-1-en-3-one 1 was prepared from 
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both acid catalyzed one-pot Robinson annulation reaction and  through Diels-Alder 
adduct followed by acid hydrolysis and aldol ring formation. The acid-catalyzed 
annulation often led to low yields (62% or lower) due to acid catalyzed polymerization of 
methyl vinyl ketone as evidenced by black oily substance formed in the reaction flask 
(26). While catalysis with proline derivatives might allow circumvention of these  
problems , we found the alternative  Diels-Alder route provided better overall yields 
(75%) (27). Hydrogenesis of enone 1 with Pd/C with an H2 balloon gave 
spiro[5.5]undecan-3-one 2. Conversion of ketone 2 to amine 8 was achieved by treatment 
with hydroxylamine followed by LiAlH4 reduction. Methylamine 9 was prepared by 
reductive amination of 8 with formaldehyde as reported.  
 
 
Scheme 1. Synthesis of spiran amine 8, 9 and guanidine 10. 
Syntheses of spiran triazole 11 and spiran amine 12-14 with extended linkers in scheme 2 
were accomplished by reductive amination as described before. 
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Scheme 2. Synthesis of spiran triazole 11 and spiran amine 12, 13 and 14 with extended 
linkers. 
 
Compound 15, with an imidazole head group, was synthesized by nucleophilic attack of 
imidazol-4-yl anion (generated by treatment of N-trityl 4-iodoimidazole) onto ketone 2 
(28),  followed by deprotection in TFA/DCM as in scheme 3. The hydroxyl group in 15 
was either reduced by Et3SiH/BF3*OEt2 to give 16 or fluorinated by DAST to give 17 
after deprotection. Ketone 2 was converted to aldehyde 6 by the Wittig reaction, followed 
by acid hydrolysis.  Comopunds 18 and 19 were then synthesized from compound 6 in 
the same manner as described for 15 and 17.  
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Scheme 3. Synthesis of spiran with imidazole head group 15, 16, 17. 
 
Scheme 4. Synthesis of spiran 18, 19. 
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Molecular Biology, in vitro cRNA transcription - The cDNA encoding to the Influenza 
virus A/Udorn/72 A/M2 protein and to the A/M2 amantadine insensitive mutants were 
inserted into pGEMHJ (a gift from N. Dascal Tel-Aviv University, Israel) for the 
expression on Xenopus oocytes. cRNA was prepared as previously  described  (29).  
 
Heterologous Expression and Electrophysiological Recordings - Stage V-VI Xenopus 
laevis oocytes were prepared as described previously (30). Oocytes injection and TEVC 
electrophysiological measurements were done as previously described (29). Amantadine 
(Sigma, St. Louis, MO) was applied to inhibit A/M2 induced currents. Data were 
analyzed using ORIGIN 8.0 software (OriginLab, Northampton, MA). 
 
Cells, viruses and plasmids - 293-T and Madin–Darby canine kidney (MDCK) cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, 
Valencia, CA) supplemented with 10% FBS. Influenza A/Udorn/72 virus (wt) and mutant 
viruses were propagated in MDCK cells overlaid with serum-free DMEM containing 3.0 
µg/ml N-acetyl trypsin (NAT; Sigma-Aldrich, St. Louis, MO) at 37°C. WT and mutant 
virus (V27A/L38F) were generated by using reverse genetics from cDNAs essentially as 
described previously (31). The eight genome- sense (pHH21) plasmids and four protein-
expressing (pcDNA3.1) plasmids used to generate influenza virus by reverse genetics 
have been described previously (31). Mutation into the M2 gene in pHH21 vector was 
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generated using Quick Change mutagenesis (Stratagene, La Jolla, CA). 293T cells were 
transfected using TransIT-LT1 (Mirus, Madison, WI) according to the manufacturer’s 
protocols.  Virus stocks were propagated in MDCK cells, and the virus titers were 
determined by plaque assay on MDCK cells. For determination of viral genome 
sequences viral RNA was extracted by using the QIAamp viral RNA kit (Qiagen, 
Valencia, CA), followed by Super Reverse Transcriptase (Molecular Genetic Resources, 
Tampa, FL.) and using genome-specific primers, and amplified with AmpliTaq DNA 
polymerase (Applied Biosystems, Foster City, CA). The complete nucleotide sequences 
of the M genes were determined using a 3100-Avant genetic analyzer (Applied 
Biosystems).   
 
Plaque reduction assays - Confluent monolayers of MDCK cells were incubated with the 
wt Udorn virus (100 plaque forming units (p.f.u.) per well) and V27A/L38F mutant virus 
(1000 and 100 p.f.u. per well) in DMEM-1% bovine serum albumin for 1 h at 37
o
C. The 
inoculums were removed, and the cells were washed with phosphate-buffered saline 
(PBS). The cells were then overlaid with DMEM-containing 0.6% Avicel 
microcrystalline cellulose (FMC BioPolymer, Philadelphia, PA) and NAT (2.0 μg/ml). 
To examine the effect of drugs (BL-1743, spiran amines and amantadine) on plaque 
formation, monolayers were preincubated with DMEM supplemented with indicated 
concentrations of the drugs at 37°C for 30 min, and virus samples were preincubated with 
DMEM-1% BSA with indicated concentrations of the drugs at 4°C for 30 min before 
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infection. At 2 to 3 days after infection, the monolayers were fixed and stained with 
naphthalene black dye solution (0.1% naphthalene black, 6% glacial acetic acid, 1.36% 
anhydrous sodium acetate).   
 
6.4 RESULTS   
6.4.1 Structure-activity relationship (SAR) of 3-substituted spiro-[5,5]-undecanes. 
Our previous SAR study of 2-[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-1743) 
revealed a very potent spiro-piperidine compound 20 with IC50 of 0.9 μM (10). However, 
compounds in this series failed to inhibit amantadine-resistant variants of A/M2, which 
prompted us to test alternative structures.  In particular, a consideration of the overlay of 
the parent compound on derivatives of amantadine suggested that conversion of the 
piperidine in spiro piperidine 20 to a 3-amino-cyclohexyl amine  while maintaining the 
second spiro-6-member ring would produce a more effective inhibitor.  We therefore 
synthesized a family of spiro-[5,5]-undecanes, in which the 3-position was substituted 
with amines or other basic substituents (Table 1). 
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Table 1. Inhibition efficiency of the synthesized compounds on A/M2 channels. 
a
Kd was 
obtained by global fitting of Circular Dichroism (CD) data of ligand titration to A/M2TM 
(22-46) using Igor Pro (wavemetrics). The variation of Kd values is ±25% based on 
different fitting values obtained from three repeats of amantadine titration and two 
repeats of compound 20 titration. See supplementary information for details. 
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The compounds were tested on A/M2 channels expressed in Xenopus oocytes using 
TEVC technique. The inhibitory effect of the compounds was confirmed by in-vivo 
plaque reduction assays of influenza A virus (A/Udorn/72).  The simple amino-
derivative, 8, showed an activity on par with that of amantadine.  However, further 
substitutions to the amine tended to cause a loss in activity.  N-methylation (compound 9) 
led to a slightly less potent compound, while the guanidine derivative, 10, had similar 
potency as methylamine 9.  Modifying the amine by addition of polar substituents and 
extended linkers (compounds 11 – 14) led to a marked decrease in activity.  On the other 
hand, replacing the amine with an imidazole group caused a slight decrease in activity 
(compound 16).  We also examined additional substitutions at the 3-methylene of 16, 
through the introduction of a hydroxyl and fluoro-substituent in 15 and 17, respectively. 
These substitutions gave rise to compounds with lower potency. Furthermore, the 
similarly substituted compounds 18 and 19 had decreased activity compared to the 
primary amine 8.  
 
In summary, these data show that the primary amino group is likely to be a nearly 
optimal substituent for the spiro-[5.5]-undecane scaffold.  We therefore turned our 
attention to determining how the piperidine for cyclohexylamine substitution in 20 vs. 8 
affected the ability of these compounds to inhibit amantadine-resistant forms of A/M2.  
 
6.4.2 Inhibition effect of spiran amine compound 8 on wt and amantadine insensitive 
A/M2 channels. 
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Amantadine resistant mutants carry naturally occurring point mutations of the pore lining 
residues of the A/M2 channel (3, 11, 12). Extensive structural, electrophysiological and 
in-silico investigations suggest that these residues form the binding pocket for the drug 
(14-18). We have tested the effect of spiran amine 8 on wt A/M2 channels and A/M2 
channels with altered amantadine sensitivity and compared the inhibition by compound 8 
to that of amantadine and BL-1743. We found that spiran amine 8 efficiently inhibits the 
activity of A/M2 wt channels and of A/M2-V27A mutants, with IC50 values of 12.6 μM 
and 84.9 µM respectively (Figure 2; Table 2).  The inhibition of V27A mutants is 
particularly interesting, given that amantadine, BL-1743, and spiro piperidine 20 gave 
less than 10% inhibition of the mutant, when applied at 100 µM concentration.  It is also 
interesting to note that the mutant V27G, which is also naturally occurring (32) is highly 
resistant to all compounds tested (Table 2).   
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Figure 2. Inhibition efficiency of amantadine, BL-1743 and spiran amine 8 on wt A/M2 
channels and A/M2 L26F, V27A and S31N mutants. Channel activity was assayed by 
TEVC for A/M2 channels expressed in Xenopus oocytes. Responses in the presence of 
various concentrations of an inhibitor (I) were normalized to the current evoked by 
application of the activating (pH 5.5) solution without inhibitor (I0). The experimental 
data are the average of three independent experiments. Each point is the mean (±SD) of 
5-8 oocytes. IC50 values in μM: A/M2 with amantadine IC50=15.76±1.24; with BL-1743 
IC50=46.25±3.56; with spiran amine 8 IC50=12.59±1.11. A/M2-L26F with amantadine 
IC50=164.46±14.40; with BL-1743 IC50>10 mM; with spiran amine 8 IC50=30.62±8.13. 
A/M2-V27A with amantadine IC50=1840; with BL-1743 IC50>10 mM; with spiran amine 
8 IC50=84.92±13.61. A/M2-S31N with amantadine IC50=237.01±22.14; with BL-1743 
IC50>10 mM; with spiran amine 8 IC50>10 mM. 
 
Table 2: Inhibition effect of amantadine, BL-1743, spiran amine 8 and spiran amine 9 on 
A/M2 wt and  amantadine insensitive mutant channels. Data presented as a percent of 
remaining A/M2 activity after application of an inhibitor (100 μM) for 2 min. The 
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experimental data are the average of three independent experiments. Each point is a mean 
(±SD) of 5-7 oocytes. 
 
 
BL-1743 SPIRAN AMINE 
8 
SPIRAN AMINE 
9 
AMANTADINE 
 % remaining activity after application of 100 μM compound 
A/M2 25.3±1.3 10.6±0.7 8.4±1.1 6.1±1.0 
A/M2-L26F 89.2±4.8 32.4±3.3 72.6±8.4 51.8±3.5 
A/M2-V27A 97.4±1.8 46.6±6.6 70.2±1.55 93.07±1.9 
A/M2-V27G 82.9±9.3 87.9±6.1 89.6±4.1 95±4.9 
A/M2-A30T 102±2.3 98.1±7.0 101. ±3.2 104.6±4.3 
A/M2-S31N 100±0.67 99.1±0.9 100±4.1 65.3±2.7 
A/M2-G34E 89.8±6.9 96. ±5. 101.7±2.8 100.4±6.7 
 
We next examined the ability of compound 8 to inhibit other pore-lining mutants.  S31N 
is a highly frequent mutation, which gives rise to decreased sensitivity to amantadine 
(IC50 = 237.0 µM versus 15.8 µM for the wt A/M2 channel, Figure 2), and complete 
resistance to rimantadine (IC50 > 10mM).  Similarly, compound 8 showed little 
inhibition of this mutant.  Other mutations deeper inside the pore than V27 (A30T and 
G34E) completely eliminate the ability of all drugs tested to inhibit the channel (Table 2).   
 
By contrast to the other mutations considered here, L26F does not involve a pore-lining 
residue, and instead involves a partially largely lipid-exposed residue that packs at the 
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interface between the helices adjacent to the V27.  Thus, this residue is expected to play a 
more subtle and less direct role in defining the steric properties of the drug-binding site.  
Indeed, amantadine inhibits this mutant with reduced affinity (IC50=164.5 µM), versus 
the much larger decreases seen for other variants.  Compound 8 is an even more potent 
inhibitor of A/M2 L26F (IC50 = 30.6 µM, Figure 2). 
 
The inhibitory effect of compounds 8 and 9 on the recombinantly expressed A/M2 wt and 
mutant channels was confirmed by in-vivo plaque reduction assays of influenza A viruses.  
Plaque formation of wt influenza virus (A/Udorn/72) was inhibited by amantadine, 8 and 
9 at concentrations ranging from 0.5 to 5 μM (Figure 3A), with compound 8 showing 
slightly more potent activity than compound 9. BL-1743 inhibited wt virus plaque 
formation only at high concentrations (50-100 μM) (Figure 3B). On the other hand, 
plaque count and size resulting from infection by an influenza virus A/M2-V27A/L38F, 
that contains the M2-V27A mutation was reduced by 50 μM spiran amine 8 (Figure 3C).  
These findings are consistent with the electrophysiological data (Figure 1). In comparison, 
amantadine and BL-1743 at the same concentration range failed to inhibit plaque 
formation of A/M2-V27A/L38F viruses (Figure 3C).  The L38F mutation is naturally 
found in the Weybridge strain of the virus. This mutation is pharmacologically silent to 
the drugs used and does not affect M2 channel function in electrophysiological 
recordings (25, 33, 34). The activity of the double mutant A/M2-V27A/L38F was tested 
by TEVC and compared to that of a single mutant A/M2-V27A. We found that sensitivity 
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of the double mutant channel to the tested compound was comparable to that of the single 
A/M2-V27A mutant. The A/M2-V27A/L38F mutant channels were not sensitive to either 
amantadine, or BL1743, while being efficiently inhibited by compound 8 (A/M2-
V27A/L38F IC50=78.21±15.06; A/M2-V27A IC50= 84.92±13.61). Based on these 
findings we decided that the results of the plaque formation assay performed on the 
double mutant A/M2-V27A/L38F adequately represent the behavior of the single A/M2-
V27A mutant. 
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Figure 3. In vivo plaque reduction assay. Wt influenza virus (A/Udorn/72) and influenza 
virus containing mutations in the M2 TM domain (V27A/L38F) were recovered from 
cloned DNA and assayed for plaque formation on MDCK cells in the presence or absence 
of drugs as described in Materials and Methods. A. Effects of amandadine, BL-1743 and 
compounds 8 and 9 (0.5 and 5 μM) on Udorn plaque formation. B. Effect of BL-1743 (50 
and 100 μM) on influenza virus plaque formation. C. Effects of amantadine, BL-1743 
and spiran amine 8 (50 μM ) on influenza mutant virus V27A/L38F plaque formation.  C, 
upper panel: ~1000 p.f.u. / well of mutant virus were used. C, bottom panel: ~100 p.f.u. / 
well of mutant virus were used. Plaque count: no drug – 99 plaques / well; amantadine 
50μM – 82 plaques / well; BL-1743 50 μM – 86 plaques / well; spiran amine 8 50 μM – 
37 plaques / well.  
 
Thus, spiran amine 8 is capable of efficiently inhibiting not only wt A/M2 channels and 
A/M2-L26F and A/M2-V27A mutant channels expressed in oocytes, but it also prevents 
replication of wt virus and these mutant recombinant viruses.  As discussed below, we 
attribute to the greater potency of compound 8 in the plaque versus the 
electrophysiological studies to kinetic effects arising from the slow kinetics of binding of 
this class of inhibitors.  Compounds are incubated with oocytes for brief periods in the 
electrophysiological experiments, but much longer periods in the plaque-binding studies.    
 
We also measured the binding of selected drugs to the transmembrane domain of wt 
A/M2 protein (M2TM, residues 22-46), using a spectroscopic assay that relies upon 
changes in the CD spectrum of M2 induced by binding of drugs (Table 1 and described in 
supplementary materials).  All drugs bound in a stoichiometry of approximately one 
drug/tetramer.  At pH 7.4, potent compounds were found to bind to the transmembrane 
tetrameric form of M2TM with low µM binding constants.  Compounds 8 and 10 were 
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found to be approximately equipotent with amantadine, displaying dissociation constants 
in the range of 7 – 8 µM (Table 1).  In agreement with the plaque assay, compound 9 was 
approximately four-fold less potent than amantadine or compound 8.  These data support 
the expectation that the drugs inhibit the channel activity by binding directly to the A/M2 
proton channel. 
 
6.4.3 Competition among inhibitors. 
In 1999 Gandhi and co-workers concluded from competition experiments with Cu(II) that 
BL-1743 inhibits A/M2 channel activity by binding inside the channel pore (24). 
However, conflicting structural studies have shown that adamantane derivatives bind 
either inside (15), or outside (21) the channel pore, although the pharmacological 
relevance of the latter finding has not been confirmed (23). Furthermore, solid-state NMR 
experiments have shown that a member of the spiran series of compounds binds A/M2 in 
a manner similar to that of amantadine (10). Given that BL-1743 appears to bind within 
the pore, we were interested to determine whether amantadine binds competitively with 
respect to this compound, or whether it binds to an independent site. 
 
The second-order rate constant (κon) for the association and inhibition of the wt A/M2 
channel with BL-1743 was calculated to be 720 M
-1
 s
-1 
(9), which is comparable with the 
κon of amantadine (600 to 900 M
-1
 s
-1
) (25).  However, the dissociation rate constant (κoff) 
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for BL-1743 is approximately an order of magnitude faster than that calculated for 
amantadine (10
-3
 s
-1
 and 10
-4
 s
-1 
respectively) (9, 25). We exploited this difference in κoff 
of BL-1743 and amantadine to investigate the mechanism of A/M2 channel inhibition by 
amantadine by testing whether this drug competes with BL-1743 for the inhibition of 
A/M2 channel activity.  For these experiments A/M2 channels were expressed in 
Xenopus oocytes, and the channel activity was assayed by TEVC. A/M2 channel activity 
was evoked by application of the low pH activating solution (pH 5.5). In the control 
experiments the channel activity was inhibited by saturating concentrations of either BL-
1743 (1000 μM) or amantadine (100 μM) alone (Figure 4A and B). As seen from Figure 
4A and 4B, the inhibition of A/M2 was essentially fully reversible in the time frame of 5 
min for BL-1743, but only about 10% complete for amantadine.  This finding is 
consistent with the slower off-rate for amantadine than for BL-1743. Compound 8 also 
showed an off-rate similar to that of amantadine, as expected from their similar IC50 
values (Figure 2, Figure 4C).   
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Figure 4: Inhibition of A/M2 channel activity by saturating concentrations of BL-1743, 
amantadine and spiran amine 8. A-C; Representative traces of A/M2 channel activity 
inhibited by either BL-1743 (1000 μM, A), amantadine (100 μM, B), or spiran amine 8 
(100 μM, C). A/M2 channel activity was induced by application of the activating solution 
(pH 5.5, red horizontal bar above the trace). The currents were inhibited by the 
application of the activating solution containing either BL-1743 (green horizontal bar, A), 
amantadine (yellow horizontal bar, B), or spiran amine 8 (orange horizontal bar, C) for 
60-90 sec. After the maximal inhibition was achieved, oocytes were superfused with the 
non-activating solution (pH 8.5, second blue horizontal bar) for 5 min to allow current 
recovery and the channel activity was assayed again by the application of the activating 
solution (second red horizontal bar).  Note that recovery was complete only for BL-1743. 
 
We next examined the competition between BL-1743 and amantadine, chosen as a 
representative example of the slow-dissociating class of inhibitors. We subjected the 
oocytes to sequential treatment with drugs and drug-free recording solutions in a manner 
designed to probe both the kinetic and thermodynamic aspects of inhibition.  A resting 
oocyte, incubated in the non-activating solution (pH 8.5), was treated as follows. 1) The 
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oocyte was acidified by the application of the activating solution (pH 5.5) (red bar in 
Figure 5); 2) The oocyte was pulsed with the activation solution containing rapidly 
reversible BL-1743 at various concentrations ranging from 3 to 1000 μM for 60 sec 
(green bar);  3) BL-1743 in the activating solution was replaced with the slowly 
reversible inhibitor amantadine (100 μM) for an additional 90 sec (yellow bar); 4) The 
pH was shifted to 8.5 to allow the system to re-equilibrate for 5 min (second blue bar); 5) 
The oocyte was re-acidified (second red bar) and the degree of recovered channel activity 
determined.   
 
Figure 5. Inhibition of A/M2 channel activity by consecutive application of BL-1743 and 
amantadine. A-D; Representative traces of the A/M2 channel activity modulated by 
consecutive application of BL- 1743 and amantadine. A/M2 channel activity was induced 
by the application of the activating solution (pH 5.5, red horizontal bar above the trace). 
The currents were first inhibited by the application of the activating solution (pH 5.5) 
containing various concentrations of BL-1743 (3-1000 μM, green horizontal bar) for 60 
sec. After maximal inhibition of the channel activity was achieved, amantadine (100 μM) 
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was substituted for BL-1743 (3-1000 μM) in the activating solution for 90 sec (yellow 
horizontal bar). The inhibitors were washed out for 5 min by the non-activating solution 
(pH 8.5, second blue horizontal bar) and the pH-induced activity of A/M2 channels was 
measured again (second red horizontal bar). Note the biphasic current upon application of 
amantadine during washout of a saturating concentration of BL-1743 (during yellow bar 
in D). 
 
As expected from a reversible second-order binding event, the rate and extent of 
inhibition observed during the BL-1743 incubation period increased in a concentration-
dependent manner (Figure 5).  The ensuing traces observed during the amantadine-chase 
period reflect several processes, including (a) the binding of amantadine to the fraction of 
channels that were not inhibited in the initial BL-1743 pulse, (b) dissociation of BL-1743 
to generate uninhibited channel, and (c) binding of amantadine to newly uninhibited 
A/M2 channels following dissociation of BL-1743. With low concentrations of BL-1743, 
little inhibition was achieved; thus, upon addition of 100 µM amantadine the kinetics 
were dominated by this process, and the trace approached a simple exponential decay 
(Figure 5A and B).  On the other hand, with a 1000 µM BL743 pulse, inhibition was 
complete and the resulting traces reflected a competition between dissociation of BL-
1743 and the on-rate for amantadine-binding, both of which occur with relaxation times 
in the sec to min time scale under these conditions (Figure 5D).  Thus, biphasic kinetics 
were observed, with the rising phase reflecting the fact that as the BL-1743 dissociates 
from the channel, amantadine does not bind instantly, leading to a partial recovery 
followed by inhibition by amantadine at longer times.  As expected, intermediate 
behavior was observed with an initial pulse of 100 µM BL-1743 (Figure 5C). 
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In the complementary experiments A/M2 channels were first inhibited by various 
concentrations of amantadine (1-100 μM) for 60 sec; then, BL-1743 (100 μM) was 
substituted for amantadine in the activating solution for 90 sec (Figure 6). The lower 
were the amantadine concentrations the higher was the effect of BL-1743 inhibition as 
evidenced by more current recovered after the 5 min long washout (Figure 6A and B). 
When amantadine was applied at a saturating concentration (100 μM), substitution with 
BL-1743 did not add to the existing inhibition by amantadine (Figure 6D).   
 
Figure 6. Inhibition of A/M2 channel activity by consecutive application of amantadine 
and BL-1743. A-D, Representative traces of the A/M2 channel activity modulated by 
consecutive application of amantadine and BL-1743.  A/M2 channel activity was induced 
by the application of the activating solution (pH 5.5, red horizontal bars above the traces). 
The currents were first inhibited by the application of the activating solution (pH 5.5) 
containing various concentrations of amantadine (1-100 μM, yellow horizontal bar) for 
60 sec. After the maximal inhibition of the channel activity was achieved, BL-1743 (100 
μM) was substituted for amantadine (1-100 μM) in the activating for 90 sec (green 
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horizontal bar). The inhibitors were washed out for 5min by the non-activating solution 
(pH 8.5, second blue horizontal bar) and the pH-induced activity of A/M2 channels was 
measured again (second red horizontal bar). Note that in no instance was a biphasic 
current observed during application of BL-1743 as amantadine was washed-out (yellow 
bars). 
 
Taken together, these results suggest competition between BL-1743 and amantadine for 
inhibition of the A/M2 channel and support the conclusion that amantadine inhibits A/M2 
channel activity by binding inside the channel pore. The results of this competition study 
also are in a good agreement with the amantadine inhibition kinetic rates reported by 
Wang et. al. (25) 
 
The reaction rate constants for the spiran amine compounds were not precisely 
determined; however, as shown in Figure 4C, the washout rate for the spiran amine 8 was 
not significantly different from that of amantadine, suggesting it should behave similarly 
to amantadine. 
 
6.4.4 Voltage dependence of inhibition of A/M2 channel activity by amantadine, BL 1743 
and spiran amine.  
Since spiran amine 8 is a positively charged molecule in aqueous solution over the pH 
range used in this study, its inhibitory effect on A/M2 channels may depend on 
membrane voltage. To address this possibility, we tested the voltage dependence of A/M2 
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channel inhibition by spiran amine 8 and compared it to that of BL-1743, spiro piperidine 
20 and amantadine. Previous studies have shown that the inhibition of A/M2 channel 
activity by BL-1743 does not depend on voltage (9), while voltage dependence of 
amantadine inhibition has not been addressed directly. We observed that inward and 
outward A/M2 channel currents measured in the presence of each of the tested 
compounds were equally inhibited in the voltage range from -40 to +40 mV (Figure 7). 
These findings indicate that inhibition by none of the tested compounds is voltage 
dependent. 
 
Figure 7.  Voltage dependence of A/M2 inhibition by amantadine, BL-1743, spiran amine 
8 and spiro piperidine 20. Inhibition of A/M2 channel activity by amantadine, BL-1743, 
spiran amine 8 and spiro piperidine 20 was assayed at various holding voltages (from -
40mV to +40mV). The mean (±SD) channel activity remaining after the maximal 
inhibition by each of the inhibitors (100 μM) was achieved was plotted as a function of 
the holding voltage. The experimental data are the average of three independent 
experiments. Each point is a mean (±SD) of 6-10 oocytes. 
 
6.5 DISCUSSION 
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 As amantadine resistant influenza A strains become prevalent, the need for novel small 
molecule inhibitors grows. Our previous SAR of the BL-1743 series of compounds 
revealed one tight binding inhibitor - spiro piperidine 20 with IC50  of 0.9 μM, which has 
been shown to perturb a larger region in the pore-lining area of wt A/M2 than amantadine 
(10). In the current study an additional set of compounds was made by converting the 
spiro-piperidine scaffold to spiran amine, which still retains the conformation of 
spirocycles for tight binding, but has a slightly more extended structure.  Compound 8 
from this series shows promising inhibitory activity against two of the naturally occurring 
A/M2 point mutants: A/M2-L26F and A/M2-V27A (Figure 2). L26 and V27 are the 
residues closest to the channel exterior (Figure 8) to have been associated with 
amantadine-resistance in naturally occuring mutants of A/M2 (12, 16, 34). It is 
interesting to note that, although these L26F and V27A were inhibited by 8, none of the 
amantadine insensitive mutants located deeper in the pore was sensitive to spirane amine 
8 (Table 2). However, of these, only S31N poses a significant clinical threat.   
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Figure 8. Structure of amantadine complexes with the transmembrane domain of A/M2 
protein. Panel A and B illustrates the crystal structure of the channel (pdb code 3K9J); 
viewed from the outside of the virus (A) and in a side-on view with on helix removed for 
clarity (B).  Panel C shows a lower resolution model (2KAD) obtained from an analysis 
solid-state NMR angular and distance restraints.  The identities of critical residues are 
shown below, showing the C-alpha and sidechain atoms. 
 
Figure 8A and 8B illustrates the position of L26 and V27 in the crystal structure of the 
transmembrane domain of A/M2 complexed with amantadine at low pH, while Figure 8C 
shows a model of the complex at high pH in phospholipid bilayers obtained by solid state 
NMR (12). Although there are significant differences between the details of these and 
other experimental models (35, 36), V27 projects directly towards the pore, while L26 is 
critical for packing at the helix-helix interface. Thus, changes to residues at these 
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positions are likely to cause changes to the N-terminal region of the channel lumen, 
precisely at a location where amantadine has been found to bind. We are currently 
conducting crystallographic and molecular dynamics analyses of these mutants to 
determine their affect on the channel structure, and also to define the mechanism by 
which compound 8 is able to inhibit these otherwise drug-resistant variants.  However, it 
is inviting to speculate that the decrease in hydrophobicity and steric bulk associated with 
the V27A mutation might increase the polarity and pore radius near the N-terminal region 
of the binding site.  In this scenario, the extended length of compound 8 would provide 
increased steric and physicochemical complementarity to the variants, particularly its 
amine group projected outward toward the exterior of the virus.   
 
It was previously shown that BL-1743 inhibits A/M2 channel activity by binding inside 
the channel pore with the κon kinetic similar to that of amantadine, but with nearly 10-fold 
faster koff kinetic (9, 25). By employing the differences in the kinetic properties of 
amantadine and BL-1743 inhibition, we tested whether these two compounds compete for 
the same binding site. Figure 5D shows that when A/M2 channels are occupied with BL-
1743, after amantadine substitution for BL-1743 in the recording solution, no additional 
inhibition by amantadine occurs, and slow re-initiation of amantadine binding starts only 
as the unbinding of rapidly reversible BL-1743 occurs.  These findings are consistent 
with bound BL-1743 molecules preventing the channel from binding amantadine. Since 
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BL-1743 binds in the pore, this result indicates that amantadine also inhibits A/M2 
channel activity by binding in the channel pore.  
 
As amantadine, BL-1743 and spirane amine 8 are all easily protonated in the pH range 
used in this study, and it is often observed that the efficacy of a positively charged 
channel inhibitor increases as membrane voltage is made more negative, we tested the 
voltage dependence of these compounds and of spiro piperidine 20 in the range of -40 to 
+40 mV. Earlier electrophysiological characterizations of AM2 inhibition by BL-1743 
revealed that the inhibition was not voltage dependent (9). The present study confirms the 
voltage-independence of BL-1743, amantadine, spiro piperidine 20, and spirane amine 8 
(Figure 7). This finding is consistent with the location of the binding site occurring on the 
N-terminal half of the pore in a location exterior (N-terminal in peptide sequence) to the 
Trp/His gate, over which the transmembrane voltage drop is expected to occur. This 
binding mode is also consistent with the site inferred from solid state NMR 
measurements of the perturbation to channel resonances associated with binding of  spiro 
piperidine 20 (10).   Furthermore, the existence of mutants conferring BL-1743 resistance 
(9, 24) suggest that the drug binding site is located on the extracellular-facing portion of 
the pore, N-terminal of H37. The lack of voltage dependence of amantadine inhibition 
and failure for intracellularly injected amantadine to inhibit (37) are also consistent with 
this binding location, and argue against a proposed mechanism of amantadine binding to 
the outer intracellular-facing side of pore of the protein (21, 22).  
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Together, these data argue for the previously proposed mode of binding to the pore of the 
channel (14-17).  However, assuming the voltage drop occurs at the His/Trp gate, these 
data do not differentiate models in which the positively charged ammonium (or 
guanidinium group of BL-1743) of the drugs are directed toward the viral exterior or 
downward toward the H37 residues. It also should be born in mind that the lack of a 
voltage-dependence might occur if the binding of the positively charged inhibitor occurs 
in an exchange in which one proton is released to the outside of the cell when one 
inhibitor molecule enters the pore without changing the total charge inside the pore.  
While this is a formal possibility that is consistent with the fact that the binding of drug 
occurs with concomitant loss of one or more protons from the H37 residues (38), it seems 
unlikely that the proton release would obligatorily occur  to the exterior, rather than the 
interior, which is the natural direction of proton flow.  
 
In summary, these results demonstrate the feasibility of designing anti-viral drugs 
effective against amantadine-resistant escape mutants of influenza A virus. Relatively 
modest modifications to BL-1743 have now resulted in a potent inhibitor of two naturally 
occurring A/M2 amantadine insensitive mutants: A/M2-L26F and A/M2-V27A. 
Moreover, the electrophysiological experiments lend support for the existence of the 
binding site in the outer portion of the channel pore (12, 15, 16, 23, 34).  Thus, three-
dimensional models in which the drug is bound in the N-terminal regions of the pore 
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should provide useful starting points for the design of even more tight-binding and broad-
spectrum agents. 
Supporting Information Available.  
Supporting information which describes the chemical synthesis of the compounds and the 
CD titration assay is available free of charge online at http://pubs.acs.org . 
6.6 REFERENCES  
1. Cox, N. J., and Subbarao, K. (1999) Influenza, Lancet 354, 1277-1282. 
2. Lagoja, I. M., and De Clercq, E. (2008) Anti-influenza virus agents: synthesis and 
mode of action, Med Res Rev 28, 1-38. 
3. Deyde, V. M., Xu, X., Bright, R. A., Shaw, M., Smith, C. B., Zhang, Y., Shu, Y., 
Gubareva, L. V., Cox, N. J., and Klimov, A. I. (2007) Surveillance of resistance 
to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated 
worldwide, J Infect Dis 196, 249-257. 
4. Hay, A. J., Wolstenholme, A. J., Skehel, J. J., and Smith, M. H. (1985) The 
molecular basis of the specific anti-influenza action of amantadine, EMBO J 4, 
3021-3024. 
5. Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., 
Sessions, W. M., Xu, X., Skepner, E., Deyde, V., Okomo-Adhiambo, M., 
Gubareva, L., Barnes, J., Smith, C. B., Emery, S. L., Hillman, M. J., Rivailler, P., 
Smagala, J., de Graaf, M., Burke, D. F., Fouchier, R. A., Pappas, C., Alpuche-
 216 
 
Aranda, C. M., Lopez-Gatell, H., Olivera, H., Lopez, I., Myers, C. A., Faix, D., 
Blair, P. J., Yu, C., Keene, K. M., Dotson, P. D., Jr., Boxrud, D., Sambol, A. R., 
Abid, S. H., St George, K., Bannerman, T., Moore, A. L., Stringer, D. J., Blevins, 
P., Demmler-Harrison, G. J., Ginsberg, M., Kriner, P., Waterman, S., Smole, S., 
Guevara, H. F., Belongia, E. A., Clark, P. A., Beatrice, S. T., Donis, R., Katz, J., 
Finelli, L., Bridges, C. B., Shaw, M., Jernigan, D. B., Uyeki, T. M., Smith, D. J., 
Klimov, A. I., and Cox, N. J. (2009) Antigenic and Genetic Characteristics of 
Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans, Science. 
6. Pinto, L. H., and Lamb, R. A. (2007) Controlling influenza virus replication by 
inhibiting its proton channel, Mol Biosyst 3, 18-23. 
7. Pinto, L. H., and Lamb, R. A. (2006) The M2 proton channels of influenza A and 
B viruses, J Biol Chem 281, 8997-9000. 
8. Hu, J., Fu, R., Nishimura, K., Zhang, L., Zhou, H. X., Busath, D. D., 
Vijayvergiya, V., and Cross, T. A. (2006) Histidines, heart of the hydrogen ion 
channel from influenza A virus: toward an understanding of conductance and 
proton selectivity, Proc Natl Acad Sci U S A 103, 6865-6870. 
9. Tu, Q., Pinto, L. H., Luo, G., Shaughnessy, M. A., Mullaney, D., Kurtz, S., 
Krystal, M., and Lamb, R. A. (1996) Characterization of inhibition of M2 ion 
channel activity by BL-1743, an inhibitor of influenza A virus, J Virol 70, 4246-
4252. 
10. Wang, J., Cady, S. D., Balannik, V., Pinto, L. H., DeGrado, W. F., and Hong, M. 
(2009) Discovery of spiro-piperidine inhibitors and their modulation of the 
 217 
 
dynamics of the M2 proton channel from influenza A virus, J Am Chem Soc 131, 
8066-8076. 
11. Bright, R. A., Shay, D. K., Shu, B., Cox, N. J., and Klimov, A. I. (2006) 
Adamantane resistance among influenza A viruses isolated early during the 2005-
2006 influenza season in the United States, JAMA 295, 891-894. 
12. Cady, S. D., Mishanina, T. V., and Hong, M. (2009) Structure of amantadine-
bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-
angle-spinning solid-state NMR: the role of Ser31 in amantadine binding, J Mol 
Biol 385, 1127-1141. 
13. Furuse, Y., Suzuki, A., and Oshitani, H. (2009) Large-Scale Sequence Analysis of 
M Gene of Influenza A Viruses from Different Species: Mechanisms for 
Emergence and Spread of Amantadine Resistance, Antimicrob Agents Chemother. 
14. Duff, K. C., Gilchrist, P. J., Saxena, A. M., and Bradshaw, J. P. (1994) Neutron 
diffraction reveals the site of amantadine blockade in the influenza A M2 ion 
channel, Virology 202, 287-293. 
15. Stouffer, A. L., Acharya, R., Salom, D., Levine, A. S., Di Costanzo, L., Soto, C. 
S., Tereshko, V., Nanda, V., Stayrook, S., and DeGrado, W. F. (2008) Structural 
basis for the function and inhibition of an influenza virus proton channel, Nature 
451, 596-599. 
16. Yi, M., Cross, T. A., and Zhou, H. X. (2008) A secondary gate as a mechanism 
for inhibition of the M2 proton channel by amantadine, J Phys Chem B 112, 7977-
7979. 
 218 
 
17. Chen, H., Wu, Y., and Voth, G. A. (2007) Proton transport behavior through the 
influenza A M2 channel: insights from molecular simulation, Biophys J 93, 3470-
3479. 
18. Khurana, E., Dal Peraro, M., DeVane, R., Vemparala, S., DeGrado, W. F., and 
Klein, M. L. (2009) Molecular dynamics calculations suggest a conduction 
mechanism for the M2 proton channel from influenza A virus, Proc Natl Acad Sci 
U S A 106, 1069-1074. 
19. Bright, R. A., Medina, M. J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. 
M., Povinelli, L., Cox, N. J., and Klimov, A. I. (2005) Incidence of adamantane 
resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 
2005: a cause for concern, Lancet 366, 1175-1181. 
20. Saito, R., Sakai, T., Sato, I., Sano, Y., Oshitani, H., Sato, M., and Suzuki, H. 
(2003) Frequency of amantadine-resistant influenza A viruses during two seasons 
featuring cocirculation of H1N1 and H3N2, J Clin Microbiol 41, 2164-2165. 
21. Schnell, J. R., and Chou, J. J. (2008) Structure and mechanism of the M2 proton 
channel of influenza A virus, Nature 451, 591-595. 
22. Pielak, R. M., Schnell, J. R., and Chou, J. J. (2009) Mechanism of drug inhibition 
and drug resistance of influenza A M2 channel, Proc Natl Acad Sci U S A 106, 
7379-7384. 
23. Jing, X., Ma, C., Ohigashi, Y., Oliveira, F. A., Jardetzky, T. S., Pinto, L. H., and 
Lamb, R. A. (2008) Functional studies indicate amantadine binds to the pore of 
 219 
 
the influenza A virus M2 proton-selective ion channel, Proc Natl Acad Sci U S A 
105, 10967-10972. 
24. Gandhi, C. S., Shuck, K., Lear, J. D., Dieckmann, G. R., DeGrado, W. F., Lamb, 
R. A., and Pinto, L. H. (1999) Cu(II) inhibition of the proton translocation 
machinery of the influenza A virus M2 protein, J Biol Chem 274, 5474-5482. 
25. Wang, C., Takeuchi, K., Pinto, L. H., and Lamb, R. A. (1993) Ion channel activity 
of influenza A virus M2 protein: characterization of the amantadine block, J Virol 
67, 5585-5594. 
26. Flaugh, M. E., Crowell, T. A., and Farlow, D. S. (1980) Acid-catalyzed 
annelation of .alpha.-alkylaldehydes and .alpha.,.beta.-unsaturated ketones. A 
one-pot synthesis of 4,4-dimethyl-2-cyclohexen-1-one, The Journal of Organic 
Chemistry 45, 5399-5400. 
27. Chan, Y., and Epstein, W. W. (1988) 4,4-DIMETHYL-2-CYCLOHEXEN-1-
ONE, Organic Syntheses 50, 496-498. 
28. Turner, R. M., Lindell, S. D., and Lay, S. V. (1991) A Facile Route to Imidazol-4-
Yl Anions and Their Reaction with Carbonyl-Compounds, Journal of Organic 
Chemistry 56, 5739-5740. 
29. Balannik, V., Lamb, R. A., and Pinto, L. H. (2008) The oligomeric state of the 
active BM2 ion channel protein of influenza B virus, J Biol Chem 283, 4895-
4904. 
30. Shimbo, K., Brassard, D. L., Lamb, R. A., and Pinto, L. H. (1996) Ion selectivity 
and activation of the M2 ion channel of influenza virus, Biophys J 70, 1335-1346. 
 220 
 
31. Takeda, M., Pekosz, A., Shuck, K., Pinto, L. H., and Lamb, R. A. (2002) 
Influenza a virus M2 ion channel activity is essential for efficient replication in 
tissue culture, J Virol 76, 1391-1399. 
32. Li, D., Saito, R., Suzuki, Y., Sato, I., Zaraket, H., Dapat, C., Caperig-Dapat, I. M., 
and Suzuki, H. (2009) In vivo and in vitro alterations in influenza A/H3N2 virus 
M2 and hemagglutinin genes: effect of passage in MDCK-SIAT1 cells and 
conventional MDCK cells, J Clin Microbiol 47, 466-468. 
33. Stouffer, A. L., Nanda, V., Lear, J. D., and DeGrado, W. F. (2005) Sequence 
determinants of a transmembrane proton channel: an inverse relationship between 
stability and function, J Mol Biol 347, 169-179. 
34. Stouffer, A. L., Ma, C., Cristian, L., Ohigashi, Y., Lamb, R. A., Lear, J. D., Pinto, 
L. H., and DeGrado, W. F. (2008) The interplay of functional tuning, drug 
resistance, and thermodynamic stability in the evolution of the M2 proton channel 
from the influenza A virus, Structure 16, 1067-1076. 
35. Pinto, L. H., Dieckmann, G. R., Gandhi, C. S., Papworth, C. G., Braman, J., 
Shaughnessy, M. A., Lear, J. D., Lamb, R. A., and DeGrado, W. F. (1997) A 
functionally defined model for the M2 proton channel of influenza A virus 
suggests a mechanism for its ion selectivity, Proc Natl Acad Sci U S A 94, 11301-
11306. 
36. Hu, J., Asbury, T., Achuthan, S., Li, C., Bertram, R., Quine, J. R., Fu, R., and 
Cross, T. A. (2007) Backbone structure of the amantadine-blocked trans-
 221 
 
membrane domain M2 proton channel from Influenza A virus, Biophys J 92, 
4335-4343. 
37. Tang, Y., Venkataraman, P., Knopman, J., Lamb, R.A., Pinto, L.H. (2005) The 
M2 proteins of Influenza A and B viruses are single-pass proton channels, in Viral 
Membrane Proteins: Structure, Function and Drug Design. (Fischer, W. B., Ed.), 
pp 101-111, Kluwer Academic / Plenum Publisher, New York. 
38. Li, C., Yi, M., Hu, J., Zhou, H. X., and Cross, T. A. (2008) Solid-state NMR and 
MD simulations of the antiviral drug amantadine solubilized in DMPC bilayers, 
Biophys J 94, 1295-1302. 
 
 
 
 
 
 
 
 
 
 
  
 222 
 
6.7 SUPPORTING INFORMATION 
 
Design and Pharmacological Characterization of Inhibitors of 
Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A 
Virus 
 
Victoria Balannik, Jun Wang, Xianghong Jing, Emma Magavern, Robert A Lamb, 
William F DeGrado, Lawrence H Pinto 
 
Chemical Synthesis. All chemicals were purchased from commercial vendors and used 
without further purification unless otherwise noted. 
1
H and 
13
C NMR spectra were 
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per 
million referenced with respect to residual solvent (CHCl3) 7.26 ppm and (DMSO-d6) 
2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. The following 
abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t ) triplet, q ) quartet, 
m ) multiplet, dd ) doublet of doublets. All reactions were carried out under a N2 
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions. 
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution 
mass spectra were obtained using an ESI technique on 3200 Q Trap LC/MS/MS system 
(applied biosystem). 
 
 
 
Spiro[5.5]undec-1-en-3-one (1) 
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Acid catalyzed reaction:(1) Cyclohexanecarbaldehyde (1.12g, 10mmol), but-3-en-2-one 
(0.70g, 10mmol) was refluxed in tolune (10ml) with catalytic amount H2SO4 (0.05ml) in 
a round bottom flask equipped with Dean-Stark trap until no more H2O condensed from 
the reaction mixture. After 5 hrs, 50ml 1M NaHCO3 was added, and the organic phase 
was separated. The aqueous phase was extracted with tolune, the combined organic phase 
was washed with brine and dried over MgSO4, the solid was filtered, and concentrated in 
vacuoto give crude yellow oil which was separated by flash column to give 1 as yellow 
oil in 62% yield. (CHCl3/hexane =30%, 50% to 100%). 
 
Diels-Alder reaction:(2) To a three-necked flask equipped with Dean-stark trap was 
added cyclohexanecarbaldehyde (11.2g, 100mmol) under N2 protection. Pyrrolidine (7.2g, 
100mmol) was added dropwise to the flask with stirring over 10 mins via syringe. The 
mixture was heated to reflux for 3.5hrs until no more H2O condensed in the Dean-Strak 
trap. The enamine intermediate was used in the next step without purification. When the 
flask was cooled down to room temperature, it was immersed in ice water bath, and 
methyl vinyl ketone (5.6g, 80mmol) was added dropwise with stirring. Cooling was 
continued for 10mins after addition, and then the mixture was stirred at ambient 
temperature for 4hrs. The final step acid hydrolysis and aldol cylization was 
accomplished with slow addition of 8 M HCl (40ml) to the reaction at 0
o
C, followed by 
stirring overnight at r.t. The resulting brown mixture was extracted twice with ether, and 
the aqueous phase was cautiously neutralized with slow addition of sodium bicarbonate 
and extracted with ether. The ether layer was combined and dried over MgSO4, 
concentrated in vacuo and purified by flash column. (CHCl3/hexane =30%, 50% to 100%, 
v/v). 
1
H NMR (360 MHz, CDCl3) δ 6.84 (d, J = 10.23 Hz, 1H), 5.88 (d, J = 10.23 Hz, 
1H), 2.43 (t, J = 6.61 Hz, 2H), 1.91 (t, J = 6.61 Hz, 2H), 1.55-1.48 (m, 10H); 
13
C NMR 
(90 MHz, CDCl3) δ 200.24, 159.22, 127.56, 36.18, 35.73, 33.99, 33.05, 26.15, 21.87; 
ESI-MS: Calculated for C11H16O (M + H)
+
 165.2, Found: 165.4. 
 
 224 
 
 
Spiro[5.5]undecan-3-one (2) 
To spiro[5.5]undec-1-en-3-one (1.64g, 10mmol) in anhydrous THF was added Pd/C 
(0.2g), the flask was subsequently charged with an H2 balloon. The mixture was stirred at 
r.t overnight and Pd/C was filtered, washed with THF. The filtrate was concentrated and 
used without purification. 95% yield. 
1
H NMR (360 MHz, CDCl3) δ 2.27 (t, J = 6.94 Hz, 
4H), 1.66 (d, J = 6.94 Hz, 4H), 1.43-1.42 (m, 10H); 
13
C NMR (90 MHz, CDCl3) δ 213.14, 
37.40, 36.36, 36.04, 32.24, 26.88, 22.17; ESI-MS: Calculated for C11H18O (M + H)
+
 
167.3, Found: 167.3 
 
 
Spiro[5.5]undecan-3-aminium chloride (8) 
To a solution of spiro[5.5]undecan-3-one (1.66g, 10mmol) in pyridine (10ml) was added 
HONH2*HCl (0.70g, 10mmol). After stirring at ambient temperature for 2hrs, pyridine 
was removed by azeotropic evaporation in vacuo with toluene for several times. The 
resulting oxime was dissolved in anhydrous THF and cooled down to 0
o
C. LiAlH4 (1.50g, 
40mmol) was added portionwise to the solution and the mixture was heated to reflux 
overnight. After cooling down to 0
o
C, the solution was quenched with H2O (1.5 mL), 15% 
NaOH (1.5 mL), and H2O (4.5 mL) sequentially. The resulting slurry was filtered. The 
filtrate was concentrated in vacuo, and purified by flash chromatography to give 
spiro[5,5]undecan-3-amine as a colorless oil in 72% yield. The hydrochloride salt was 
prepared by purging HCl gas into the ether solution of spiro[5,5]undecan-3-amine at 0 °C, 
followed by centrifugation and decanting of the ether supernatant. 
1
H-NMR (360 MHz, 
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CDCl3) δ 8.30 (br s, 3H), 3.13-3.12 (m, 1H), 1.96-1.91 (m, 2H), 1.76-1.66 (m, 4H), 1.42-
1.38 (m, 8H), 1.22-1.21 (m, 2H), 1.34-1.06 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 51.59, 
40.37, 34.33, 32.63, 31.79, 26.97, 26.33, 21.97, 21.77; ESI-MS: Calculated for C11H21N 
(M + H)
+
 168.3, Found: 168.5. 
 
 
 
N-methylspiro[5.5]undecan-3-aminium chloride (9) 
To a solution of spiro[5,5]undecan-3-amine (1.67 g, 10 mmol), formaldehyde (0.82 ml, 
10 mmol, 37% wt in H2O), and NaBH(OAc)3 (3.18 g, 15 mmol) in dichloroethane (20 
mL) was added AcOH (0.12 mL, 2 mmol), and the resulting suspension was stirred 
overnight, quenched with NaHCO3, and extracted with CH2Cl2 twice. The combined 
organic layer was washed with brine and dried over MgSO4. The solution was filtered, 
concentrated in vacuo, and purified by flash chromatography. The compound was 
converted to the hydrochloride by purging HCl gas into the ether solution of N-
methylspiro[5.5]undecan-3-amine at 0°C, followed by centrifugation and subsequent 
decanting of the ether supernatant. The resulting white solid (0.39 g, 80% yield) was 
dried in vacuo. 
1
H-NMR (360 MHz, CDCl3) δ 9.45 (br s, 2H), 3.74-3.71 (m, 1H), 2.64 (t, 
J = 5.67 Hz, 3H), 2.00-1.97 (m, 2H), 1.97-1.80 (m, 4H), 1.63-1.43 (m, 8H), 1.23-1.20 (m, 
2H), 1.11-1.06 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 59.26, 40.73, 34.58, 32.16, 32.02, 
30.06, 26.94, 24.30, 21.98, 21.18; ESI-MS: Calculated for C11H23N (M + H)
+
 182.3, 
Found: 182.5. 
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1-(spiro[5.5]undecan-3-yl)guanidine (10) 
Spiro[5.5]undecan-3-amine (0.34 g, 2 mmol), HgCl2 (0.54 g, 2 mmol), and 1,3- bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (0.58 g, 2 mmol) were stirred in DMF (10 
mL) under a N2 atmosphere for 24 h. H2O was added to the reaction mixture, and the 
white precipitate was removed by filtration. The precipitate was washed with CH2Cl2 
twice, and the combined filtrate was extracted with CH2Cl2, washed with brine and dried 
over MgSO4, concentrated in vacuo, and purified by flash chromatography. The Boc 
protecting group was removed by 50% TFA/CH2Cl2 for 2 h at RT. Excess TFA was 
removed by passing N2 through the solution to give a yellow solid which was 
subsequently purified by flash chromatography (0.31 g, 74% over two steps). 
1
H-NMR 
(360 MHz, CD3OD) δ 3.70-3.64 (m, 1H), 1.91-1.83 (m, 4H), 1.60-1.53 (m, 10H), 1.34-
1.24 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 159.35, 50.23, 41.03, 31.79, 27.60, 26.98, 
22.43, 22.08; ESI-MS: Calculated for C11H23N3 (M + H)
+
 210.3, Found: 210.2. 
 
 
N-(spiro[5.5]undecan-3-yl)-1H-1,2,4-triazol-3-amine (11) 
Synthesis of 11 was accomplished following the same procedure described for 9. 72% 
yield. 
1
H-NMR (360 MHz, CD3OD) δ 7.56 (s, 1H), 3.52-3.48 (m, 1H), 1.79-1.71 (m, 4H), 
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1.45-1.40 (m, 10H), 1.25-1.20 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 147.41, 53.25, 
41.80, 36.34, 34.05, 33.06, 31.18, 29.26, 28.19, 23.19, 23.12, 22.83; ESI-MS: Calculated 
for C13H22N4 (M + H)
+
 235.3, Found: 235.3.  
 
 
N
1
-(spiro[5.5]undecan-3-yl)ethane-1,2-diaminium chloride (12) 
Synthesis of 12 was accomplished following the same procedure described for 9, 
followed by TFA deprotection. 78% yield. 
1
H-NMR (360 MHz, CD3OD) δ 3.31-3.26 (m, 
4H), 3.13-3.05 (m, 1H), 1.92-1.88 (m, 2H), 1.81-1.77 (m, 2H), 1.65-1.58 (m, 2H), 1.44-
1.40 (m, 8H), 1.24-1.10 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 59.65, 42.83, 41.90, 
40.66, 37.26, 35.48, 32.96, 32.93, 27.97, 25.29, 22.95, 22.70; ESI-MS: Calculated for 
C13H26N2 (M + H)
+
 211.4, Found: 211.5.  
 
 
 
 
N
1
-(spiro[5.5]undecan-3-yl)propane-1,3-diaminium chloride (13) 
Synthesis of 13 was accomplished following the same procedure described for 9, 
followed by TFA deprotection. 74% yield. 
1
H-NMR (360 MHz, CDCl3) δ 9.05 ( br s, 2H), 
8.15 (br s, 3H), 3.32-3.18 (m, 4H), 3.03-3.01 (m, 1H), 2.46-2.42 (m, 2H), 2.09-2.01 (m, 
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2H), 1.78-1.74 (m, 4H), 1.41-1.40(m, 8H), 1.21-1.07 (m, 4H); 
13
C-NMR (90 MHz, 
CDCl3) δ 58.80, 42.64, 41.08, 37.91, 34.84, 32.02, 27.00, 24.79, 24.34, 22.01; ESI-MS: 
Calculated for C14H28N2 (M + H)
+
 225.4, Found: 225.7. 
 
 
N
1
-((1H-imidazol-5-yl)methyl)-N2-(spiro[5.5]undecan-3-yl)ethane-1,2-diaminium 
chloride (14) 
Synthesis of 14 was accomplished following the same procedure described for 9. 71% 
yield. 
1
H-NMR (360 MHz, CDCl3) δ 8.85 (s, 1H), 7.54 (s, 1H), 3.85 (s, 2H), 3.40-3.38 
(m, 2H), 3.31-3.30 (m, 1H), 3.22-3.18 (m, 1H), 2.85-2.83 (m, 1H), 1.88-1.82 (m, 4H), 
1.61-1.57 (m, 2H), 1.46-1.43 (m, 8H), 1.38-1.35 (m, 2H), 1.30-1.27 (m, 2H); 
13
C-NMR 
(90 MHz, CDCl3) δ 136.03, 132.15, 119.55, 59.63, 59.48, 41.97, 40.64, 35.70, 32.95, 
27.97, 25.29, 22.96, 22.67; ESI-MS: Calculated for C17H30N4 (M + H)
+
 291.4, Found: 
291.7. 
 
 
3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (5)(3)  
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4-Iodo-1-trityl-1H-imidazole (0.44g, 1mmol) in THF was protected with N2 in a three 
neck flask, EtMgBr in THF (1mmol) was added dropwise and the mixture was stirred for 
30mins at r.t. Spiro[5.5]undecan-3-one (0.18g, 1.1mmol) in THF was added dropwise 
and the mixture was stirred overnight. The reaction was quenched with saturated NH4Cl 
and extracted with CH2Cl2. The combined CH2Cl2 was dried with MgSO4 and 
concentrated in vacuo. Flash column purification (CHCl3 to 5% CH3OH/CH3Cl, v/v) 
gave 0.34g spiro[5.5]undecan-3-yl(1-trityl-1H-imidazol-4-yl)methanol as white solid 
(Yield: 70%). 
1
H-NMR (360 MHz, CDCl3) δ 7.34 (d, J =1.35 Hz, 1H), 7.32-7.30 (m, 9H), 
7.13-7.05 (m, 6H), 6.67 (d, J =1.35 Hz, 1H), 1.93-1.87 (m, 2H), 1.54-1.29 (m, 16H); 
13
C-
NMR (90 MHz, CDCl3) δ 142.73, 138.53, 130.01, 128.58, 128.24, 116.57, 70.74, 33.38, 
32.65, 31.99, 27.22, 22.08, 21.95; ESI-MS: Calculated for C33H36N2O (M + H)
+
 477.7, 
Found: 477.7. 
 
 
 
3-(1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (15) 
3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (0.48g, 1mmol) was dissolved in 3ml 
20% TFA/CH2Cl2, the mixture was stirred 2hrs at room temperature. Excess TFA and 
CH2Cl2 were removed by purging N2, the final product was subsequently purified by 
flash column (5% CH3OH/CH2Cl2 to 10% CH3OH/CH2Cl2, v/v) to gave white solid 
(0.19g, Yield: 82%). 
1
H-NMR (360 MHz, CDCl3) δ 8.82 (d, J = 1.08 Hz, 1H), 7.45 (d, J 
= 1.08 Hz, 1H), 2.70 (s, 1H), 1.99-1.98 (m, 2H), 1.96-1.95 (m, 2H), 1.85-1.81 (m, 2H), 
1.71-1.64 (m, 10H), 1.33-1.29 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 138.62,  136.42, 
117.34, 73.21, 35.24, 33.13, 32.86, 28.14, 22.96, 22.89; ESI-MS: Calculated for 
C14H22N2O (M + H)
+
 235.2, Found: 235.7. 
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5-(spiro[5.5]undecan-3-yl)-1H-imidazole (16) 
To a stirred solution of 3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (0.48g, 
1mmol) in CH2Cl2 at 0
o
C was added Et3SiH (0.383ml, 2.4mmol), followed by BF3*OEt2 
(0.377ml, 3mmol). The solution was allowed to warm to r.t and stirred for 2hrs. The 
reaction was quenched with saturated NH4Cl and extracted with CH2Cl2. The combined 
CH2Cl2 was dried with MgSO4 and concentrated in vacuo. Flash column purification 
(CHCl3 to 2% CH3OH/CH3Cl) yielded 0.37g 4-(spiro[5.5]undecan-3-yl)-1-trityl-1H-
imidazole as white solid (Yield: 80%). The trityl protection group was subsequently 
removed by treatment with 20%TFA/CH2Cl2 as described for 15. (Yield: 78%). 
1
H-NMR 
(360 MHz, CDCl3) δ 8.81 (s, 1H), 7.43 (s, 1H), 6.30 (s, 1H), 2.35-2.34 (m, 2H), 2.12-
2.10 (m, 2H), 1.84-1.70 (m, 1H), 1.66-1.63 (m, 2H), 1.48-1.46 (m, 8H), 1.38-1.35 (m, 
4H); 
13
C-NMR (90 MHz, CDCl3) δ 136.35, 127.63, 115.40, 42.63, 38.09, 37.55, 36.24, 
33.47, 32.19, 28.24, 27.91, 23.82, 22.93, 22.87; ESI-MS: Calculated for C14H22N2 (M + 
H)
+
 219.4, Found: 219.4. 
 
 
4-(3-fluorospiro[5.5]undecan-3-yl)-1H-imidazole (17) 
DAST (0.146ml, 1mmol) was added to anhydrous CH2Cl2 under a N2 atmosphere. The 
solution was cooled to -78
o
C with dry ice/acetone mixture, 3-(1-trityl-1H-imidazol-4-
yl)spiro[5.5]undecan-3-ol (0.49g, 1mmol) in CH2Cl2 was added dropwise. After addition, 
the solution was allowed to warm to room temperature and stirred for another 2 hrs. H2O 
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was added and CH2Cl2 layer was separated. The organic layer was washed with brine, 
dried over MgSO4, concentrated in vacuo and purified by flash column 
(2%CH3OH/CH2Cl2 to 5% CH3OH/CH2Cl2, v/v) to yield 0.37g yellow solid. (Yield: 
75%). The trityl protection group was subsequently removed by treatment with 
20%TFA/CH2Cl2 as described for 15. (Yield: 81%).  
1
H-NMR (360 MHz, CD3OD) δ 
8.82 (d, t = 1.4 Hz, 1H), 7.44 (d, t = 1.4 Hz, 1H), 1.98-1.93 (m, 2H), 1.84-1.80 (m, 2H), 
1.66-1.63 (m, 2H), 1.53-1.49 (m, 10H), 1.39-1.36 (m, 2H); 
13
C-NMR (90 MHz, CD3OD) 
δ 134.91, 115.54, 69.65, 43.34, 33.88, 32.85, 28.14, 22.96, 22.89; ESI-MS: Calculated for 
C14H21FN2 (M + H)
+
 237.3, Found: 237.4. 
 
Spiro[5.5]undecane-3-carbaldehyde (6) 
To a three neck N2 protected RBF was added (Methoxymethyl)triphenylphosphonium 
chloride (0.348g, 1mmol) and THF (10ml). The solution was cooled down to -78
o
C and 
LDA (1.2mmol) was added dropwise via syringe, after addition the solution was slowly 
warmed to room temperature (15mins) and kept stirring for 1hr. The solution was again 
cooled down to -78
o
C and spiro[5.5]undecan-3-one (0.166g, 1mmol) in THF was added 
dropwise via syringe. The reaction was left stirring overnight, and quenched cautiously 
with H2O, CH2Cl2 was added and the solutin was extracted with saturated NH4Cl, brine, 
and dried over anhydrous MgSO4. The solution was filtrated and dried in vacuum to give 
brown solid. The brown solid was washed with ether several times (3×5ml), the ether 
solution was combined and dried in vacuum again until no more brown solid formed. To 
this brown oil was added THF (2ml) and 5M HCl, the solution was heated to reflux for 
2hrs, cooled down to r.t and neutralized with 1M NaHCO3, extracted with CH2Cl2, and 
dried with anhydrous MgSO4. The final product was purified by flash column (50% 
CH2Cl2/Hexane to 100% CH2Cl2) to give 0.116g spiro[5.5]undecane-3-carbaldehyde as 
brown oil. (Yield: 70% for two steps). 
1
H-NMR (360 MHz, CDCl3) δ 9.63 (s, 1H), 2.22-
2.18 (m, 1H), 1.82-1.21 (m, 18H); 
13
C-NMR (90 MHz, CDCl3) δ 205.30, 50.51, 45.12, 
40.10, 35.35, 33.54, 32.31, 32.87, 29.92, 27.07, 21.84, 21.69, 21.15. ESI-MS: Calculated 
for C12H20O (M + H)
+
 181.3, Found: 181.5. 
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(1H-imidazol-5-yl)(spiro[5.5]undecan-3-yl)methanol (18) 
Synthesis of 18 was accomplished following the same procedure as described for 15. 74% 
yield. 
1
H-NMR (360 MHz, CDCl3) δ 8.78 (s, 1H), 7.36 (s, 1H), 4.56 (d, J= 6.25 Hz, 2H), 
1.70-1.61 (m, 4H), 1.42-1.36 (m, 8H), 1.29-1.19 (m, 5H), 1.04-1.03 (m, 2H); 
13
C-NMR 
(90 MHz, CDCl3) δ 138.24, 134.87, 116.80, 70.59, 45.65, 42.94, 37.42, 33.41, 33.18, 
28.20, 25.05, 24.10, 22.96, 22.76; ESI-MS: Calculated for C15H24N2O (M + H)
+
 249.4, 
Found: 249.7. 
 
 
5-(fluoro(spiro[5.5]undecan-3-yl)methyl)-1H-imidazole (19) 
Synthesis of 19 was accomplished following the same procedure as described for 17.
 1
H-
NMR (360 MHz, CDCl3) δ 8.74 (s, 1H), 7.35 (s, 1H), 4.46 (m, 1H), 1.93-1.68 (m, 4H), 
1.42-1.36 (m, 9H), 1.28-1.22 (m, 4H), 1.12-1.07 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 
138.24, 134.83, 116.80, 98.4, 45.55, 42.96, 37.52, 33.44, 33.19, 28.21, 25.05, 24.10, 
22.97, 22.76; ESI-MS: Calculated for C15H23FN2 (M + H)
+
 251.4, Found: 251.4. 
 
CD titrations:  CD titrations were conducted using materials and procedures described in 
a previous study.(4) Synthetic M2TM 22-46 (41 µM) was dissolved in DPC micelles 
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(detergent concentration, 2.5 mM) potassium phosphate buffer (10mM), pH 7.4. For 
titrations, the drug was added from concentrated solutions in the same buffer. Spectra 
were recorded in a 1 mm path length cuvette using a Jasco J-810 spectropolarimeter 
(Jasco, Easton, MD) at 25°C with 1 nm step scans (4 sec acquisitions; 6 accumulations). 
To compute the ellipticity ratio (θ223/θ209) the ellipticity at 223±2 nm and at 209±2 nm 
were averaged to improve signal-to-noise.  
 
The ratio of the mean residue ellipticity (θ223/θ209) is shown vs. the concentration of 
various compounds below.  Also included in each panel for reference is a curve for 
rimantadine, which is a tight-binding inhibitor. To obtain dissociation constants for 
binding of the drugs to the tetramer it is necessary to consider the monomer/tetramer 
equilibrium of the peptide, which is not 100% tetrameric under the conditions of the 
assay.  The equilibrium is shown below (eq. S1, in which Mon is the monomer, Tet the 
tetramer, Drug is amantadine or another ligand, and n the number of independent binding 
sites per tetramer).  Thus, the experimentally observed curves depend on the 
peptide/detergent ratio, which defines the fraction of monomer vs. tetramer.(4, 5)  As the 
fraction of tetramer is decreased, larger concentrations of drug are needed to drive the 
equilibrium towards the tetrameric form.  However, if the dissociation constant for 
tetrameric formation is known from independent experiments (Ktet).(4) the desired 
ligand-dissociation constant (Kd) can be determined. 
4MonTet+nDrugTnDrug
KtetKd
                                              eq. S1 
 
The change in the ellipticity ratio versus ligand concentration is analyzed using IGOR 
Pro (Wavemetrics) and functions derived from the above equilibrium scheme.  The 
experimental observable is the ellipticity ratio at a given concentration of peptide, 
detergent, and ligand. The mass balance equations are: 
                                                      eq.S2 
 
total
4 n4
F
total
tet tet d
Pep [Mon]+4[Tet]+4[Tet nDrug]
[Mon] [Drug ]4[Mon]
Pep [Mon]+ +4
K K K
 

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           eq.S3 
 
in which the subscript denotes total and free, respectively.  Equation S2 and S3 are solved 
numerically for [DrugF] as a function of [Peptotal], Ktet, and Kd using the root-finding 
algorithm in IGOR Pro.  Ktet is known independently from analytical 
ultracentrifugation(4) , leaving n and Kd as fitting variables. 
 
The experimental curves are analyzed according to the final fitting equation S4 in which 
Robs is the ellipticity ratio observed at a given ligand concentration, and Rmon, RTet and 
RTetDrug  are the ellipticity ratios associated with the monomeric, tetrameric, and 
amantadine-bound tetrameric species.  
 
Robs=(Rmon[Mon]+ 4RTet[Tet] + 4RTetDrug[Tet·nDrug])/Peptotal                                              eq. S4 
 
The variable Rmon is treated as a constant, and determined independently from data at low 
peptide/detergent ratios.(5)  We find that the most accurate values of the parameters can 
be obtained by global fitting, in which Rtet n, and RTetDrug are global parameters, and the 
values of Kd  is allowed to vary for each compound.  Because rimantadine binds very 
tightly, inclusion of curves for this molecule in the global fits, helps to constrain the 
values of RTetDrug.  Kbind for rimantadine was obtained using a more extensive number of 
experiments and points, and this value was held constant in the global fitting of the 
remaining compounds.  Using this procedure, we find the value of n is 1.04 ± 0.4, very 
close to the theoretical value of 1.0 molecule ligand bound per tetramer. The values 
quoted in Table 1 of the main manuscript are from duplicate runs.  
 
 
 4 n
F
total F
tet d
n[Mon] [Drug ]
Drug =[Drug ]+
K K
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7.1 Abstract 
Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in viral 
membrane. It is the target of amantadine and rimantadine class of antiviral drugs. Most of 
current circulating influenza A virus carry drug resistant mutations mapped alongside the 
drug binding site, namely S31N, V27A and L26F etc, each of which might be dominant 
in a given flu season. Among those mutations, V27A mutation was shown to be evolved 
from drug selection pressure, and has not shown to be druggable despite years of 
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extensive medicinal chemistry research efforts and library screening. As it is impractical 
to predict which mutation would dominate in the next influenza A viruses outbreak, there 
is an urgent need to develop novel antivirals targeting all strains of flu viruses, especially 
V27A. Herein, based on X-ray structure of amantadine complexed A/M2 and dynamic 
influence of A/M2 upon drug binding from earlier solid state NMR studies, we designed 
a series of potent spiran amine inhibitors targeting not only wt, but more importantly both 
A/M2-27A and L26F mutants with low micromolar IC50s. The potencies of these 
inhibitors were further verified in in vivo plaque reduction assay. ssNMR study indicated 
the binding of the drug inside the channel. Molecular dynamics (MD) simulations of the 
potent inhibitors M2WJ180 and M2WJ206 on A/M2-V27A inhibition is consistent with 
our design assumption that the drug indeed occupies a larger portion of the channel and is 
able to fill in the extra space created by the V27A and L26F mutations. Our study for the 
first time demonstrated the druggability of A/M2 mutants and resulted in a potent lead 
compound that will be further pursed in animal study. 
 
7.2 Introduction 
The outbreak of highly pathogenic swine flu H1N1 caused global health crisis back in the 
early of 2009
1
. While vaccine offers first line protection against influenza A virus 
infection, its effectiveness is diminished due to the gap between vaccine development and 
massive production, immunization
2
, during which time the influenza A virus might 
undergo antigenic drift or antigenic shift that results in new types of viruses capable of 
escaping from previous vaccine
3
. This is what happened for the vaccine recall from 
Sanofi Pasteur because of the effectiveness dropped below its pre-specific limit over 
time
4
. Another option of preventing and treating influenza A viruses infection is 
chemotherapy with small molecule inhibiting either neuraminidase (zanamivir and 
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oseltamivir) or M2 channel (amantadine and rimantadine)
5
. Increasing number of 
influenza A strains become resistant to oseltamivir (Tamiflu) in the past years, and the 
use of zanamivir is limited by poor bioavailability and non-conventional administration 
by inhalation. The use of amantadine and rimantadine to treat influenza A virus infection 
was suspended by CDC in U.S until further notice due to the rapid development of 
resistance and central neuron system (CNS) side effects
6
. Thus there is an urgent need to 
develop novel antivirals capable of targeting all strains of influenza A viruses. 
Comparing with neuraminidase, A/M2 is more conserved in the transmembrane drug 
binding site with only three major drug resistant mutations S31N, V27A and L26F. Thus 
from the drug development point of view, inhibitors targeting those mutants would be 
more advantageous to be used as antiviral drugs. 
 
A/M2 forms a homotetrameric channel in viral membrane which selectively conducts 
proton
7,8
. Once viruses enter the infected cell by sialic acid receptor mediated endocytosis, 
the low pH in the endosome activates A/M2 and facilitates proton influx which results in 
the fusion of viral membrane and the endosome membrane, and subsequently releasing 
the viruses’ RNA into the cytoplasm9. Another function of A/M2 is to equilibrate the pH 
across Golgi in order to prevent the premature conformation change of hemaglutalin
10-12
.   
 
The predominant A/M2 mutations conferring amantadine resistance are S31N, V27A and 
L26F etc, all of which are mapped alongside the drug binding site
13
. Although S31N is 
the predominant mutation in certain years, recent studies showed that S31N mutation is 
not the result of drug selection pressure due to the fact that (1) S31N was identified even 
before amantadine was used to treat influenza A virus infection, (2) In certain areas 
where amantadine was never used
14,15
. Instead V27A was identified to be the major 
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mutation emerging from drug selection pressure, and V27A is indeed the dominant 
mutation in certain flu seasons
16,17
. Thus it would be of higher priority to design V27A 
inhibitors because this mutation will become dominant when any A/M2 inhibitors 
become in use. However, despite years of medicinal chemistry research efforts focusing 
on develop novel antivirals targeting drug-resistant influenza A/M2 by either compound 
synthesis or library screening, it has not been shown that small molecule inhibitors are 
able to target amantadine resistant A/M2 channel. Part of the failure might due to the lack 
of structural information of A/M2 mutants, as well as the difficulties associated with 
membrane protein study such as protein production, assay and structural characterization 
of drug binding. What makes it even more challenge for A/M2 drug design is due to the 
fact that unlike enzymes’ active sites, there is no polar residues, except S31 which 
hydrogen bonds to V27 backbone carbonyl,  in the A/M2 drug binding site that inhibitor 
can directly interact, except hydrophobic interaction, this is seen from X-ray structure of 
amantadine complexed A/M2 - there is no specific interaction formed between drug and 
the protein
13
.  
 
From both X-ray
13
 and solution NMR
18
 structures of A/M2, V27 forms a selection gate at 
the N-terminal lumen which filter hydronium versus other cations like K
+
 and Na
+
. Very 
recent high resolution (1.65Å) structure of A/M2 TM showed V27 forms the narrowest 
valve of the central cavity (2 Å)
19
, which only allows the passage of hydrated proton.  
Our hypothesis of V27A resistance to amantadine might be due to the fact that valine to 
alanine mutation creates a larger cavity in the N-terminal luminal which results in a shape 
mismatch between the central channel cavity and amantadine. 
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We rationalize that by expanding the size of the inhibitor to complement that of the drug 
binding site, we might be able to target V27A mutant. Here we report our inhibitor design 
principle in targeting A/M2-V27A mutant, synthesis strategy, influenza A virus inhibition 
results, ssNMR characterization of drug binding and mechanism of inhibition by 
molecular dynamics (MD) simulation. 
 
7.3 Results 
7.3.1 Homology modeling of V27A mutant indicates V27A mutation creates a larger 
cavity at N-terminal luminal site 
V27 forms a lid at the N-terminal luminal site of A/M2 with side chain pointing towards 
the channel.  Our design hypothesis of V27A inhibitor is that V27A mutation expanded 
the drug binding site at the N-terminal of A/M2, thus causes a shape mismatch between 
amantadine and the mutant channel which result in escape from inhibition.  To 
investigate how V27A and L26F mutations affect the size and the shape of the binding 
site, we built theoretical models of the structures these mutants in the apo form using the 
recently solved high resolution structure of A/M2
19
 as initial configuration.  Initial 
models were obtained by replacing the sidechains of Val27 and Leu26 with alanine and 
phenalanine, respectively, and refined by performing classical MD simulations in a 
bilayer of DMPC lipids hydrated by explicit solvent molecules.  After a relaxation phase 
of several ns with the protein gradually released, the structures of the mutants were 
observed to be stable over a timespan of few tens of ns (backbone RMSD of the order of 
1 Å).  As expected, the mutation of the valines into alanines at position does not perturb 
significantly the overall structure of the bundle.  Therefore the effect of the mutation can 
be easily rationalized by observing that replacing the bulky Val sidechain with a small 
methyl moiety results into an expansion of the pore radius in the region lining the 
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amantadine binding site (Figure 1.).  Particularly noteworthy, however, is the fact that a 
similar net effect is observed upon mutation of Leu26, which is not pore-lining, into 
phenylalanine.  In this case the introduction of the phenyl groups results in a less tight 
helix-packing, and, as a result, the entry region of the pore is more disordered and 
features, on average, a larger radius.  
 
 
Figure 1 | Shape modulation of the drug-binding pocket in the pore of A/M2 channel. A 
cartoon representation of the A/M2-TM helix bundle is shown for wt (a), V27A (b), and 
L26F (c). The molecular surface of the channel pore is highlighted and pore-lining 
residues Leu/Phe26 (brown), Val-Ala27 (blue), His37 (orange), and Trp41 (violet) are 
shown as sticks. Pore waters and amantadine are shown for wt as red spheres and sticks, 
respectively. The positions of water oxygens and amantadine are obtained from the 
crystal structure of the G34A mutant
19
, and the ssNMR structure of the A/M2-amantadine 
complex
20
, respectively. Foe each structure, the radius of the pore (computed using 
Hole
21
) is plotted  as a function of the displacement along the channel axis in the region 
between His37 and Val-Ala27; the range of values corresponding to the entry region of 
the channel pore is highlighted in pink.  
 
7.3.2 Design and synthesis of inhibitors targeting V27A mutant based on shape 
complementary principle 
A common feature of most known A/M2 inhibitors contains a polar head group 
(positively charged amine) and a hydrophobic aliphatic scaffold. Among the every few 
scaffolds other than adamantane that have been explored for A/M2 inhibition, our 
previous structural and activity relationship (SAR) study of BL-1743 revealed one of the 
most potent inhibitor spiro-piperidine M2WJ10 against A/M2 (IC50 = 0.92 µM), being 
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16 fold more potent than amantadine
22
. More importantly, solid state NMR (ssNMR) 
characterization of M2WJ10 binding to A/M2 in DMPC bilayers showed that spiro-
piperidine influences the dynamics and magnetic environment of more residues within 
the transmembrane helices than amantadine. This result sheds light on V27A inhibitor 
design and suggests spiro scaffold is more advantageous for V27A inhibition over 
amantadine, because its extended conformation is able to fill in the extra space created by 
bulkier valine to smaller alanine mutation. Indeed, one carbon extension from spiro-
piperidine M2WJ10 gave spiran amine M2WJ34 that shown moderate inhibition against 
V27A (IC50 = 84.9 µM)
23
. To the best of our knowledge, this is the first example of small 
molecule reported to be active against V27A mutant. Docking of M2WJ34 with A/M2-
V27A indicates extra space in the channel. Thus to further improve the potency, two 
focused libraries of spiran amines were designed based on spiran amine M2WJ34 
scaffold; one with expanded ring size (M2WJ164, M2WJ152, M2WJ180), another with 
extended head group (M2WJ151, M2WJ198). As negative control, M2WJ189 with 
reduced ring size was also included for comparison. 
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Figure 2 | Inhibitor design to target A/M2 V27A mutant. (a) Known examples of wt 
A/M2 inhibitors (b) Two libraries of spiran amines were designed to either expand the 
ring size or extend the polar head group region. 
The synthesis of ring expanded spiran amines started with one pot robinson annelation 
reaction using H2SO4 as catalyst
24
. Spiro enones were prepared from aldehydes in 50-70% 
yield with an optimized procedure. Reduction of the enones with Et3SiH/PdCl2 gave the 
spiro ketones in quantitative yield
25
. Subsequently the spiro ketones were converted to 
amines (M2WJ189, M2WJ34, M2WJ164) using a two step amination reaction in 72-80% 
yield. For ring expansion of the cyclohexanone, it was converted to lactam using 
hydroxylamine-O-sulfonic acid/formic acid mediated rearrangement
26
 followed by 
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LiAlH4 reduction to give M2WJ196 in 70% yield.  One carbon homologation of the 
spiro cyclohexanone was achieved via the corresponding diazo-hydroxy ester which was 
converted into the beta-keto ester, using ethyl diazoacetate/LDA, then a catalytic amount 
of rhodium(II) acetate
27
. Finally the keto ester was hydrolyzed under acidic condition to 
afford the ketone intermediates, which were subsequently transformed to amines. For 
expansion in the amino head group, reductive cyanation of spiro[5,5]undecan-3-one with 
tosyl-methylisocyanide (TOSMIC) gave the nitrile
28
. The nitrile was either reduced to 
amine M2WJ151 by LiAlH4 or hydrolyzed to the corresponding acid, which was 
converted to methyl ketone using 2.2eq CH3Li. Ethyl amine M2WJ198 was synthesized 
by treatment of methyl ketone with hydroxylamine, followed by LiAlH4 reduction. All 
amines were finally prepared as their hydrochloride salts before testing. 
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Figure 3 | Synthesis scheme of designed A/M2-V27A inhibitors. Details about 
experiment procedure can be found in supplement. 
 
7.3.3 Spiran amines are active aganist A/M2-V27A mutant in recombinant Oocyte 
electrophysiology assay 
The inhibitors were tested in Oocyte cells expressing either wt or V27A mutant A/M2 
using two electrode patch clamp (TEV) electrophysiology method. The potency of 
inhibitors was expressed as percent inhibition of A/M2 proton conductance with 100 μM 
inhibitor applied. The initial hit [5,5]spiran amine M2WJ34 only has moderate activity 
against V27A mutant with IC50 of 84.9 μM, however, by expanding either cyclohexane 
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rings of M2WJ34 to cycloheptane, a dramatic increase in potency was seen for both 
M2WJ152 and M2WJ164 against V27A with IC50s of 68.1 and 28.1 μM, respectively. 
In contrast, wt M2 was insensitive to this structural transformation as all three inhibitors 
have similar IC50s. Next we rationalized that by adding the beneficial effects of ring 
expansion, we would be able to further increase the potency. Indeed, the activity of 
[6,6]spiran amine M2WJ180 was increased 8 fold against V27A mutant comparing with 
the initial hit [5,5]spiran amine M2WJ34. M2WJ180 was also more active than 
M2WJ34 in inhibiting wt M2 with IC50 of 8.7 μM. As a control to test our hypothesis 
that V27A mutant favors binding of bulkier molecule due to the expanded A/M2 central 
cavity, M2WJ189 with cyclopentyl ring was synthesized and found to be 4 fold less 
active than M2WJ34 on V27A inhibition, but it was 4 fold more active on wt A/M2. 
Consistent with the previous result that a primary amine is more active than a secondary 
amine in targeting V27A mutant, 3-azaspiro[6.6]tridecane M2WJ196 was found 20 fold 
less active than M2WJ180.  For the second library with extended head group, one carbon 
insertion of M2WJ34 yielded M2WJ151, which was 2.5 fold more potent than M2WJ34. 
1-spirosubstituted ethylamine M2WJ198, analog of rimantadine, was 3.4 fold more 
potent than M2WJ34 on V27A inhibition with enantiomeric mixture tested. Overall, a 
positive correlation has seen between increased inhibitor size (hydrophobicity) and 
potency on A/M2-V27A inhibition. 
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Table 1 | Electrophysiology measurement of inhibitors potencies in two electrode voltage 
clamp assay. 
 
Inhibitor ID Amantadine M2WJ10 M2WJ34 M2WJ152 M2WJ164 
Structures 
 
    
A/M2-wt % 
inhibition/IC50 
90.8% 
16.0 μM 
95.0% 
0.92 μM  
89.0% 
12.6 μM 
94.4% 
13.2 μM 
95.0% 
13.0 μM 
A/M2-V27A % 
inhibition/ IC50 
6.9% 
N.D 
11.04% 
N. D 
53.4%/84.9 
mM 
54.8%/68.1 
mM 
70.2%/28.1 
mM 
Inhibitor ID M2WJ180 M2WJ189 M2WJ196 M2WJ151 M2WJ198 
Structures 
 
  
  
A/M2-wt 
%inhibition/IC50 
90.4% 
8.7 μM 
95.9% 
3.3 μM 
86.0% 
13.8 μM 
90.5% 
8.9 μM 
85.8% 
16.0 μM 
A/M2-V27A % 
inhibition/IC50 
82.7% 
11.3 μM 
25.2% 
318.6 μM 
26.0% 
220.4 μM 
67.7% 
31.1 μM 
75.6% 
25.2 μM 
 
7.3.4 Further optimization yielded Spiroadamantane as one of the most potent V27A 
inhibitor 
The drug binding site of A/M2-V27A has a shape of truncated cone, which suggests a 
polycyclic scaffold would better fit inside the channel. Aside from increasing the ring 
size in order to fill the extra space inside the A/M2 channel, another strategy would be to 
convert the bottom cyclohexane ring of M2WJ34 to bicyclo[3.3.1]nonane (Intermediate I, 
Figure 4a), which can be further constrained by a methylene linkage to give 
spiroadamantane M2WJ206.  This inhibitor was synthesized using robinson annelation 
reaction starting from 2-adamantanecarboaldehyde as described above (Supporting 
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information). This structure transformation resulted in the most potent A/M2-V27A 
inhibitor-spiroadamantane M2WJ206 that is 265 fold more potent than M2WJ34. More 
encouraging, this inhibitor was also highly active against another amantadine resistant 
mutant L26F, consistent with homology modeling result that L26F and V27A have 
similar expanded central cavities. 
a 
 
b 
 
Figure 4 | Spiroadamantane inhibitor design and its does response curve on wt, V27A, 
L26F and S31N inhibition. 
 
7.3.5 Spiran amines were shown to be active in plaque reduction assay 
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The inhibitory effect of four of the most potent inhibitors on V27A mutant was confirmed 
by in vivo plaque reduction assay of influenza A virus. Both the size and number of 
plaque formation were significantly reduced by all four inhibitors at 10 μM concentration. 
Consistent with the electrophysiology result, M2WJ206 was most potent and inhibited 
plaque formation dramatically at as low as 1 µM concentration. As negative control, 
amantadine showed no inhibition of A/M2-V27A viruses replication even at 50 µM 
concentration. Thus, spiran amines are not only capable of effectively inhibiting wt A/M2 
channels and amantadine resistant A/M2-V27A mutant channels in electrophysiology 
assay; they are also active in in vivo plaque reduction assays of influenza A viruses. 
 
 
 
Figure 5 | Plaque reduction assay of spiran amines on A/M2-V27A mutant virus. Effects 
of compounds on influenza A virus (A/Udorn/72)  V27A mutant were evaluated by 
plaque formation on MDCK cells in the presence or absence of the compounds (10 μM or 
dose dependent) as described previously (XX). M2WJ206 is able to significantly reduce 
A/M2-V27A replication in as low as 5 µM conc. As control, amantadine has no effect on 
virus replication at up to 50 µM. 
 
 
7.3.6 Solid state NMR (ssNMR) indicated binding of spiran amine in the central 
cavity of V27A 
Solid state NMR (ssNMR) spectroscopy is advantageous in characterizing membrane 
protein structural change as the protein can be reconstituted in a more native bilayer 
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environment, thus better mimic its native conformation. We used ssNMR to study how 
spiran amine M2WJ180 binds to A/M2-V27A mutant channels, as it will offer insightful 
clue for next generation of drug design. A/M2-V27A transmembrane (TM) peptide (22-
46) was synthesized with three residues A27, V28 and G34 uniformly 15N and 13C 
double labeled (Supporting Information). When reconstituted in DMPC bilayers, the V28 
15N chemical shift was cleared changed by 2ppm upon titrating 4 drugs/channel. In 
addition, G34 chemical shift change was previously shown to be characteristic of drug 
binding in wt A/M2 as it forms a kink in the drug bound form. Binding of M2WJ180 to 
A/M2-V27A split the G34 15N peak, indicating the drug binding site locates close to 
G34.  
 
 
 
Figure 6 | ssNMR characterization of spiran amine M2WJ180 binding to A/M2-V27A 
mutant in DMPC bilayers. 
 
7.3.7 Molecular Dynamics (MD) simulation of drug binding 
To gain insight into the relationship between potency and size of the aliphatic scaffold, 
we performed classical MD simulations on A/M2 mutants V27A and L26F in complex 
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with M2WJ180 and M2WJ206; focusing on the binding site, we analyzed the 
conformational distribution of the drug molecules and of the H-bonded water molecules. 
Using the case of amantadine bound to wt as a reference, we first compared the binding 
mode of M2WJ180 to wt and V27A.  
 
The binding mode of M2WJ180 to wt is significantly different from that of amantadine: 
the more extended aliphatic scaffold of M2WJ180 is constrained in one direction by the 
steric hindrances provided by the bulky Val27 sidechains, therefore a net shift of 2/3 Å 
toward the histidine tetrad is observed in the position of the amine group (Fig. 7).  As a 
result some of the highly structured water molecules solvating the amine group of 
amantadine are not present in the wt:M2WJ180 (Fig. 7).  
 
 
           Figure 7 | Heavy atoms density maps in different M2TM:drug complexes, as computed 
from 20 ns MD runs; the density is plotted with respect to the coordinate along the pore 
axis (indicated as z) and to the distance from it (r). Protein atoms are shown in green 
(with labels indicating important pore-lining residues), water oxygens in red, the drug's 
nitrogen atoms in blue and carbon atoms in black. Shown are the following mutant:drug 
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complexes: (a) WT:amantadine, (b) WT:M2WJ180, (c) V27A:M2WJ180, (d) 
WT:M2WJ206, (e) V27A:M2WJ206, and (f) L26F:M2WJ206. 
 
Interestingly, the arrangement of M2WJ180 into the pore of V27A highly resembles that 
of the wt:amantadine structure.  Although the drug molecule is less tightly bound, the 
position of the amine group and the conformation of the solvating water molecules are in 
striking agreement with those observed in the wt:amantadine case. M2WJ206 is 
analogous to M2WJ180 when binding to wt, in that some of the water molecules 
observed in the wt:amantadine complex are absent when M2WJ206 binds; however, in 
the V27A:M2WJ206 complex, the entire water cluster is recovered.  Furthermore, the 
mobility of M2WJ206 in the V27A pore is significantly decreased from M2WJ180 in 
the same conditions.  Finally, the L26F:M2WJ206 closely resembles the wt:M2WJ206 
structure. 
 
7.4 Discussion 
Despite extensive medicinal chemistry research efforts dedicated towards discovery of 
influenza A virus M2 proton channel inhibitors, the druggability of A/M2 mutants has not 
been demonstrated. As most of current circulating influenza A virus carry drug resistant 
mutants and we can’t predict which mutation would be dominant in the next flu pandemic, 
there is urgent need to develop novel antiflu drugs. Among variety of drug resistant 
mutations, V27A is directly linked to drug selection pressure, thus poses a higher priority 
to be targeted for drug discovery. Unlike the active sites of enzymes, the N-term side of 
the pore of M2 does not feature any polar group, except for a ring of hydroxyls from the 
Ser31 residues, constantly H-bonded to the backbone carbonyl oxygens of Val27. 
Therefore the affinity of alkyl-amines for M2 results, at least in part, from finely-tuned 
hydrophobic interactions between the side chains of the residues lining the channel pore 
and the aliphatic scaffold of the drug molecule. Homology modeling suggests that 
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mutation of valine residues into alanine at position 27  may increase the radius of the 
channel pore  at the N-terminal lumen site  and create a shape mismatch between the 
binding site and amantadine. A bulkier inhibitor is, thus, expected to show a higher 
affinity. Guided by earlier ssNMR study of spiro-piperidine M2WJ10 binding to wt 
A/M2 in DLPC bilayers, a series of spiran amines with expanded ring size and head 
group were designed and found to inhibit V27A mutant with high potencies. Further 
structure modification by integrating adamantane and spiro scaffold resulted in the most 
of potent inhibitor M2WJ206 with IC50 of 0.3 µM. To further test our working 
hypothesis we investigated the binding mode of these novel inhibitors by means of 
computational molecular modeling techniques. The prominent role in determining the 
affinity played by the relatively mobile pore waters, along with the intrinsic flexibility of 
the target protein, poses serious computational challenges that cannot be addressed by the 
commonly adopted semi-rigid docking approaches. Therefore we performed MD 
simulations on theoretical structural models using the experimental structure of the 
complex between wt-A/M2 and amantadine as initial configuration. By sampling the 
equilibrium configurations of the wt:amantadine, wt:M2WJ180, wt:M2WJ260, 
V27A:M2J180, V27A:M2WJ206, and L26F:M2WJ206 complexes, we were able to 
single out similarities and differences in the average conformation and mobility of the 
drug molecule and pore waters. Interestingly, the behavior of the bulky M2WJ180 and 
M2WJ206 inhibitors in the pore of the mutated channels is similar to that of amantadine 
in the binding site of wt-A/M2. 
 
7.5 Methods 
Inhibitor synthesis. All starting material chemicals were purchased from commercial 
vendors and used without purification. Reactions were carried out using HPLC grade 
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solvents under N2 atmosphere. Compounds were purified by silica gel flash column 
chromatography and characterized by ESI-MS, 
1
H-NMR and 
13
C-NMR. Details about the 
inhibitor synthesis procedure and characterization can be found in the supplement 
information. 
 
Peptide synthesis. A/M2(22-46)-V27A peptide with A27, V28 and G34 selectively 
15
N 
and 
13
C labeled were manually synthesized using Fmoc chemistry at elevated temperature 
(75˚C for both coupling and deprotection) in a semin-automated Quest synthesizer using 
Rink Amide Chemmatrix resin (Matrix Innovation Inc, Canada). 5 eq amino acid, 5 eq 
HCTU, 10 eq DIEA in NMP were used for 5 mins coupling. 5% piperazine and 0.1 M 
HOBt in DMF were used as the deprotection solution in order to minimize aspartamide 
formation. The peptide was cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O 
and precipitated from ether after removal of TFA. Ether was decanted after centrifugation 
and the peptide was washed with cold ether again. Final peptide was dissolved in 50% B’ 
(59.9% isopropanol, 30% acetonitrile, 10% H2O, and 0.1% TFA)/50% A (99.9% H2O, 
0.1% TFA) and purified by preparative C4 reverse phase HPLC with a linear gradient of 
70% B’ to 85% B’. The peptide was eluted at 78% B’. The purity and identify of the 
peptide was confirmed by analytical HPLC and MALDI-MS. Calculated MS: 2782.38, 
Observed MS: 2782.90.  
 
Molecular Dynamics (MD) simulations 
All simulations in this work were performed on the transmembrane region of the A/M2 
bundle, spanning residues 25 to 46 and identified in the following as M2TM. The high-
resolution structure of M2TM from Acharya et al
19
 was used as initial configuration.  
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M2TM was embedded in a hydrated membrane of Dimyristoylphosphatidylcholine 
(DMPC) molecules, and periodic boundary conditions were applied with a 87 Å x 87 Å x 
77 Å periodic box. The protein and the lipids were modeled using the CHARMM27 force 
field
29
, and water molecules using the TIP3P force field
30
.  The electrostatic potential was 
solved by the particle mesh Ewald (PME) method
31
 with an accuracy threshold of 10-6, a 
real space spherical cutoff of 12 Å, and a fast Fourier transform (FFT) grid spacing of 0.8 
Å.  Lennard-Jones interactions were cut off at 12 Å, with a switching function starting 
from 10 Å.  The equations of motion were solved with the velocity Verlet integrator 
using a timestep of 1.5 fs.  The lengths of all bonds involving hydrogen atoms were kept 
constrained with the SHAKE method
32
.  The system was run at 310 K and 1 atm using 
Langevin temperature
33
 and Langevin piston pressure
34,35
, coupling schemes.  Decay 
times for the thermostat and barostat were chosen to be 1 ps and 0.1 ps, respectively. MD 
simulations were performed with NAMD
36
.  
 
Solid State NMR (ssNMR) 
Membrane sample preparation 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Polar Lipids) was used to 
reconstitute A27, V28 and G34 labeled V27A-M2TM by a detergent dialysis protocol . 
The dry lipid powder was suspended in 1 mL of pH 7.5 phosphate buffer (10 mM 
NaH2PO4/Na2HPO4, 1 mM EDTA, and 0.01 mM NaN3), votexed, and free-thawed 8 
times to create uniform lipid vesicles. The peptide powder was codissolved with ~20 mg 
octyl-b-D-glucopyranoside (OG, Sigma-Aldrich) in 1 mL of the same buffer. The 
peptide/OG solution was then mixed with 1 mL lipid vesicle solution, votexed for 2 hours 
and dialyzed with a 3.5-kDa molecular weight cutoff against 1 L buffer at 4°C for 3 days. 
The buffer was changed every 8-12 hours to remove the detergent. The protein-lipid 
precipitate appeared after one day of dialysis. The proteoliposome solution was 
centrifuged at 150,000g and 6 °C for 4 hours to yield a membrane pellet with ~40 wt% 
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water. The final protein : lipid molar ratio was 1 : 8. The pellet was packed into 4 mm 
MAS rotors for solid-state NMR experiments.  
 
One apo sample and two drug-bound samples were prepared. For the drug-bound 
samples, M2WJ180 was dissolved in 0.5 ml methanol/water (1 : 1) solution and directly 
titrated into the rotor to achieve a drug : channel ratio of 1 : 1 and 4 : 1, respectively.  
 
Solid-state NMR 
Solid-state NMR experiments were carried out on a 400 MHz (9.4 Tesla) and a 600 MHz 
(14.1 Tesla) Bruker AVANCE spectrometer using 4 mm MAS probes. Typical radio-
frequency fields were 40-50 kHz for 
13
C and 
15
N and 60-70 kHz for 
1
H. 
13
C and 
15
N 
chemical shifts were referenced to the a-Gly CO signal at 176.49 ppm on the TMS scale 
and the 
15
N signal of N-acetyl-valine at 122 ppm on the liquid ammonia scale, 
respectively.  
 
Two-dimensional 
13
C-
13
C correlation spectra were measured using a 
1
H-driven 
13
C spin 
diffusion pulse sequence [Takegoshi, 2001 #2] with a 40 ms DARR mixing time. 2D 
heteronuclear 
15
N-
13
C correlation spectra were measured using a REDOR sequence with 
a 0.8 ms mixing time for 
13
C-
15
N coherence transfer [Hong, 1998 #1]. All experiments 
were performed at 273 K and under 7 kHz MAS.  
 
Additional information Supporting information including inhibitors and peptide 
synthesis, characterization, ssNMR sample preparation, electrophysiology and plaque 
reduction assay experimental conditions are available on the web. 
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7.7 Supporting information 
 
Designing inhibitors targeting drug resistant Influenza A virus 
M2 proton channel 
 
Chemical Synthesis. All chemicals were purchased from commercial vendors and used 
without further purification unless otherwise noted. 
1
H and 
13
C NMR spectra were 
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per 
million referenced with respect to residual solvent (CHCl3) 7.26 ppm and (DMSO-d6) 
2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. The following 
abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t ) triplet, q ) quartet, 
m ) multiplet, dd ) doublet of doublets. All reactions were carried out under a N2 
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions. 
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution 
mass spectra were obtained using an ESI technique on 3200 Q Trap LC/MS/MS system 
(applied biosystem).  
 
General procedure for acid catalyzed robinson annulation reaction: 
 
The procedure is modified from original reference to get better yield.  
 
Carbaldehyde (10mmol), but-3-en-2-one (10mmol) was refluxed in benzene (10ml) with 
catalytic amount H2SO4 (0.05ml) in a round bottom flask equipped with Dean-Stark trap. 
The mixture was first heated to 45
o
C for 1.5hrs, and then increased to reflux until no 
more H2O condensed from the reaction mixture (1.5hr). Another equivalent of bu-3-2-
one (10mmol) was added and refluxed for an additional 1.5hrs. The mixture was cooled 
down and 20ml of 1 M NaHCO3 was added and the organic phase was separated. The 
aqueous phase was extracted with benzene, and the combined organic phase was washed 
with brine and dried over MgSO4. The solid was filtered, and concentrated in vacuo to 
give crude dark brown oil which was separated by flash column chromatography (Ethyl 
acetate/Hexane =15% to 25%) to give spiro enone as yellow oil. 
 
spiro[4.5]dec-6-en-8-one (65% Yield) 
CHO
n
n= 0, 1, 2
+
O
n
O
cat. H2SO4
Benzene
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1
H-NMR (360 MHz, CDCl3) δ 6.74 (d, J = 7.2 Hz, 2H), 5.84 (d, J = 7.2 Hz, 2H), 2.44 (t, 
J = 7.2 Hz, 2H), 1.89 (t, J = 7.2 Hz, 2H), 1.76-1.67 (m, 8H); 
13
C-NMR (90 MHz, CDCl3) 
δ 200.19, 159.78, 126.76, 44.32, 38.31, 35.59, 34.15, 24.73; ESI-MS: Calculated for 
C10H14O (M + H)
+
 151.2, Found: 151.3 
 
The characterization of spiro[5.5]undec-1-en-3-one was reported before. 
 
. 
Spiro[5.6]dodec-1-en-3-one 
 
1
H-NMR (360 MHz, CDCl3) δ 6.75 (d, J = 7.2 Hz, 2H), 5.79 (d, J = 7.2 Hz, 2H), 2.39 (t, 
J = 7.2 Hz, 2H), 1.81 (t, J = 7.2 Hz, 2H), 1.62-1.49 (m, 12H); 
13
C-NMR (90 MHz, 
CDCl3) δ 199.89, 159.40, 126.02, 38.26, 37.81, 34.18, 33.61, 30.65, 23.10; ESI-MS: 
Calculated for C12H18O (M + H)
+
 179.3, Found: 179.3 
 
General procedure for reduction of spiro enone with PdCl2/Et3SiH 
 
To spiro enone (10mmol) in absolute EtOH was added PdCl2 (0.2g), Et3SiH (20mmol) 
was added dropwise to the mixture with stirring. The mixture was refluxed for 4hrs and 
PdCl2 was filtered, washed with EtOH. The filtrate was concentrated and purified by 
flash column chromatography (Ethyl acetate/Hexane =15% to 25%) to give spiro ketone 
as yellow oil.  
 
Spiro[4.5]decan-8-one (85% Yield) 
O
O
O
n
O
Et3SiH
PdCl2
n
O
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1
H-NMR (360 MHz, CDCl3) δ 2.34 (t, J = 7.2 Hz, 2H), 1.76 (t, J = 7.2 Hz, 2H), 1.71-1.67 
(m, 4H), 1.59-1.55 (m, 4H); 
13
C-NMR (90 MHz, CDCl3) δ 212.97, 42.15, 39.31, 37.95, 
37.48, 24.73; ESI-MS: Calculated for C10H16O (M + H)
+
 153.2, Found: 153.2 
 
The characterizations of spiro[5.5]undecan-3-one were reported before. 
 
 
Spiro[5.6]dodecan-3-one (88% Yield) 
 
1
H-NMR (360 MHz, CDCl3) δ 2.31 (t, J = 7.2 Hz, 2H), 1.67 (t, J = 7.2 Hz, 2H), 1.57-1.50 
(m, 12H); 
13
C-NMR (90 MHz, CDCl3) δ 213.32, 38.65, 37.81, 37.71, 35.25, 30.66, 
23.17; ESI-MS: Calculated for C12H20O (M + H)
+
 181.3, Found: 181.3. 
 
General procedure for reductive amination of spiro ketone 
 
To a solution of spiro ketone (10mmol) in EtOH (50ml) was added HONH2*HCl 
(30mmol) and NaOAc (40mmol). The mixture was heated to reflux for 2hrs. Solvent was 
removed in vacuo and the residue was extracted with CH2Cl2 and H2O. The aqueous 
layer was extracted with CH2Cl2 again. The combined CH2Cl2 was dried with MgSO4 and 
concentrated in vacuo. The resulting oxime was dissolved in anhydrous THF and cooled 
down to 0
o
C. LiAlH4 (0.80g, 20mmol) was added portionwise to the solution and the 
mixture was heated to reflux overnight. After cooling down to 0
o
C, the solution was 
quenched with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4 mL) sequentially. The 
resulting slurry was filtered. The filtrate was acidified with 4M HCl in 1,4-dioxane and 
O
O
O
n
O
1. NH2OH*HCl
CH3COONa
2. LiAlH4
3. HCl
n
NH3
+Cl-
n=0 M2WJ189
n=1 M2WJ34
n=2 M2WJ164
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concentrated in vacuo. The final product was purified by flash chromatography to give 
spirane amine hydrochloride salt as yellow solid. 
 
Spiro[4.5]decan-8-aminium chloride (M2WJ189) (Yield: 75%) 
 
1
H-NMR (360 MHz, CDCl3) δ 3.12-3.08 (m, 1H), 1.67-1.45 (m, 16H); 
13
C-NMR (90 
MHz, CDCl3) δ 52.53, 42.96, 37.54, 36.52, 29.96, 26.63; ESI-MS: Calculated for 
C10H19N (M + H)
+
 154.3, Found: 154.3. 
 
The characterizations of spiro[5.5]undecan-3-aminium chloride (M2WJ34) were reported 
before. 
 
 
 
Spiro[5.6]dodecan-3-aminium chloride (M2WJ164) (Yield: 72%) 
 
1
H-NMR (360 MHz, CDCl3) δ 3.12-3.08 (m, 1H), 1.67-1.45 (m, 16H); 
13
C-NMR (90 
MHz, CDCl3) δ 52.70, 45.53, 37.93, 36.51, 36.24, 32.64, 32.32, 28.20, 24.74, 24.55; ESI-
MS: Calculated for C12H23N (M + H)
+
 182.3, Found: 182.3. 
 
3-azaspiro[6.6]tridecan-3-ium chloride (M2WJ196) 
 
To a solution of hydroxylamine-O-sulfonic acid (1.70g, 15mmol) and 95% formic acid 
(9ml) under N2 protection was added dropwise spiro[5.6]dodecan-3-one (1.80g, 10mmol) 
NH3
+Cl-
NH3
+Cl-
NH3
+Cl-
NH2OSO3H
HCOOH
HN
O
1. LiAlH4
2. HCl
-Cl+H2N
M2WJ196
O
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in 3ml of 95% formic acid. The solution was heated under reflux for 5hrs and then cooled 
to ambient temperature. The reaction mixture was diluted with H2O (15ml) and 
neutralized to pH 7 with 6 N NaOH. The aqueous solution was extracted three times with 
30ml CHCl3. The combined organic layer was dried with MgSO4 and used for the next 
step reduction without purification. 3-azaspiro[6.6]tridecan-4-one was dissolved in 
anhydrous THF and cooled down to 0
o
C. LiAlH4 (0.80g, 20mmol) was added portionwise 
to the solution and the mixture was heated to reflux overnight. After cooling down to 
0
o
C, the solution was quenched with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4 
mL) sequentially. The resulting slurry was filtered. The filtrate was acidified with 4M 
HCl in 1,4-dioxane and concentrated in vacuo. The final product was purified by flash 
chromatography to give 3-azaspiro[6.6]tridecan-3-ium chloride (M2WJ196) as yellow 
solid (1.35g, 62% Yield). 
1
H-NMR (360 MHz, CD3OD) δ 3.31-3.27 (m, 2H), 3.12-3.10 
(m, 2H), 1.73-1.65 (m, 4H), 1.52-1.47 (m, 6H), 1.30-1.27 (m, 8H); 
13
C-NMR (90 MHz, 
CD3OD) δ 43.42, 40.75, 39.52, 39.47, 37.51, 36.64, 32.18, 23.76, 21.73; ESI-MS: 
Calculated for C12H23N (M + H)
+
 182.3, Found: 182.5. 
General procedure for ring expansion reaction 
 
To a solution of spiro ketone (5mmol) and ethyl diazoacetate (1.15g, 10mmol) in 
anhydrous THF (20ml) at -78
o
C was added LDA (5ml, 2M in hexane) dropwise under N2 
atmosphere. The reaction was stirred at the same temperature for 2hrs and warmed to 
ambient temperature. Aqueous NH4Cl (40ml, 30% w/w) was added and extracted with 
diethyl ether. The combined organic layers were washed with water, brine, dried over 
anhydrous MgSO4, filtered and concentrated in vacuo to give the diazo-hyroxyl ester 
intermediate as brown oil. CH2Cl2 (30ml) was added and the flask was flushed with N2 
atmosphere.  Rodium(II) acetate dimer (8mg) was then added and the mixture was stirred 
at ambient temperature for 1hr. The catalyst was filtered and the filtrate was concentrated 
in vacuo to give the crude β-keto ester as yellow oil which was used for the next step 
hydrolysis without further purification. To a solution of β-keto ester, acetic acid (10ml), 
water (5ml) was added para-toluenesulfonic acid (1mmol, 0.19g). The solution was 
heated to reflux for 24hrs. After cooling to ambient temperature, the reaction mixture was 
diluted with water (20ml) and extracted with diethyl ether (30ml×3). The combined ether 
was dried over anhydrous MgSO4 and purified by flash column chromatography (20-
30% Ethyl acetate/Hexane) to give spiran ketone as yellow oil. 
 
spiro[5.6]dodecan-9-one (Yield: 72%) 
n
O
N2
O
O
LDA
n
HO
N2
O
O
cat Rh(OCOCH3)2
n
O
O
O
AcOH, TsOH
ref lux
2
n
O
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1
H-NMR (360 MHz, CDCl3) δ 2.47 (t, J = 7.2 Hz, 2H), 2.42 (t, J = 7.2 Hz, 2H), 1.67-1.62 
(m, 4H), 1.52-1.30 (m, 12H); 
13
C-NMR (90 MHz, CDCl3) δ 211.23, 43.95, 41.72, 38.81, 
36.69, 35.39, 33.04, 26.69, 21.82, 19.31; ESI-MS: Calculated for C12H20O (M + H)
+
 
181.3, Found: 181.1. 
 
spiro[6.6]tridecan-3-one (Yield: 75%) 
 
1
H-NMR (360 MHz, CDCl3) δ 2.46 (t, J = 7.2 Hz, 2H), 2.40 (t, J = 7.2 Hz, 2H), 1.70-1.63 
(m, 2H), 1.59-1.55 (m, 2H), 1.51-1.41 (m, 14H); 
13
C-NMR (90 MHz, CDCl3) δ 215.17, 
43.96, 41.44, 39.08, 39.03, 38.76, 35.24, 31.11, 22.80, 19.54; ESI-MS: Calculated for 
C13H22O (M + H)
+
 195.3, Found: 195.4. 
 
Spiro[5.6]dodecan-9-aminium chloride (M2WJ152) was synthesized according to the 
general reductive amination procedure. (Yield: 70%) 
 
1
H-NMR (360 MHz, CD3OD) δ 3.18-3.13 (m, 1H), 1.78-1.61 (m, 6H), 1.47-1.37 (m, 
10H), 1.36-1.29 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 83.25, 67.76, 67.56, 64.45, 
64.25, 56.25, 55.71, 51.08, 51.06, 48.02; ESI-MS: Calculated for C12H23N (M + H)
+
 
182.3, Found: 182.4. 
 
spiro[6.6]tridecan-3-aminium chloride (M2WJ180) was synthesized according to the 
general reductive amination procedure (Yield: 75%) 
 
O
O
-Cl+H3N
-Cl+H3N
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1
H-NMR (360 MHz, CD3OD) δ 3.14-3.13 (m, 1H), 1.74-1.48 (m, 12H), 1.48-1.28 (m, 
6H), 1.18-1.09 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 55.47, 41.03, 41.01, 40.40, 
39.88, 36.65, 35.82, 32.51, 28.39, 23.91, 23.87, 20.08; ESI-MS: Calculated for C13H25N 
(M + H)
+
 196.3, Found: 196.3. 
 
Spiro[5.5]undecane-3-carbonitrile 
 
To a solution of spiro[5.5]undecan-3-one (1.66g, 10mmol) and tosylmethylisocyanide 
(2.54g, 13mmol) in DME (50ml) and abs. EtOH (1ml) was added KO
t
Bu (2.69g, 
24mmol) portionwise during 0.5 hr at -10
o
C. After addition, the reaction mixture was 
stirred at 0
o
C for 1hr then 2hr at ambient temperature. Solvent was removed in vacuo and 
the resulting residue was extracted with diethyl ether (50ml×3) and the combined 
organic layer was washed with water (50ml×3). The organic layer was dried with 
anhydrous MgSO4, concentrated under reduced pressure and purified by flash column 
chromatography (50% - 100% CH2Cl2/Hexane) to give the nitrile as colorless solid 
(1.28g, 72% Yield).  
1
H-NMR (360 MHz, CDCl3) δ 2.58-2.53 (m, 1H), 1.83-1.70 (m, 
4H), 1.63-1.58 (m, 2H), 1.40-1.26 (m, 8H), 1.28-1.20 (m, 4H); 
13
C-NMR (90 MHz, 
CDCl3) δ 122.79, 34.41, 31.88, 28.37, 26.88, 24.73, 21.64, 21.55; ESI-MS: Calculated for 
C12H19N (M + H)
+
 178.3, Found: 178.2. 
 
 
spiro[5.5]undecan-3-ylmethanaminium chloride (M2WJ151) 
 
Spiro[5.5]undecane-3-carbonitrile (1.77g, 10mmol) in anhydrous THF was cooled down 
to 0
o
C. LiAlH4 (0.80g, 20mmol) was added portionwise to the solution and the mixture 
was heated to reflux overnight. After cooling down to 0
o
C, the solution was quenched 
with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4 mL) sequentially. The resulting 
slurry was filtered. The filtrate was acidified with 4M HCl in 1,4-dioxane and 
concentrated in vacuo. The final product was purified by flash chromatography to give 
spiro[5.5]undecan-3-ylmethanaminium chloride (M2WJ151) as yellow solid (1.70g, 78% 
Yield). 
1
H-NMR (360 MHz, CD3OD) δ 2.90 (m, 2H), 1.84-1.81 (m, 2H), 1.72-1.62 (m, 
3H), 1.54-1.50 (m, 8H), 1.36-1.32 (m, 4H), 1.20-1.16 (m, 2H); 
13
C-NMR (90 MHz, 
O
TOSMIC
CN
tBuOK
CN
1. LiAlH4
2. HCl
NH3
+Cl-
M2WJ151
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CD3OD) δ 46.62, 42.61, 37.89, 36.98, 33.28, 33.20, 20.08, 26.35, 22.83, 22.71; ESI-MS: 
Calculated for C12H23N (M + H)
+
 182.3, Found: 182.3 (Take it again)  
. 
spiro[5.5]undecane-3-carboxylic acid 
 
 
 
 
 
 
spiro[5.5]undecane-3-carbonitrile (1.77g, 10mmol) was dissolved in AcOH (20ml), 
H2SO4 (5ml) and H2O (10ml) was added and the mixture was heated to reflux overnight. 
The solution was cooled down to ambient temperature and diluted with H2O (100ml). 
The aqueous layer was extracted with diethyl ether (100ml×3), the combined organic 
layer was dried over MgSO4 and concentrated in vacuo. The product was purified by 
flash column chromatography (10%-20% CH3OH/CH2Cl2) to give colorless solid (1.53g, 
78% Yield). 
1
H-NMR (360 MHz, CDCl3) δ 2.32-2.25 (m, 1H), 1.78-1.58 (m, 6H), 1.52-
1.35 (m, 8H), 1.24-1.21 (m, 2H), 1.12-1.04 (m, 2H); 
13
C-NMR (90 MHz, CDCl3)  δ 
183.13, 43.55, 40.96, 35.78, 32.75, 32.05, 27.10, 23.97, 21.86, 21.71; ESI-MS: 
Calculated for C12H20O2 (M - H)
+
 195.3, Found: 195.3 
 
 
Spiro[5.5]undecane-3-carboxylic acid (1.96g, 10mmol) in anhydrous diethyl ether (50ml) 
was cooled down to 0
o
C, CH3Li (22mmol) was added dropwise in 30mins. The resulting 
mixture was stirred at the same temperature for two more hours and warmed to ambient 
temperature overnight. Saturated NH4Cl aqueous solution was added and was extracted 
with diethyl ether (50ml× 3). The organic layers were combined and dried over 
anhydrous MgSO4. The product was purified by flash column chromatography (20%-
30% Ethyl acetate/Hexane) as yellow oil (1.40g, 72% Yield) 
1
H-NMR (360 MHz, 
CDCl3) δ 2.30-2.22 (m, 1H), 2.11 (s, 3H), 1.71-1.63 (m, 4H), 1.55-1.47 (m, 2H), 1.47-
1.36 (m, 8H), 1.23-1.20 (m, 2H), 1.87-1.01 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 
212.44, 52.07, 41.32, 36.05, 32.39, 32.15, 28.10, 27.07, 23.60, 21.84, 21.67; ESI-MS: 
Calculated for C13H22O (M + H)
+
 195.3, Found: 195.3 
 
1-(spiro[5.5]undecan-3-yl)ethanaminium chloride (M2WJ198) 
COOH
CH3Li
O
CN
AcOH, H2SO4
ref lux
COOH
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1-(spiro[5.5]undecan-3-yl)ethanaminium chloride (M2WJ198) was synthesized according 
to the procedure described above for reductive amination. 
1
H-NMR (360 MHz, CDCl3) δ 
3.14-3.07 (m, 1H), 1.70-1.64 (m, 3H), 1.59-1.56 (m, 1H), 1.37-1.35 (m, 12H), 1.31-1.19 
(m, 4H), 1.08-1.01 (m, 2H); 
13
C-NMR (90 MHz, CDCl3) δ 53.10, 42.14, 41.71, 36.12, 
36.09, 32.16, 32.03, 27.11, 24.39, 23.29, 21.93, 21.77, 16.39; ESI-MS: Calculated for 
C13H25N (M + H)
+
 196.3, Found: 196.3 
 
 
Figure 1. Synthesis scheme of spiroadamantane M2WJ206 
2-adamantanecarbaldehyde was synthesized from 2-adamantone in two steps according 
to literature procedures. It was first converted to vinyl ether by witting reaction, and then 
followed by acid hydrolysis. Due to the instability of the aldehyde, it was used 
immediately for the next step robinsin annelation reaction. The following enone reduction 
and amination steps were performed as described above. 
 
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohex[2]en]-4'-one 
 
1
H-NMR (360 MHz, CDCl3) δ 7.50 (d, J = 10.8 Hz, 2H), 5.92 (d, J = 10.8 Hz, 2H), 2.43 
(t, J = 6.48 Hz, 2H), 2.14-2.09 (m, 6H). 1.97 (d, J = 2.52 Hz, 1H), 1.89 (d, J = 2.52 Hz, 
1H), 1.75-1.62 (m, 8H); 
13
C-NMR (90 MHz, CDCl3) δ 199.92, 158.61, 127.89, 40.29, 
O
1. NH2OH*HCl
CH3COONa
2. LiAlH4
3. HCl
-Cl+H3N
M2WJ198
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39.14, 35.30, 33.36, 33.26, 32.97, 31.79, 28.22, 27.31; ESI-MS: Calculated for C15H20O 
(M + H)
+
 217.3, Found: 217.4. 
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohexan]-4'-one 
 
1
H-NMR (360 MHz, CDCl3) δ 2.30 (t, J = 6.84 Hz, 4H), 2.09-2.05 (m, 4H), 1.95 (t, J = 
6.84 Hz, 4H), 1.90 (br s, 2H), 1.72 (br s, 4H), 1.65-1.61 (m, 4H); 
13
C-NMR (90 MHz, 
CDCl3) δ 213.04, 39.46, 36.95, 36.77, 34.36, 33.93, 33.03, 28.36; ESI-MS: Calculated for 
C15H22O (M + H)
+
 219.3, Found: 219.4. 
 
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohexan]-4'-aminium chloride (M2WJ206) 
 
 
1
H-NMR (360 MHz, CD3OD) δ 3.10-3.05 (m, 1H), 2.45-2.42 (m, 2H), 2.16-2.13 (m, 
2H), 2.07-2.04 (m 2H), 1.97 (br s, 1H), 1.84-1.82 (m, 4H), 1.73 (br s, 2H), 1.61-1.49 
(6H), 1.26 (br s, 1H), 1.08-1.02 (m, 2H); 
13
C-NMR (90 MHz, CD3OD) δ 52.04, 40.73, 
40.32, 37.61, 33.97, 33.38, 30.67, 29.83, 26.54; ESI-MS: Calculated for C15H25N (M + 
H)
+
 220.4, Found: 220.7. 
 
 
  
Two-Electrode Voltage-Clamp Analysis.  
WT A/M2-pGEM3 cDNA and mutant DNA V27A were linearized using HindIII, and 
corresponding mRNAs were generated by in vitro transcription reactions on the 
linearized cDNA using a T7 mMESSAGE mMACHINE transcription kit (Ambion, 
Austin, TX) and injected into oocytes as described previously (1, 2). Currents were 
measured 48–72 h after injection of oocytes as described (1, 2). Currents were acquired 
and analyzed using the pCLAMP 10.0 software package (Axon Instruments, Sunnyvale, 
CA). 
 
Plaque Assays.  
Cells, Viruses, and Plasmids. 293-T and Madin–Darby canine kidney (MDCK) cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen Invitrogen, 
Carlsbad, CA) supplemented with 10% FBS. Influenza A/Udorn/72 virus (WT) and 
mutant viruse (V27A) were propagated in MDCK cells overlaid with serum-free DMEM 
containing 2.0 g/ml N-acetyl trypsin (NAT; Sigma-Aldrich, St. Louis,MO) at 37°C. WT 
and mutant viruses were generated by using reverse genetics from cDNAs essentially as 
described previously (3). Val27Ala mutation into the M2 gene in pHH21 was 
generated using Quick Change mutagenesis (Stratagene, La Jolla, CA). 293-T cells were 
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transfected using TransIT-LT1 (Mirus, Madison, WI) according to the manufacturer 
protocols. Virus stocks were propagated in MDCK cells, and the virus titers were 
determined by plaque assay on MDCK cells. The viral M gene sequences were 
determined as described previously (2).  
 
In vivo plaque reduction assay was carried out similarly as described previously (2). 
Briefly, MDCK cell monolayers were preincubated with DMEM supplemented with the 
drug at various concentrations at 37 °C for 30 min, and virus samples were preincubated 
with DMEM 1% BSA with the drug at the same concentration for MDCK cells at 4 °C 
for 30 min before infection. Then DMEM medium were replaced with virus samples with 
or without drugs and incubated at 37 °C for 1hr. The inoculums were removed, and the 
cells were washed with phosphate buffered saline (PBS). The cells were then overlaid 
with DMEM containing 1.2% Avicel microcrystalline cellulose (FMC BioPolymer, 
Philadelphia, PA) (4) and NAT (1.0 g/ml). To examine the effect of the drugs on plaque 
formation, at 2 days after infection, the monolayers were fixed and stained with 
naphthalene black dye solution (0.1% naphthalene black, 6% glacial acetic acid, 1.36% 
anhydrous sodium acetate).   
 
 
(1) Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion 
channel activity. Cell 69:517–528. 
 
(2) Jing X, et al. (2008) Functional studies indicate amantadine binds to the pore of 
the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci USA 
105:10967–10972 
 
(3) Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA (2002) Influenza A virus M2 
ion channel activity is essential for efficient replication in tissue culture. J Virol 
6:1391–1399 
 
(4) Matrosovich M, Matrosovich T, Garten W, Klenk HD (2006) New low-viscosity 
overlay medium for viral plaque assays. Virol. J. 3.63, doi: 10.1186/1743–422X-
3–63. 
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Chapter 8 
Exploring Silaspiran Amines as Potent Inhibitors of Influenza A Virus 
M2 Channel 
 
8.1 Abstract 
Substitution of carbon with its close analog silicon yields organosilanes, which are 
intrinsically unnatural and has yet to be found toxic. This transition has been successful 
in pesticide industry and recently been explored in many aspects of medicinal chemistry 
research, including protease inhibitors,
1-3
 kinase inhibitors,
4
 cyclooxygenase-2 (COX-2) 
inhibitors.
5, 6
 As carbon to silicon switch increases both the molecule’s size and 
hydrophobicity scale, and therefore is well suited in designing influenza A virus M2 
channel inhibitors because of the positive correlation between hydrophobicity and 
antiviral potency from the previous structure-activity relationship studies.
7, 8
 Herein, we 
report the design of organosilane inhibitors based on spiran amine scaffold, which 
yielded a series of silaspiran amine inhibitors that are more potent than their carbon 
analogs. 
 
8.2 Introduction 
Influenza A virus is a serious human health threat and there is an urgent and continuing 
effort in developing small molecule antiviral agents.
9
 Drug resistance is the predominant 
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issue in anti-influenza inhibitor research due to the reassortment ability of infecting 
influenza A viruses across different species such as human, swine and pig.
10
  
 
A/M2 forms a homotetrameric proton selective channel in viral membrane and plays an 
essential role in mediating viral uncoating
11
 and budding.
12
 Additionally, it also 
equilibrates the pH across the Golgi apparatus to prevent the premature conformational 
switch of hemagglutinin.
13-15
 A/M2 is a proven antiviral target in the treatment of 
influenza A virus infection. A/M2 inhibitors like amantadine and rimantadine have been 
used for decades, but their effectiveness have been diminished due to emerging drug 
resistance and side effects, which prompted the Centers for Disease Control and 
Prevention (CDC) to recommend the discontinued use of this class of drugs. 
Nevertheless, A/M2 is more conserved than other drug targets of influenza A virus with 
only three major mutations, S31N, V27A and L26F, which locate at the transmembrane 
domain drug binding site.
16, 17
 The structures of A/M2 transmembrane domain were 
solved both by solution NMR
18, 19
 and X-ray crystallography,
20, 21
 which make the 
rational design of A/M2 inhibitor feasible.  
 
Carbon to silicon switch is a widely explored strategy in developing and marketing 
organosilane pesticides.
22, 23
 There is a growing interest in the pharmaceutical industry to 
fine tune the pharmacological or pharmacokinetic properties of marketed drugs using the 
same transition.
24-27
 Apart from the increased size and hydrophobicity scale of silicon 
comparing to its carbon counterpart, organosilane can also be designed to mimic the 
 273 
 
unstable carbon intermediate or lead to novel scale scaffolds that are not accessible to 
carbon analogs.
28, 29
 The most common switch from a carbon to silicon can be 
categorized in two classes (Scheme 8.1 a and 8.1 b). In the first case, a quaternary carbon 
is replaced with a silicon
4
 (Scheme 8.1 a). In the second case, a carbonyl is replaced with 
a sterically hindered silanediol to mimic the transition state of an amide bond hydrolysis 
by protease
3
 (Scheme 8.1 b).  
 
Scheme 8.1 | Common strategies of carbon to silicon switch in drug design 
 
In designing A/M2 inhibitors as anti-influenza virus drugs, hydrophobicity plays a critical 
role in improving potency. The pore facing residues of A/M2 channel are V27, A30, S31 
and G34,
20, 21
 which form a hydrophobic binding pocket that favors binding of a cage 
shape molecule like adamantane or spiran amines. The carbon to silicon switch is well 
suited in this case because replacing the spiro carbon quaternary center by silicon 
increases both the hydrophobicity and the size of the spiran amine (Scheme 8.2). This 
strategy is more advantageous than introducing extra hydrophobic substitutions, as it 
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might cause a shape mismatch between the inhibitor and the pore binding site, 
consequently leading to a decreased potency.  
 
Scheme 8. 2 | Design principle of A/M2 inhibitors 
 
8.3 Results and Discussion 
Silaspiran amines are more potent than their carbon analogs 
To test the effectiveness of a carbon to silicon switch in A/M2 inhibitor design, we first 
examined one of the commercially available silicon containing amine-3-aminopropyl 
trimethylsilane hydrochloride M2WJ212 (Gelest, Cat # SIA0612.0, Figure 8.1). 
Encouragingly, it showed 75.5 ± 0.5% inhibition against wt A/M2 at 100 µM 
concentration in two electrode voltage clamp (TEVC) assay with full length Udorn AM2 
protein in the Xenopus oocytes membrane
30
. In comparison, amantadine showed 86.5% 
inhibition at the same concentration. This is by far the smallest molecule (less than 8 
carbons) that is active against A/M2 at this level.  
 
Figure 8. 1 | The smallest influenza A virus M2 inhibitor 
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Next, two silicon containing spiran amines (M2WJ224 and M2WJ210) were designed 
and synthesized based on the previously identified spiran amines. The synthesis started 
from dichlorosilane, double substitution of the chlorides with vinyl magnesium bromide 
yielded the divinyl cyclosilane.
31, 32
 Without purification,   it underwent an initial 
hydroboration with 9-borabicyclo[3.3.1]nonane (9-BBN), followed by an exchange 
reaction with borane-methyl sulfide complex (BMS) and methanolysis to give the 
silaborinane intermediate.
33
 Next following Brown’s dichloromethyl methyl ether 
(DCME) process and oxidation with 30% H2O2 furnished the spirosilicon ketone 
intermediate in a one pot process with 40~50% overall yield.
31, 32
 Finally, the ketone was 
converted to amine using the two step hydroxylamine condensation/reduction followed 
by the previous published procedure with ~75% yield.
8
  
 
Scheme 8.3 | Synthesis scheme of silaspiran amines 
 
Our previous structure-activity relationship study of BL-1743 revealed a series of spiran 
amines that are not only active against wt A/M2, but also V27A mutant.
7, 8
 A positive 
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correlation of hydrophobicity and potency was seen for spiran amines. As expected, both 
the silaspiran amines were equally potent as their carbon counterparts against wt A/M2 
(Table 8.1). More interestingly; there is a dramatic increase in potency of silaspiran 
amine inhibitors for V27A inhibition. This enhanced activity might correlate with 20% 
longer bond length of Si-C (1.87Å) compared to the C-C (1.54Å) bond, and the increased 
volume of the inhibitor can fill in the extra space created by the bulkier Val to smaller 
Ala mutation.  
 
Table 8. 1 | Comparison of influenza A virus M2 inhibition between silaspiran amines 
and its carbon analogs 
 
 
Additionally, two 4,4-disubstituted silacyclohexane amine derivatives (M2WJ225 and 
M2WJ226) were designed and synthesized (Scheme 8.4). The synthesis of M2WJ225 
was accomplished using the procedures described above. For the synthesis of M2WJ226, 
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the intermediate ketone, 1,1-dimethylsilinan-4-one, was converted to nitrile using 
TOSMIC, which was subsequently reduced by LiAlH4.  
 
Scheme 8. 4 | Synthesis scheme of 4,4-dimthyl silacyclohexane amines 
Both inhibitors showed high potency against wt A/M2 and only minimal inhibition 
against V27A mutant (Table 8.2), which is consistent with our previous structure-activity 
relationship studies results that V27A mutation expands the drug binding site, thus 
requires bulkier molecules to fill in the extra space. 
 
Table 8. 2 | Influenza A virus M2 channel inhibition by 4,4-dimethyl silacyclohexane 
amines 
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8.4 Conclusion 
Biologically active organosilanes, which are discovered through either rational design or 
high throughput screening, are attractive analogs of their carbon counterparts due to their 
unique properties. A carbon to silicon switch retains the overall 3-D conformation of the 
inhibitor, thus providing a minimal perturbation of the binding between the ligand and the 
receptors. Nevertheless, the larger covalent radius of silicon (1.17Å) compare to carbon 
(0.77Å), and the higher hydrophobicity renders the organosilane based inhibitors with 
improved bioavailability. Organosilanes are also in general easier to synthesize than their 
carbon analogs. In certain cases allow access to novel scaffolds that are not accessible by 
the standard carbon chemistry.
28
 In this report, we explored the carbon to silicon switch 
in designing A/M2 inhibitors against influenza virus infection. The silaspiran amines are 
found to be equally potent as the their carbon counterparts against wt A/M2, and are more 
potent in targeting drug resistant A/M2-V27A mutant, which highlight their promise for 
further optimization.  
 
8.5 Experimental details 
Two electrode voltage (TEV) clamp assay 
Details about the experimental set up can be found in previous reports.
8
 
 
Chemical synthesis 
All chemicals were purchased from commercial vendors and used without further 
purification. Cyclotrimethylenedimethylsilane and Cyclotetramethelenedimethylsilane 
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were purchased from Gelest (PA, USA) and used without purification. 
Dimethyldivinylsilane was purchased from Sigma-Aldirch. 
1
H and 
13
C NMR spectra 
were recorded on either DMX-360 or DRX-500 NMR spectrometer. Chemical shifts are 
reported in parts per million referenced with respect to residual solvent (CDCl3 = 7.27 
ppm and DMSO-d6 = 2.50 ppm) or from internal standard tetramethylsilane (TMS = 0.00 
ppm). The following abbreviations were used in reporting spectra: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet. All reactions were carried out under a N2 
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions. 
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution 
mass spectra were obtained on an LC platform from Micromass using an ESI technique. 
General procedure of dichloro substitution with divinyl magnisum bromide 
Dichlorosilane (10 mmol) in ether (20 ml) was cooled down to 0
o
C using ice-water bath. 
Vinyl magnesium bromide (22 ml, 1M in THF, 22 mmol) was added dropwise via 
syringe over 30 mins. The resulting solution was slowly warm to room temperature and 
continued stirring for 3h. The reaction was quenched with water (5 ml), and extracted 
with saturated NH4Cl and ether. The aqueous phase was extracted two times with ether. 
The ether layers were combined and washed with brine, dried with MgSO4, filtered, and 
the solvent was removed under reduced pressure with cool water bath (~10
o
C in order to 
prevent the evaporation of the product due to low boiling point). The final product 
appeared as a yellow oil. 
 
General procedure of converting divinylsilane to 1-silacyclohexan-4-one 
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Hydroboration and methanolysis reaction 
To a divinylsilane (10 mmol) in n-hexane (20 ml) was added 9-borabicyclo[3.3.1]nonane 
(9-BBN) dimer (10 mmol), the mixture was heated to reflux for 2hrs. After cooling the 
reaction mixture to room temperature, BH3•SMe2 (10 mmol) was added dropwise with 
caution and the mixture was refluxed for 1h.  The borane mixture was cooled to room 
temperature, methanol (3.5 ml) was added dropwise, which resulted in vigorous hydrogen 
gas formation. The mixture was stirred overnight and concentrated in vacuo. 
 
Brown’s DCME process and oxidation reaction 
The above borinane was dissolved in THF (30 ml) and cooled down to 0
o
C with ice-
water bath. Dichloromethyl methyl ether (10 mml) was added, followed by lithium t-
butoxide (50 ml, 1M in THF, 50 mmol). The temperature was raise to rt and stirred for 
30mins. Ethanol (12 ml) and NaOH (1.2 g, 30 mmol) dissolved in H2O (3.5 ml) were 
added sequentially, followed by dropwise addition of 30% H2O2 (3.3 ml). The solution 
was heated to reflux for 3 hrs and hydrolyzed with water (100 ml). The product was 
extracted with ethyl acetate (3 × 100ml), the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (10-20% Ethyl acetate/hexane) to give the silaspiro ketone as yellow oil.  
 
6-silaspiro[5.5]undecan-3-one 
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1
H NMR (360 MHz, CDCl3) δ 2.50 (t, J = 5.4 Hz, 4H), 1.71-1.66 (m, 4H), 1.44-1.42 (m, 
2H), 0.95 (t, J = 5.4 Hz, 4H), 0.716 (t, J = 4.68 Hz, 4H); 
13
C NMR (90 MHz, CDCl3) δ 
215.27, 37.84, 30.07, 24.67, 11.60, 8.02.  
 
5-silaspiro[4.5]decan-8-one 
1
H NMR (360 MHz, CDCl3) δ 2.545 (t, J = 7.2 Hz, 4H), 1.64-1.60 (m, 4H), 1.03 (t, J = 
7.2 Hz, 4H), 0.69-0.65 (m, 4H); 
13
C NMR (90 MHz, CDCl3) δ 214.72, 68.13, 25.79, 
10.98, 9.73. 
 
1,1-dimethylsilinan-4-one 
1
H NMR (360 MHz, CDCl3) δ 2.48 (t, J = 5.4 Hz, 4H), 0.92 (t, J = 5.4 Hz, 4H), 0.14 (s, 
6H); 
13
C NMR (90 MHz, CDCl3) δ 215.20, 37.96, 10.84, -2.92. 
 
5-silaspiro[4.5]decan-8-aminium chloride 
1H NMR (360 MHz, DMSO) δ 8.07 (brs, 3H), 2.92-2.90 (m, 1H), 2.15-2.13 (m, 2H), 
1.54-1.52 (m, 6H), 0.79-0.66 (m, 4H), 0.56-0.51 (m, 4H); 
13C NMR (90 MHz, DMSO) δ 
51.28, 28.90, 26.35, 26.31, 9.74, 9.68, 8.85; The calculated mass for C9H19NSi (M + H)
+
 
is 170.3, Found 170.3. 
 
6-silaspiro[5.5]undecan-3-aminium chloride 
1
H NMR (360 MHz, CD3OD) δ 3.03-2.99 (m, 1H), 2.19-2.17 (m, 2H), 1.73-1.62 (m, 6H), 
1.46-142 9m, 2H), 1.00-0.97 (m, 2H), 0.78-0.75(m, 2H), 0.70-0.61 (m, 4H); 
13
C NMR 
 282 
 
(90 MHz, CD3OD) δ 54.28, 31.29, 29.83, 25.63, 25.51, 12.83, 10.88, 9.44; The calculated 
mass for C10H21NSi (M + H)
+
 is 184.4, Found 184.3. 
 
1,1-dimethylsilinan-4-aminium chloride 
1H NMR (360 MHz, DMSO) δ 2.89-2.84 (m, 2H), 2.08-2.06 (m, 2H), 1.59-10.56 (m, 
2H), 0.76-0.73 (m, 2H), 0.57-0.51 (m, 2H), 0.04 (s, 3H), 0.01 (s, 3H); 
13
C NMR (90 
MHz, DMSO) δ 51.62, 27.84, 10.34, -2.71, -4.55; The calculated mass for C7H17NSi (M 
+ H)
+
 is 144.4, Found 144.3. 
 
1,1-dimethylsilinane-4-carbonitrile 
1
H NMR (360 MHz, CDCl3) δ 2.66-2.62 (m, 1H), 1.98-1.95 (m, 4H), 0.90-0.84 (m, 2H), 
0.67-0.61 (m, 2H), 0.08 (s, 3H), 0.04 (s, 3H); 
13
C NMR (90 MHz, CDCl3) δ 122.39, 
30.91, 27.51, 11.50, -3.15, -3.41. 
 
(1,1-dimethylsilinan-4-yl)methanaminium chloride 
1H NMR (360 MHz, DMSO) δ 8.02 (brs, 3H), 2.61-2.60 (m, 2H), 1.90-1.88 (m, 2H), 
1.48-1.46 (m, 2H), 1.25-1.18 (m, 2H), 0.71-0.68 (m, 2H), 0.48-0.43 (m, 2H), 0.03 (s, 
3H), 0.00 (s, 3H); 
13C NMR (90 MHz, DMSO) δ 44.05, 37.97, 27.19, 11.93, -2.23, -4.33; 
The calculated mass for C8H19NSi (M + H)
+
 is 158.3, Found 158.4. 
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9.1 ABSTRACT Inhibitors targeting the influenza A virus M2 (A/M2) proton channel, 
have lost their effectiveness due to widespread resistance.  As a first step in the 
development of new inhibitors that address this problem, we have screened several 
focused collections of small molecules using two electrode voltage patch clamp assay 
(TEV) on Oocyte. M2 inhibitors generally contain a polar amine group and an apolar 
hydrophobic scaffold. In this study, diverse head group and scaffolds have been explored. 
It has been found that not only amine, but also hydroxyl, aminooxyl, guanidine, amidine 
compounds are active against A/M2 proton channel. Moreover, A/M2 proton channel is 
able to accommodate a wide range of structural variation in the apolar scaffold. This 
study offers information to guide the next generation of A/M2 proton channel inhibitor 
design. 
 
9.2 INTRODUCTION 
Influenza A viruses present a severe human health threat due to the ease of transmission 
via the upper respiratory system.  Influenza A virus constantly undergoes antigenic drift 
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and antigenic shift, which allow them to escape from immunization.
1
 Although 
vaccination is the first line defense against influenza A virus infection, its effecitiveness is 
diminished by the continuing development of novel strains that escape neutralization, as 
well as the delay between the observation of the predominant seasonal strains and the 
development and dissemination of an effective vaccine. Currently there are two classes of 
small molecule anti-influenza virus drugs:
2
 one class is zanamivir and oseltamivir that 
targets neuraminidase; another class is A/M2 channel inhibitors including amantadine and 
rimantadine. Widespread resistance to both oseltamivir (the only orally bioavailable 
neuraminidase inhibitor) as well as A/M2 inhibitors presents a major health risk.  
  
The A/M2 protein forms a homotetrameric proton selective channel 
3, 4
 that is essential 
for viral replication.
5, 6
 Once influenza virus enters cell by endocytosis, A/M2 channel is 
activated by the low pH of the endosome and facilitates acidification of the viral interior, 
which results in the dissociation of ribonucleoprotein from matrix protein M1 required 
for virus infection.
5
 Amantadine targets A/M2 channel by blocking its pore. 
7, 8
  The 
number of drug-resistant variants of A/M2 is limited by the very conserved nature of the 
binding site within the channel. V27A, L26F and S31N are the only widely occurring 
drug-resistant variants seen in transmissible strains of the virus.
9-11
  Other mutations are 
observed in vitro or in patients undergoing treatment with amantadine or rimantadine, 
12, 
13
 but the channel of these variants tend to have altered properties that appear to decrease 
their fitness for transmission in viruses that infect humans, swines, or birds. 
14-16
 
 
Extensive medicinal chemistry efforts have been devoted to identify A/M2 channel 
inhibitor with higher potency and reduced side effects.
2
  However, very few chemotypes 
other than the adamantane scaffold have been studied for A/M2 channel inhibition.
2, 17
 
One exception is a spiro-piperidine (Figure 1), which emerged from our previous 
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structure-activity relationship (SAR) study of 2-[3-azaspiro(5,5)undecanol]-2-imidazoline 
(BL-1743).
18
  Further structure modification yielded another class of spiran amines 
(Figure 1) that are not only active against wide type (WT) A/M2 but also A/M2-V27A 
mutant channel.
19
 Encouraged by these initial results, we decided to explore both head 
group and scaffold diversity to develop new generations of A/M2 inhibitors, which might 
similarly be modified to improve potency towards drug-resistant mutants in subsequent 
studies. Inhibitors tested in this study were either synthesized or purchased through 
commercial vendors. 
 
   
Figure 1. Chemical structures of known A/M2 inhibitors. 
 
Herein we described our rationale for compound selection, assay results and 
structure-activity relationships (SAR) of these A/M2 channel inhibitors. 
 
9.3 RESULTS AND DISCUSSION 
The inhibitors were tested in two electrode patch clamp assay (TEVC) using Xenopus 
laevis frog oocytes microinjectected with RNA expressing the A/M2 protein as in a 
previous report.
20
 Oocytes expressing A/M2 channel were initially clamped at -20 mV in 
pH 8.5 buffer, in which the A/M2 channel is inactive; then the A/M2 channel was 
activated by lowering the buffer solution to pH 5.5. When the inward A/M2 current 
reached a maximum, 100 µM inhibitor was applied for 2 min at pH 5.5 buffer solution. 
The remaining current after 2 min application was compared to the maximal current 
before the application of the inhibitor. The potency of the inhibitors was expressed as the 
NH3
+Cl-
Amantadine
H2
+Cl-
N
Spiro-piperidine
NH3
+Cl-
Spiran amine
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percentage inhibition of A/M2 current observed after 2 min incubation with 100 µM 
compounds, and IC50’s were collected for selected potent compounds.  We note that, 
because small molecule inhibitors bind relatively slowly to A/M2, the inhibition does not 
reach equilibrium during the two-minute incubation period. Thus, the IC50 values 
reported here are greater (lower apparent potency) than the true dissociation constants.
19, 
21
   
 
9.3.1 SAR of the polar headgroup 
A common feature of all known M2 channel inhibitors is the presence of a polar head 
group, generally a primary or secondary amine, connected to a hydrophobic scaffold. 
Interestingly, the crystal structure and SSNMR structure of amantadine complexed A/M2 
did not identify any specific interactions with the amino group and protein;
22, 23
 instead, 
our most recent high resolution X-ray structure showed a cluster of well organized water 
molecules that might mediate a hydrogen bond with His37.
24
  The water cluster is 
highly polarized to stabilize an incoming hydronium ion, which might be mimicked by 
the ammonium group.  This observation led us to ask whether the primary ammine 
might be substituted by other polar groups without significantly affecting the activity.   
 
Inhibitors bearing one polar head group 
To explore whether the amine can be substituted by any other polar head groups, we 
examined the following panel of compounds based on adamantane scaffold (Table 1). 
 
Table 1. Activities of Adamantane analogs with diverse polar head groups on WT A/M2 
inhibition in two electrode voltage clamp assay (TEV). 
Compound 
ID 
Amantadine M2WJ116 M2WJ99 M2WJ140 M2WJ75 M2WJ161 
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Structure 
     
 
% inhibition 
IC50 (µM) 
90.8 ± 2.5% 
16.0 
3.4 ± 2.9% 
N.A 
87.0 ± 4.1% 
N.A 
85.4 ± 1.1% 
20.6 
97.0 ± 0.8% 
14.6 
95.2 ± 0.8% 
4.4 
Compound 
ID 
M2WJ77 M2WJ112 M2WJ117 M2WJ119 M2WJ127 M2WJ120 
Structure 
   
  
 
% inhibition 
IC50 (µM) 
70.0 ± 3.5% 
N.A 
72.3 ± 2.6% 
N.A 
74.9 ± 0.7% 
N.A 
68.8 ± 4.0% 
28.8 
85.8 ± 2.0% 
13.5 
92.3 ± 1.7% 
14.3 
   
Amantadine showed 90.8 ± 2.5 % inhibition (IC50 = 16.0 µM) against WT A/M2 channel 
and was used as benchmark for comparison. The negatively charged 1-adamantyl 
sulfonic acid M2WJ116 was inactive, consistent with M2’s function of stabilizing a 
positively charged permeant ion. Amino-oxyl M2WJ99 and 1-adamantol M2WJ140 were 
nearly as active as the corresponding amine, giving a similar degree of inhibition at 100 
µM. When the amine was substituted by guanidine M2WJ75 (IC50 = 14.6 µM), the 
activity was retained at the same level. In contrast, the 1-adamantyl biguanidine M2WJ77 
was much less active than 1-adamantyl guanidine M2WJ75, possibly due to the decrease 
of hydrophobicity or the increase bulk of the polar group. Interestingly, when the amine 
was substituted by amidine M2WJ161, the potency increased nearly four-fold with an 
IC50 of 4.4 µM.  N'-hydroxyadamantane-1-carboximidamide M2WJ112 was also less 
NH3
+Cl- SO3H
O
NH3
+Cl- OH
NH
-Cl+H2N NH2 -Cl+H2N NH2
NH
-Cl+H2N
N
H
NH2
+Cl-
NH2
-Cl+H2N
H
N
OH
O NH2
O OH NH3
+Cl-
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active than amantadine when comparing percentage inhibition at 100 µM. Neutral 
compounds such as amide M2WJ117 and 2-adamantanone M2WJ119 both showed 
decreased activities relative to the corresponding amine. 2-methyl -2-adamantanol 
M2WJ127 (IC50 = 13.5 µM) had activity similar to the 1-adamantol M2WJ140 (IC50 = 
20.6 µM), being slightly more active than amantadine (IC50 = 16.0 µM). This finding was 
consistent with earlier in vitro activity of 2-methyl-2-adamantol in influenza virus 
induced cytopathic effect (CPE) assay, despite it didn’t show any binding in the Trp-41 
fluorescence assay.
25
 2-aminoadamantane was shown to have similar activity as 
amantadine. In fact, a series of 2-substitited adamantane molecules are highly active 
against influenza A virus in in vitro viral CPE assay.
26
   
  
Additionally, for the spiran class of inhibitors, converting either the primary amine of 
M2WJ34 or the secondary amine of M2WJ10 to the corresponding hydrazine in 
M2WJ124 and M2WJ98, respectively, decreased potency. This is possibly due to a 
decrease in the basicity of the terminal amine (Table 2).  In comparison, both the 
glutarimide M2WJ51 and aminoglurarimide M2WJ85 were only weakly active against 
A/M2, probably due to the introduction of hydrogen bond acceptors and the strong 
decrease in basicity. 
 
Table 2. Activities of spiran amines/hydrazines on WT A/M2 inhibition in two electrode 
voltage clamp assay (TEV). 
Compound 
ID 
M2WJ34 M2WJ124 M2WJ10 M2WJ98 M2WJ51 M2WJ85 
Structure 
      
NH3
+Cl-
NH
NH3
+Cl- H2
+Cl-
N N
NH3
+Cl- H
NO O NO O
NH2
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In conclusion, these results are consistent with previous studies showing that alcohols can 
substitute for amines in M2 inhibitors
25
 and expand the range of groups that can be 
considered for design. Inhibitors with negatively charged compounds are strongly 
disfavored.   
 
Inhibitors bearing more than one polar head groups 
Pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane is a particularly good synthetic precursor for 
multi-functional inhibiors, as the diketone can be easily converted to a diol, hydroxyl 
amine, or hydroxyl ketone.
27
 Our recent high resolution X-ray crystal structure of A/M2 
revealed two layers of well organized water molecule positioned above the 
proton-accepting H37 residues.
24
 We rationalized that an additional polar head group 
might potentially hydrogen bonds to or displace these water molecules.  
 
The desired compounds were synthesized by standard procedures from the starting 
diketone (Scheme 1).  In this series, the mono-amine M2WJ199 showed the most potent 
inhibition against A/M2 channel (IC50 = 7.8 µM), followed by amino alcohol M2WJ208 
(IC50 = 24.3 µM). Diol M2WJ136 was also active, but to a less extent than the amino 
alcohol at 100 µM percentage inhibition.  Mono-alcohol M2WJ194 showed only 
moderate inhibition against A/M2 channel. The lower activities of compounds with an 
additional polar head group might be due to the increased polarity leading to a greater 
dehydration penalty upon entering the A/M2 channel pore. 
% 
inhibition 
IC50 
(µM) 
89.0 ± 1.3% 
12.6 
78.8 ± 1.5% 
30.6 
95.0 ± 0.9% 
0.9 
95.8 ± 0.3% 
7.1 
35.0 ± 2.9% 
N. A 
29.0 ± 3.7% 
N. A 
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Scheme 1. Synthesis scheme of A/M2 inhibitors with more than one polar head groups 
 
 
 
Table 3. Activities of A/M2 inhibitor with more than one polar head groups on A/M2 
inhibition in two electrode voltage clamp assay (TEV). 
O
O
1. HO(CH2)2OH, TsOH (cat)
benzene, reflux
2. NaBH4, EtOH
O
OH
1. H2NNH2, diglycol, 120
oC
CrO3, AcOH
H2O, 90
oC
OH
1. NH2OH*HCl
CH3COONa
NH3
+Cl-
2. KOH, 190oC
O
2. LiAlH4
3. HCl
M2WJ194
M2WJ199
OH
1. NH2OH*HCl
CH3COONa
2. LiAlH4
3. HCl
NH3
+Cl-
M2WJ208
3. HCl, CH3OH
Intermediate I
Intermediate II
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Compound ID M2WJ136 M2WJ194 M2WJ199 M2WJ208 M2WJ59 
Structure 
 
  
  
% inhibition 
IC50 (µM) 
76.2 ± 0.7% 
N.A 
56.7 ± 2.1% 
N.A 
95.5 ± 0.6% 
7.8 
86.0 ± 0.5% 
24.3 
80.0 ± 2.2% 
N.A 
Compound 
ID 
M2WJ63 M2WJ61 M2WJ56 M2WJ209 M2WJ218* 
Structure 
 
   
 
% inhibition 
IC50 (µM) 
50.0 ± 3.0% 
N.A 
5.0 ± 2.8% 
N.A 
13.0 ± 1.5% 
N.A 
40.2 ± 0.8% 
N.A 
90.3 ± 1.3% 
16.0 
*The percentage inhibition of M2WJ218 against V27A and S31N mutant of A/M2 was 
3.9 ± 1.1 µM and 15.3 ± 1.7 µM respectively. 
 
Encouraged by the result that diol compounds showed good activity against A/M2, we 
next examined two commercially available diols (M2WJ59 and M2WJ63, 
stereochemistry is not defined by the vendor). Both were found be less active than 
amantadine at 100 µM percentage inhibition. An additional hydroxyl group at the 3 
position of amantadine caused a dramatic decrease on A/M2 inhibition (M2WJ61). 
Another disubstituted oxyadamantane analog M2WJ56 was also not active. Taking 
together, this might due to either steric mismatch or decreased hydrophobicity. The ring 
contracted bisnoradamantane diol M2WJ209 was only moderately active, highlighting 
hydrophobic contact is important for tight binding.   
 
Earlier work by Clercq et al examined additional 2-amino substitution on the potency of 
OH
OH
OH
NH3
+Cl- OH
NH3
+Cl-
OH
OH
OH
OH
OH
NH3
+Cl-
O
OH
NH3
+Cl-
OHOH -Cl+H3N OH
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rimantadine against influenza A virus, two compounds with 1,2-diaminoethyl groups 
were just equally potent to rimantadine.
26, 28
 Taken together with our data, we conclude 
that additional polar groups have so far been tolerated, but do not enhance the potency.  
 
M2WJ218 was designed by Chou et al
29
 to potentially targeting drug resistant A/M2 
mutants based on the solution NMR structure of WT A/M2.
30
 The design principle was 
based on introducing additional hydroxyl group at the 2 position of rimantadine to tie the 
two adjacent helices together; this inhibitor was equally potent as amantadine (IC50 = 
16.0 µM) and had no inhibitory effect on either S31N or V27A mutants (Table 3). These 
results agreed with our crystal structure of A/M2, which showed inhibitor bind inside the 
channel with no specific interaction between inhibitor and protein. 
 
9.3.2 Diverse hydrophobic scaffolds 
Chen et al reported their screening of 70 primary amines including linear, aromatic, 
monocyclic, bicyclic and tricyclic compounds as inhibitors of A/M2.
31
 Five compounds 
were found to have potency against A/M2 comparable to amantadine. We have 
examined >30 amines with various sized apolar groups, focusing primarily on 
compounds with sizes and shapes roughly conforming the steric requirements of the 
binding site.  Some of the structures are shown in Table 4. Consistent with previous 
findings; amines with aromatic substitutions (M2WJ176 and M2WJ177) are significantly 
less active than the corresponding hydrocarbons. This inactivity might reflect decreased 
hydrophobicity, increased planarity, and a less optimal fit to the binding site. 
 
 
Table 4. Activities of A/M2 inhibitor with diverse scaffolds on A/M2 inhibition in two 
electrode voltage clamp assay (TEV). 
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Compound ID M2WJ176 M2WJ177 M2WJ179 M2WJ187 M2WJ36 M2WJ139 
Structure 
 
  
 
  
% inhibition 
IC50 (µM) 
39.7 ± 0.5% 
N.A 
5.8 ± 2.8% 
N.A 
86.6 ± 1.1% 
20.7 
27.9 ± 0.8% 
N.A 
94.1 ± 0.5% 
9.2 
74.8 ± .02% 
N.A 
Compound 
ID 
M2WJ186 M2WJ105 M2WJ55 M2WJ113 M2WJ200 M2WJ201 
Structure 
  
  
  
% inhibition 
IC50 (µM) 
45.3 ± 0.4% 
N.A 
74.0 ± 3.4% 
N.A 
90.2 ± 2.5% 
N.A 
83.8 ± 0.6% 
N.A 
92.0 ± 0.5% 
29.1 
81.3 ± 2.2% 
23.5 
 
All linear alkyl amines tested (up to 8 carbon atoms) in a previous report were found to 
be inactive, and to the best of our knowledge, active acyclic compounds have yet to be 
characterized.  Surprisingly, the branched alkyl amine M2WJ179 was nearly as active as 
amantadine (IC50 = 20.7 µM), suggesting A/M2 channel can accommodate a wide range 
of structural diversity.  
 
The pore-lining residues that contact the apolar region of amantadine include V27, A30 
and G34, which create a hydrophobic drug binding pocket that shows a preference for 
inhibitors with clogP > 1.5.
22
 The results presented here, together with previous studies 
by Chen et al
31
 show that a minimum of eight aliphatic carbons are required for potent 
inhibition. Tetramethyl cyclopropane amine M2WJ187, which has 7 aliphatic carbons, 
showed weak inhibition (27.9% inhibition), which is the maximum we have observed for 
NH3
+Cl-
NH3
+Cl-
NH3
+Cl-
-Cl+H3N NH3
+Cl- NH2
+Cl-
NH2
+Cl-
NH2
+Cl- HN
NH2
+Cl-
NH2
NH2
+Cl-
NH3
+Cl- NH3
+Cl-
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a compound of this molecular weight. M2WJ36 showed higher activity than amantadine 
and has the same number of carbon as amantadine (IC50 = 9.2 µM). Three bicyclic 
inhibitors (M2WJ139, M2WJ186 and M2WJ105) were also tested and found to be less 
active than amantadine at 100 µM percentage inhibition. Four ring expanded adamantane 
inhibitors (M2WJ55, M2WJ113, M2WJ200 and M2WJ201) showed similar activity as 
amantadine, this result suggests A/M2 is insensitive to slightly scaffold modification. 
 
9.4 CONCLUSION 
As an initial step towards the design of inhibitors of drug-resistant inhibitors of M2, it is 
important to first understand the mechanism by which the WT protein binds inhibitors.  
X-ray crystal structures
22, 24
 and SSNMR structures
23
 of the channel have indicated that 
amantadine binds with its aliphatic region projecting towards an apolar pocket (Figure 2).  
These structures indicate that there is sufficient space in the pocket accommodate larger 
hydrophobic groups, by displacing the polar group downward towards His37, with 
concomitant rearrangement or displacement of the water seen in the unliganded structure.  
The SAR shown in this paper for both the polar head group and apolar scaffold is 
consistent with this mode of binding. In the previous literature, almost all potent A/M2 
channel inhibitors are cyclic compounds with an amine head group.
2
 In this study we 
found that 1) amine is not essential for the activity and can be substituted by hydroxyl, 
guanidine, amidine, aminooxyl groups; 2) potent inhibition does not require a cyclic 
scaffold, so long as the shape of the molecule conforms to the cavity, such as the linear 
branched amine (M2WJ179); 3) compound hydrophobicity is very important for the 
potency of the inhibitor, the effective A/M2 inhibitor should be with clogP >1.5 or the 
number of aliphatic carbon equal to or more than 8.  While these compounds are active 
against the WT protein, they were found to be less potent or inactive against V27A and/or 
S31N.  This is understandable, because both mutations would increase the polarity of 
 298 
 
the pore.   
 
 
Fig. 2. Structure of amantadine (purple 
carbon atoms) in complex with the 
transmembrane domain of M2, as 
determined by solid-state NMR
23
 
(PDB: 2KQT) , with the water structure 
seen in the high-resolution 
crystallographic structure (PDB: 
3LBW) superimposed. Six water 
molecules from 3LBW, shown as red 
spheres lie above the four His37 and 
Trp41 residues shown near the bottom 
of the structure (sidechains shown in 
stick).  The apolar region of the drug 
projects into the cavity formed by 
Val27, Ser31, and Ala30 (near the 
upper portion of the structure), while 
the ammonium group projects 
downwards towards the water cluster. 
One helix has been removed for clarity.   
 
A second mode of binding suggested by Chou and coworkers involves a more peripheral 
site on the surface of the protein.
30
 Chou et al proposed that, if this mode of binding were 
correct, compound M2WJ218 should be a potent inhibitor of both WT protein as well as 
S31N, given that the peripheral binding sites were on the surface of the protein.
29
  On 
the other hand, the prediction of the pore-binding model was that this compound should 
bind only to the WT protein. We therefore have tested this compound, and found it to be a 
good inhibitor of WT.  However, it did not show significant inhibition of the mutants.  
Thus, these results are fully consistent with the pore-binding site being the 
pharmacologically relevant site of inhibitor binding, and do not support the peripheral 
mode of binding.  In summary, these results are fully consistent with the expectation that 
drugs bind within the pore, and focus future work on this location for the design of future 
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inhibitors. 
 
SUPPORTING INFORMATION AVAILABLE Experimental procedures for the 
synthesis and characterization of A/M2 inhibitors (
1
H, 
13
C and ESI-MS). This material is 
available free of charge via the Internet at http://pubs.acs.org 
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Chemical Synthesis. All chemicals were purchased from commercial vendors and used 
without further purification unless otherwise noted. 
1
H and 
13
C NMR spectra were 
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per 
million referenced with respect to residual solvent (CHCl3) 7.26 ppm (CH3OH) 3.31 ppm 
and (DMSO-d6) 2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. 
The following abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t ) 
triplet, q ) quartet, m ) multiplet, dd ) doublet of doublets. All reactions were carried out 
under a N2 atmosphere, unless otherwise stated. HPLC grade solvents were used for all 
the reactions. Column chromatography was performed using silica gel (230-400 mesh). 
Low-resolution mass spectra were obtained using an ESI technique on 3200 Q Trap 
LC/MS/MS system (applied biosystem).  
 
 
M2WJ116 was ordered from ChemBridge Cooperation, Cat #: 5163148 
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M2WJ99 was synthesized according to the literature reported procedure.
1
 (Yield: 72% 
over two steps). 
1
H NMR (360 MHz, DMSO) δ 5.24 (m, 2H), 2.07 (br s, 3H), 1.65 (br s, 
6H), 1.60-1.52 (m, 6H); 
13
C NMR (90 MHz, DMSO) δ 74.13, 40.31, 36.15, 29.77; The 
calculated mass for C10H17NO (M + H)
+
 is 168.1, Found 168.2. 
 
M2WJ116 was purchased from Sigma-Aldrich, Cat #: 130346 
 
 
M2WJ75 was synthesized according to the previous published procedure. 
2
 
1
H NMR (360 
MHz, CD3OD) δ 2.14-2.12 (m, 3H), 1.99-1.96 (m, 6H), 1.77-1.74 (m, 6H); 
13
C NMR (90 
MHz, CD3OD) δ 154.26, 53.83, 42.51, 36.86, 31.03; The calculated mass for C11H19N3 
(M + H)
+
 is 194.2, Found 194.7. 
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M2WJ161 was purchased from Matrix Scientific, Cat #: 007343 
 
 
M2WJ77 was purchased from Sigma-Aldrich, Cat #: L254843 
 
A suspension of 1-adamantyl carbonitrile (1.61g, 10mmol), hydroxylamine hydrochloride 
(1.04g, 15mmol) and NaHCO3 (1.25g, 15mmol) in CH3OH (25ml) was heated to reflux 
for 4hrs. After cooling down to rt, solvent was removed under reduced pressure and the 
crude product was extracted with ethyl acetate and H2O. The organic layer was dried over 
MgSO4 and filtered, 4M HCl in dioxane (3ml) was added to the filtrate and it was 
concentrated. The product was purified by flash column chromatography (5-15% 
CH3OH/CH2Cl2) to give M2WJ112 as white solid (Yield 75%). 
1
H NMR (360 MHz, 
CD3OD) δ 2.06-2.04 (m, 4H), 2.02-2.00 (m, 3H), 1.86-1.84 (m, 2H), 1.80-1.72 (m, 6H); 
13
C NMR (90 MHz, CD3OD) δ 126.30, 41.09, 40.87, 37.92, 36.88, 29.88, 28.78; The 
calculated mass for C11H18N2O (M + H)
+
 is 195.1, Found 195.0.  
 
M2WJ117 was purchased from Sigma-Aldrich, Cat #: 390607. 
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M2WJ119 was purchased from Sigma-Aldrich, Cat #: 146048. 
 
 
M2WJ127 was purchased from Fisher Scientific, Cat #:33927. 
 
 
M2WJ120 was purchased from Sigma-Aldrich, Cat #: 153818. 
 
The synthesis of spiran hydrazine M2WJ124 started from spiro[5.5]undecan-3-one, 
which was prepared according to previous published procedure.
3
 
Spiro[5.5]undecan-3-one (1.66g, 10mmol) and hydrazine hydrate (0.50g, 10mmol) was 
refluxed in CH3OH (20ml) for 3hrs.
4
 The reaction mixture was cooled down to rt and 
concentrated in vacuo. The amino imine intermediate was used for the next step without 
purification. To a solution of the crude amino imine in THF (10ml) was added a solution 
of borane-THF (1M, 30ml, 30mmool) at room temperature. The reaction was stirred at 
room temperature for 15hrs and concentrated in vacuo. The residue was dissolved in 6M 
HCl (20ml) and heated to 100
o
C refluxing for 2hrs. After cooling to room temperature, 
the solution was basified to pH 12 with 6M NaOH and extracted with CHCl3 three times. 
The combined organic layer was dried over MgSO4 and filtered. 4M HCl in dioxane 
(4ml) was added and the filtrate was concentrated under reduced pressure. The final 
product was purified by flash column chromatography (10-20% CH3OH/CH2Cl2) to give 
M2WJ124 as white solid. (Yield: 68% over two steps). 
1
H NMR (360 MHz, CDCl3) δ 
8.49 (br s, 4H), 3.44-3.37 (m, 1H), 2.02-2.01 (m, 2H), 1.81-1.73 (m, 4H), 1.39-1.36 (m, 
8H), 1.19-1.11 (m, 2H), 1.10-1.04 (m, 2H); 
13
C NMR (90 MHz, CDCl3) δ 61.21, 40.68, 
34.37, 32.26, 32.04, 26.98, 23.12, 21.99, 21.84; The calculated mass for C11H22N2 (M + 
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H)
+
 is 183.2, Found 183.7. 
 
  
Hydrazine hydrate (0.5g, 10mmol) was added dropwise to a refluxing solution of 
3-Oxaspiro[5,5]undecane-2,4-dione in DMF (20ml). After addition, the solution was 
slowly cooled down to room temperature. Solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography (2-5% 
CH3OH/CH2Cl2) to give M2WJ85 as white solid. (Yield: 72%). 
1
H NMR (360 MHz, 
CD3OD) δ 2.52 (s, 2H), 2.46 (s, 2H), 1.53-1.46 (m, 10H); 
13
C NMR (90 MHz, CDCl3) δ 
176.14, 42.38, 37.12, 36.89, 27.05, 22.71; The calculated mass for C10H16N2O2 (M + H)
+
 
is 197.1, Found 197.2. 
M2WJ98 was synthesized by LiAlH4 reduction of M2WJ85. To M2WJ85 (1.96g, 
10mmol) in anhydrous THF was added LiAlH4 (0.76g, 20mmol) at 0
o
C, the resulting 
slurry was heated to reflux for 4 hrs. The solution was cooled to 0
o
C and quenched with 
H2O (0.75 mL), 15% NaOH (0.75 mL), and H2O (2.25 mL) sequentially. The resulting 
slurry was filtered. The filtrate was dried over MgSO4, filtered, concentrated in vacuo. 
Hydrochloride salt was made by adding 4M HCl in 1,4-dioxane to the ether solution of 
the above amine at 0
o
C, followed by centrifuge and decant the ether supernatant. The 
final product was purified by flash chromatography to give the hydrazine M2WJ98 as 
white solid. (Yield: 65%). 
1
H NMR (360 MHz, CDCl3) δ 2.60 (t, J = 5.52 Hz, 4H), 1.52 
(t, J = 5.52 Hz, 4H), 142-1.40 (m, 6H), 1.33-1.26 (m, 4H); 
13
C NMR (90 MHz, CDCl3) δ 
56.05, 36.87, 36.44, 30.14, 26.99, 21.82; The calculated mass for C10H20N2 (M + H)
+
 is 
169.2, Found 169.2. 
 
 
M2WJ51 was purchased from Bosche Scientific, Cat #:P3149 
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Pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane-8,11-dione was purchased from Sigma-Aldrich, 
Cat #309575, 98% 
 
General procedure of converting ketone to amine 
A solution of ketone (1mmol), NH2OH*HCl (208.5mg, 3mmol) and CH3COONa 
(328.1mg, 4mmol) in EtOH (10ml) and H2O (1ml) was heated to reflux for 2hrs. Solvent 
was removed in vacuo and the residue was dissolved in CH2Cl2 and extracted with H2O 
twice. The organic layer was dried with MgSO4 and the solvent was removed in vacuo to 
give the oxime intermediate. Without further purification, the oxime was dissolved in 
anhydrous THF (10ml) and cooled to 0
o
C on an ice-water bath. LiAlH4 (0.4g, 10.5mmol) 
was added portion-wise to the stirring mixture. The solution was warmed up to ambient 
temperature and heated at reflux for 4hrs. The reaction was quenched by sequentially 
addition of 0.4 ml H2O, 0.4 ml 15% NaOH solution and 1.2 ml H2O. The resulting slurry 
was filtered and the solvent was removed in vacuo. 4M HCl in 1,4-dioxane (1ml) was 
added to the oily residue and the solvent was removed again in vacuo to give white solid 
crude product which was subsequently purified by silica gel flash column 
chromatography to yield the final amino hydrochloride salt. 
 
The ketone alcohol intermediate I was synthesized according to the literature procedure 
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without modification.
5
 It was converted to the amino alcohol M2WJ208 according to the 
above general procedure of converting ketone to amine. (Yield: 75%). 
1
H NMR (360 
MHz, DMSO) δ 8.55 (br s, 3H), 7.09 (br s, 1H), 3.76-3.75 (m, 1H), 2.94-2.93 (m, 1H), 
2.72-2.712 (m, 1H), 2.62-2.61 (m, 1H), 2.55-2.54 (m, 1H), 2.35-2.34 (m, 1H), 2.27-2.22 
(m, 2H), 1.59 (d, J = 7.56 Hz, 1H), 1.59-1.45 (m, 2H), 1.00 (d, J = 7.56 Hz, 1H); 
13
C 
NMR (90 MHz, DMSO) δ 69.41, 49.07, 44.23, 44.20, 42.82, 42.42, 42.25, 37.30, 35.43, 
33.52, 20.31; The calculated mass for C11H15NO (M + H)
+
 is 177.2, Found 177.2. 
 
M2WJ194 was synthesized from reduction of intermediate I according to the published 
procedure. 
5
 (Yield: 80%). 
1
H NMR (360 MHz, CDCl3) δ 3.95-3.93 (m, 1H), 2.79-2.70 
(m, 1H), 2.69-2.50 (m, 2H), 2.48-2.35 (m, 2H), 2.32-2.15 (m, 4H), 1.72-1.69 (m, 1H), 
1.50 (br s, 1H), 1.19-1.12 (m, 1H), 1.11-1.06 (m, 1H). 
13
C NMR (90 MHz, CDCl3) δ 
74.60, 47.25, 45.98, 43.34, 42.25, 42.23, 40.14, 39.07, 36.16, 35.36, 29.02; The 
calculated mass for C11H14O (M + H)
+
 is 163.1, Found 162.8. 
 
M2WJ199 was synthesized from the ketone intermediate II according to the above 
general procedure of converting ketone to amine. (Yield: 78%). 
1
H NMR (360 MHz, 
CDCl3) δ 8.23 (br s ,3H), 3.26-3.24 (m, 1H), 2.92-2.89(m, 2H), 2.68-2.58 (m, 4H), 
2.32-2.30(m, 2H), 1.89-1.74 (m, 2H), 1.30-1.21 (m, 2H). 
13
C NMR (90 MHz, CDCl3) δ 
51.69, 47.14, 44.83, 43.69, 42.07, 41.26, 40.57, 37.15, 35.37, 34.48, 29.58; The 
calculated mass for C11H15N (M + H)
+
 is 162.2, Found 162.1. 
 
 
M2WJ66 was purchased from Enamine, Cat #:T0500-7514 
 
M2WJ59 was purchased from Cambridge Corporation, Cat # 5190950 
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M2WJ63 was purchased from Sigma-Aldrich, Cat # S434051 
 
M2WJ61 was purchased from ChemBridge cooperation, Cat #:4003530 
 
 
M2WJ56 was purchased from Aurora Fine Chemicals, Cat #: K00.039.656  
 
M2WJ209 was synthesized according to the literature reported procedure using SmI2 
reduction. 
6
 (Yield: 32%). 
1
H NMR (360 MHz, CDCl3+CD3OD) δ 1.70 (d, J = 4.68 Hz, 
4H), 1.54 (d, J = 4.68 Hz, 4H), 1.04 (s, 6H). 
13
C NMR (90 MHz, CDCl3+CD3OD) δ 
78.92, 56.92, 41.85, 16.37; The calculated mass for C10H16O2 (M + H)
+
 is 169.1, Found 
169.4. 
 
General procedure of LiAlH4 mediated reduction 
In anhydrous THF was added LiAlH4 (X g) at 0
o
C, the resulting slurry was heated to 
reflux for 4 hrs. The solution was cooled to 0
o
C and quenched with H2O (X mL), 15% 
NaOH (X mL), and H2O (3X mL) sequentially. The resulting slurry was filtered. The 
filtrate was dried over MgSO4, filtered, concentrated in vacuo. Hydrochloride salt was 
made by adding 4M HCl in 1,4-dioxane to the ether solution of the above amine at 0
o
C, 
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followed by decanting the ether supernatant. The final product was purified by flash 
chromatography to give the ammonium hydrochloride.  
 
 
M2WJ218 was synthesized according to the above general procedure of LiAlH4 mediated 
reduction. The starting material 1-Adamantyl(amino)acetic acid was purchased from 
Matrix Scientific, Cat #: 027469. (Yield: 82%). 
1
H NMR (360 MHz, CD3OD) δ 3.88 (dd, 
J = 11.52 Hz, 3.6 Hz, 1H), 3.62-3.57 (m, 1H), 2.78 (dd, J = 9.18 Hz, 3.6 Hz, 1H), 2.03 
(br s, 3H), 1.81-1.74 (m, 6H), 1.68-1.66 (m, 6H). 
13
C NMR (90 MHz, CD3OD) δ 64.01, 
59.27, 39.47, 37.75, 35.16, 29.65; The calculated mass for C12H21NO (M + H)
+
 is 196.2, 
Found 196.2. 
 
 
M2WJ176 4-tert-butylbenzylamine was purchased from Sigma-Aldrich. Cat #631280 
97% 
  
M2WJ177 2-aminoindan was purchased from Sigma-Aldrich. Cat # 479128.  97% 
   
M2WJ179 tert-Octylamine was purchased from Sigma-Aldrich, Cat #: O6000 95% 
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Diphenylphosphorylazide (DPPA) (1.29 ml, 6 mmol) and triethylamine (0.84ml, 6mmol) 
were added to a solution of 2,2,3,3-Tetramethylcyclopropanecarboxylic acid (0.71 g, 5 
mmol) in 10 ml toluene at ambient temperature. The reaction was heated to reflux for 3 
hours. The mixture was concentrated in vacuo. An additional 10 ml CH2Cl2 and 10 ml 
H2O were added to the reaction mixture, the organic layer was separated and washed 
sequentially with H2O, saturated NaHCO3 and brine and dried over MgSO4. Solvent was 
removed by rotary evaporation and 50ml of 6 N HCl was added. The solution was stirred 
at ambient temperature for 3 hours. NaOH solution was added until pH 10, the resulting 
solution was extracted by CH2Cl2 (30ml) for 3 times. 4M HCl in dioxane (3 ml) was 
added to the combined CH2Cl2 layers and the mixture was dried over MgSO4. Further 
flash column chromatography purification gave 2,2,3,3-tetramethylcyclopropanaminium 
chloride as a white power (0.83g, Yield: 82%). 
1
H NMR (360 MHz, CD3OD) δ 3.35 (s, 
1H), 1.16 (s, 12H); 
13
C NMR (90 MHz, CD3OD) δ 43.02, 23.24, 22.19; The calculated 
mass for C7H15N (M + H)
+
 is 114.1, Found 114.2 
 
 
M2WJ36 was synthesized according to the above general procedure of converting ketone 
to amine. (Yield: 78.2%) 
1
H-NMR (360 MHz, CD3OD) δ 3.49-3.44 (m, 1H), 2.25-2.24 
(m, 1H), 2.11-2.05 (m, 3H), 2.00-1.93 (m, 3H), 1.72-1.70 (m, 1H), 1.60-1.57 (m, 1H), 
1.29-1.20 (m, 2H), 1.04-0.93 (m, 3H); 
13
C-NMR (90 MHz, CD3OD) δ 50.98, 43.69, 
40.69, 38.66, 33.95, 32.07, 31.71, 31.50, 26.36; The calculated mass for C10H17N (M + 
H)
+
 is 152.1, Found 152.5. 
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3-Azabicyclo[3.2.2]nonane 99% was purchased from ChemService Inc. Cat # 2040 
 
 
 
4-Oxo-3-aza-tricyclo[4.2.1.0(2.5)]nonane was purchased from Fisher Scientific Cat 
#26810. It was reduced to M2WJ186 with LiAlH4 according to the general procedure of 
LiAlH4 reduction described above. (Yield: 80%). 
1
H NMR (360 MHz, CD3OD) δ 
4.40-4.36 (m, 1H), 4.19-4.17 (m, 1H), 3.85-3.82 (m, 1H), 2.78-2.10 (m, 4H), 1.70-1.64 
(m, 3H), 1.19-1.16 (m, 2H); 
13
C NMR (90 MHz, CD3OD) δ 65.80, 48.26, 38.96, 36.97, 
36.93, 30.49, 25.25, 22.63; The calculated mass for C8H13N (M + H)
+
 is 124.1, Found 
124.2 
 
 
Bicyclo[2.2.1]heptane-2,3-dicarboxylic Acid was purchased from TCI America, Cat 
#N0753. The diacid (1.84g, 10mmol) and urea (2.40g, 40mmol) was heated to 180
o
C 
under N2 atmosphere for 3hrs. When it was cooled down to room temperature, anhydrous 
THF was added, and the solution was cooled to 0
o
C with ice bath. LiAlH4 (3.04g, 
80mmol) was added portionwise to the solution, and heated to reflux for 4hrs. The 
solution was cooled down to 0
o
C with ice bath, 3ml of H2O, 3ml 15% NaOH and 9ml of 
H2O was sequentially added. The resulting slurry was filtered. 5ml of 4M HCl in 
1,4-dioxane was added and the solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography (10% CH3OH/CH2Cl2) to give 
M2WJ105 as white solid (1.24g, Yield: 72.0%). 
1
H NMR (360 MHz, CDCl3) δ 3.32-3.30 
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(m, 2H), 3.26-3.21 (m, 2H), 2.93-2.90 (m, 2H), 2.36-2.34 (m, 2H), 1.78-1.74 (m, 1H), 
1.68-1.65 (m, 1H), 1.58-1.51 (m, 4H); 
13
C NMR (90 MHz, CDCl3) δ 47.11, 45.78, 44.34, 
41.30, 23.23; The calculated mass for C9H15N (M + H)
+
 is 138.1, Found 138.2. 
 
  
M2WJ55 was purchased from Chembridge Corporation. Cat # 5875453. 
 
 
4-Azatricyclo[4.3.1.13,8]undecan-5-one was purchased from Sigma-Aldrich. Cat 
#403164. 98%. It was reduced to M2WJ113 according to the above general procedure of 
LiAlH4 mediated reduction. (Yield: 82%). 
1
H-NMR (360 MHz, CD3OD) δ 2.80-2.77 (m, 
3H), 1.84-1.82 (m, 1H), 1.61-1.52 (m, 6H), 1.36-1.31 (m, 2H), 1.17-1.36 (m, 4H); 
13
C-NMR (90 MHz, CD3OD) δ 53.72, 52.61, 37.17, 34.98, 34.87, 32.09, 27.27; ESI-MS: 
Calculated for C10H17N (M + H)
+
 152.2, Found: 152.3 
 
 
M2WJ200 was purchased from Matrix Scientific, Cat #:038588 
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M2WJ201 was synthesized according to literature reported procedure using curtius 
rearrangement reaction.
7, 8
 The starting material was purchased from Matrix Scientific, 
Cat #: 037551 (Yield: 76%). 
1
H-NMR (360 MHz, CD3OD) δ 2.28-2.24 (m, 2H), 
1.96-1.91 (m, 4H), 1.89-1.82 (m, 4H), 1.76-1.72 (m, 4H), 1.55-1.52 (m, 2H); 
13
C-NMR 
(90 MHz, CD3OD) δ 53.91, 43.16, 42.46, 40.72, 38.90, 37.36, 35.87, 33.76, 32.54, 30.98, 
28.38; ESI-MS: Calculated for C11H19N (M + H)
+
 166.2, Found: 166.3 
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